<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for infantile haemangiomas of the skin - Novoa, M - 2018 | Cochrane Library</title> <meta content="Interventions for infantile haemangiomas of the skin - Novoa, M - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006545.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for infantile haemangiomas of the skin - Novoa, M - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006545.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006545.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for infantile haemangiomas of the skin" name="citation_title"/> <meta content="Monica Novoa" name="citation_author"/> <meta content="Hospital San Jose‐Fundacion Universitaria de Ciencias de la Salud" name="citation_author_institution"/> <meta content="Eulalia Baselga" name="citation_author"/> <meta content="Hospital de la Santa Creu i Sant Pau" name="citation_author_institution"/> <meta content="Sandra Beltran" name="citation_author"/> <meta content="Hospital San Jose‐Fundacion Universitaria de Ciencias de la Salud" name="citation_author_institution"/> <meta content="Lucia Giraldo" name="citation_author"/> <meta content="Hospital San Jose‐Fundacion Universitaria de Ciencias de la Salud" name="citation_author_institution"/> <meta content="Ali Shahbaz" name="citation_author"/> <meta content="University of Alberta" name="citation_author_institution"/> <meta content="Hector Pardo‐Hernandez" name="citation_author"/> <meta content="Ingrid Arevalo‐Rodriguez" name="citation_author"/> <meta content="inarev7@yahoo.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD006545.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/04/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006545.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006545.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006545.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenal Cortex Hormones [adverse effects, therapeutic use]; Adrenergic beta‐Antagonists [administration &amp; dosage]; Antineoplastic Agents [therapeutic use]; Bleomycin [therapeutic use]; Hemangioma, Capillary [*therapy]; Lasers, Dye [therapeutic use]; Methylprednisolone [adverse effects, therapeutic use]; Photochemotherapy [methods]; Prednisolone [adverse effects, therapeutic use]; Propranolol [administration &amp; dosage]; Radiotherapy [methods]; Randomized Controlled Trials as Topic; Remission Induction [methods]; Skin Neoplasms [*therapy]; Timolol [administration &amp; dosage]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006545.pub3&amp;doi=10.1002/14651858.CD006545.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xsb6SJyC";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006545\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006545\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006545\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006545\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","pt","ms","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006545.pub3",title:"Interventions for infantile haemangiomas of the skin",firstPublishedDate:"Apr 18, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xsb6SJyC&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006545.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006545.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006545.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006545.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006545.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006545.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006545.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006545.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006545.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006545.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7392 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006545.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/full#CD006545-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/full#CD006545-sec-0382"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/full#CD006545-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/full#CD006545-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/full#CD006545-sec-0052"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/full#CD006545-sec-0053"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/full#CD006545-sec-0081"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/full#CD006545-sec-0373"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/appendices#CD006545-sec-0392"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/table_n/CD006545StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/table_n/CD006545StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for infantile haemangiomas of the skin</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/information#CD006545-cr-0002">Monica Novoa</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/information#CD006545-cr-0003">Eulalia Baselga</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/information#CD006545-cr-0004">Sandra Beltran</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/information#CD006545-cr-0005">Lucia Giraldo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/information#CD006545-cr-0006">Ali Shahbaz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/information#CD006545-cr-0007">Hector Pardo‐Hernandez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006545.pub3/information#CD006545-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Ingrid Arevalo‐Rodriguez</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/information/en#CD006545-sec-0405">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 April 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006545.pub3">https://doi.org/10.1002/14651858.CD006545.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006545-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006545-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006545-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006545-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006545-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006545-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006545-abs-0001" lang="en"> <section id="CD006545-sec-0001"> <h3 class="title" id="CD006545-sec-0001">Background</h3> <p>Infantile haemangiomas (previously known as strawberry birthmarks) are soft, raised swellings of the skin that occur in 3% to 10% of infants. These benign vascular tumours are usually uncomplicated and tend to regress spontaneously. However, when haemangiomas occur in high‐risk areas, such as near the eyes, throat, or nose, impairing their function, or when complications develop, intervention may be necessary. This is an update of a Cochrane Review first published in 2011. </p> </section> <section id="CD006545-sec-0002"> <h3 class="title" id="CD006545-sec-0002">Objectives</h3> <p>To assess the effects of interventions for the management of infantile haemangiomas in children. </p> </section> <section id="CD006545-sec-0003"> <h3 class="title" id="CD006545-sec-0003">Search methods</h3> <p>We updated our searches of the following databases to February 2017: the Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, PsycINFO, AMED, LILACS, and CINAHL. We also searched five trials registries and checked the reference lists of included studies for further references to relevant trials. </p> </section> <section id="CD006545-sec-0004"> <h3 class="title" id="CD006545-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) of all types of interventions, versus placebo, active monitoring, or other interventions, in any child with single or multiple infantile haemangiomas (IHs) located on the skin. </p> </section> <section id="CD006545-sec-0005"> <h3 class="title" id="CD006545-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. The primary outcome measures were clearance, a subjective measure of improvement, and adverse events. Secondary outcomes were other measures of resolution; proportion of parents or children who consider there is still a problem; aesthetic appearance; and requirement for surgical correction. We used GRADE to assess the quality of the evidence for each outcome; this is indicated in <i>italics</i>. </p> </section> <section id="CD006545-sec-0006"> <h3 class="title" id="CD006545-sec-0006">Main results</h3> <p>We included 28 RCTs, with a total of 1728 participants, assessing 12 different interventions, including lasers, beta blockers (e.g. propranolol, timolol maleate), radiation therapy, and steroids. Comparators included placebo, an active monitoring approach, sham radiation, and interventions given alone or in combination. </p> <p>Studies were conducted in a number of countries, including China, Egypt, France, and Australia. Participant age ranged from 12 weeks to 13.4 years. Most studies (23/28) included a majority of females and different types of IHs. Duration of follow‐up ranged from 7 days to 72 months. </p> <p>We considered most of the trials as at low risk of random sequence generation, attrition bias, and selective reporting bias. Domains such as allocation concealment and blinding were not clearly reported in general. We downgraded evidence for issues related to risk of bias and imprecision. </p> <p>We report results for the three most important comparisons, which we chose on the basis of current use. Outcome measurement of these comparisons was at 24 weeks' follow‐up. </p> <p><b><i>Oral propranolol versus placebo</i> </b> </p> <p>Compared with placebo, oral propranolol 3 mg/kg/day probably improves clinician‐assessed clearance (risk ratio (RR) 16.61, 95% confidence interval (CI) 4.22 to 65.34; 1 study; 156 children; <i>moderate‐quality evidence</i> ) and probably leads to a clinician‐assessed reduction in mean haemangioma volume of 45.9% (95% CI 11.60 to 80.20; 1 study; 40 children; <i>moderate‐quality evidence</i> ). We found no evidence of a difference in terms of short‐ or long‐term serious adverse events (RR 1.05, 95% CI 0.33 to 3.39; 3 studies; 509 children; <i>low‐quality evidence</i>), nor in terms of bronchospasm, hypoglycaemia, or serious cardiovascular adverse events. The results relating to clearance and resolution for this comparison were based on one industry‐sponsored study. </p> <p><b><i>Topical timolol maleate versus placebo</i> </b> </p> <p>The chance of reduction of redness, as a measure of clinician‐assessed resolution, may be improved with topical timolol maleate 0.5% gel applied twice daily when compared with placebo (RR 8.11, 95% CI 1.09 to 60.09; 1 study; 41 children;<i>low‐quality evidence</i> ). Regarding short‐ or long‐term serious cardiovascular events, we found no instances of bradycardia (slower than normal heart rate) or hypotension in either group (1 study; 41 children; <i>low‐quality evidence</i>). No other safety data were assessed, and clearance was not measured. </p> <p><b><i>Oral propranolol versus topical timolol maleate</i> </b> </p> <p>When topical timolol maleate (0.5% eye drops applied twice daily) was compared with oral propranolol (via a tablet taken once per day, at a 1.0 mg/kg dose), there was no evidence of a difference in haemangioma size (as a measure of resolution) when measured by the proportion of patients with a clinician‐assessed reduction of 50% or greater (RR 1.13, 95% CI 0.64 to 1.97; 1 study; 26 participants; <i>low‐quality evidence</i> ). Although there were more short‐ or long‐term general adverse effects (such as severe diarrhoea, lethargy, and loss of appetite) in the oral propranolol group, there was no evidence of a difference between groups (RR 7.00, 95% CI 0.40 to 123.35; 1 study; 26 participants; <i>very low‐quality evidence</i>). This comparison did not measure clearance. </p> <p>None of our key comparisons evaluated, at any follow‐up, a subjective measure of improvement assessed by the parent or child; proportion of parents or children who consider there is still a problem; or physician‐, child‐, or parent‐assessed aesthetic appearance. </p> </section> <section id="CD006545-sec-0007"> <h3 class="title" id="CD006545-sec-0007">Authors' conclusions</h3> <p>We found there to be a limited evidence base for the treatment of infantile haemangiomas: a large number of interventions and outcomes have not been assessed in RCTs. </p> <p>Our key results indicate that in the management of IH in children, oral propranolol and topical timolol maleate are more beneficial than placebo in terms of clearance or other measures of resolution, or both, without an increase in harms. We found no evidence of a difference between oral propranolol and topical timolol maleate with regard to reducing haemangioma size, but we are uncertain if there is a difference in safety. Oral propranolol is currently the standard treatment for this condition, and our review has not found evidence to challenge this. However, these results are based on <i>moderate‐</i> to <i>very low‐quality evidence</i>. </p> <p>The included studies were limited by small sample sizes and risk of bias in some domains. Future trials should blind personnel and participants; describe trials thoroughly in publications; and recruit a sufficient number of children to deduce meaningful results. Future trials should assess patient‐reported outcomes, as well as objective outcomes of benefit, and should report adverse events comprehensively. Propranolol and timolol maleate require further assessment in RCTs of all types of IH, including those considered problematic, as do other lesser‐used interventions and new interventions. All treatments should be compared against propranolol and timolol maleate, as beta blockers are approved as standard care. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006545-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006545-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006545-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006545-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006545-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006545-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD006545-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD006545-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006545-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006545-abs-0005" lang="en"> <h3>Treatments for haemangiomas (a cluster of small blood vessels that form a lump) of the skin in children </h3> <p><b>What is the aim of this review?</b> </p> <p>This Cochrane Review aimed to assess the benefits and harms of treatments for haemangiomas of the skin in infants and children (known as 'infantile haemangiomas'). We collected and analysed 28 relevant clinical trials to answer this question. </p> <p><b>Key messages</b> </p> <p>Only one of our key comparisons (propranolol versus placebo) measured clearance of the haemangioma, with <i>moderate‐quality evidence</i> supporting this result. We found <i>low‐</i> or <i>moderate‐quality evidence</i> for the following specific measures of resolution: reduction in volume, redness, and size. We found <i>very low‐</i> and <i>low‐quality evidence</i> for results concerning side effects, meaning we were unable to draw definitive conclusions about safety. </p> <p>Oral propranolol is currently the standard treatment for this condition, and we did not find evidence to contest this treatment in terms of efficacy and safety. However, potential biases in the design of many of the included trials affect our confidence in the results of the review. High‐quality future research should assess the effects of propranolol and timolol maleate, as well as other new and older medications, on outcomes that are important to patients. </p> <p><b>What was studied in the review?</b> </p> <p>Infantile haemangiomas are soft, raised swellings on the skin, often with a bright‐red surface caused by a non‐cancerous overgrowth of blood vessels in the skin. The majority of lesions are uncomplicated and will shrink on their own by age seven; however, some require treatment if they occur in high‐risk areas (e.g. near the eyes) or cause psychological distress. </p> <p>We included all types of treatment for infantile haemangiomas, which could have been given alone or in combination, or compared to each other, to a 'placebo' (i.e. a treatment with no active agent), or against children whose haemangiomas were untreated but observed. </p> <p><b>What are the main results of the review?</b> </p> <p>We included 28 studies, with a total of 1728 participants, which assessed lasers, beta blockers (e.g. propranolol), steroids, radiation therapy, and other treatments. Treatments were compared against an active monitoring approach (observation), placebo, sham radiation, or other interventions (given alone or in combination with another treatment). Studies were conducted in multiple countries; participant age ranged from 12 weeks to 13.4 years; and most studies included more girls than boys (23/28). Children had different types of haemangioma. Duration of follow‐up ranged from 7 days to 72 months. </p> <p>The following results were measured 24 weeks after the beginning of treatment. All non‐safety outcomes presented here were clinician assessed (i.e. assessed by the physician in charge of a patient). </p> <p>When compared with placebo treatment, propranolol taken by mouth at a dose of 3 mg/kg/day is probably more beneficial in terms of complete or almost‐complete clearance of swelling and reduction in volume of the haemangioma (<i>moderate‐quality evidence</i> ). We found no evidence of a difference between the two treatments in terms of short‐ or long‐term serious or other side effects (<i>low‐quality evidence</i>). Most of the evidence for this comparison was based on an industry‐sponsored study. </p> <p>Timolol maleate 0.5% gel applied topically twice daily may reduce redness as a measure of resolution when assessed against placebo (<i>low‐quality evidence</i> ). Short‐ or long‐term serious cardiovascular events were not reported in either group. There were no other safety data for timolol maleate compared with placebo (<i>low‐quality evidence</i>). This comparison did not assess clearance of the swelling. </p> <p>There was no evidence of a difference between propranolol taken by mouth (via a tablet once per day, at a 1.0 mg/kg dose) and topical timolol maleate (0.5% eye drops applied twice daily) in terms of their effect on reducing haemangioma size by 50% or more (<i>low‐quality evidence</i> ). There were more general short‐ or long‐term side effects (such as severe diarrhoea, tiredness, and decreased appetite) with propranolol, but due to very <i>low‐quality evidence</i>, these results are uncertain. This comparison did not assess clearance of the swelling. </p> <p>Most of the comparisons assessed, including those described above, did not report on the following outcomes: parent or child's opinion of improvement; the proportion of parents or children who consider there is still a problem; and cosmetic appearance. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>We searched for studies up to February 2017.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006545-sec-0382" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006545-sec-0382"></div> <h3 class="title" id="CD006545-sec-0383">Implications for practice</h3> <section id="CD006545-sec-0383"> <p>Our Cochrane Review updated the evidence on the effects of different interventions for the management of infantile haemangiomas (IHs). We included 12 interventions, 28 studies, and 30 comparisons. We assessed the quality of the evidence underlining three key treatment comparisons, and have been able to draw the following conclusions. </p> <p> <ul id="CD006545-list-0016"> <li> <p>There is moderate‐quality evidence that, when compared with placebo, oral propranolol is probably beneficial in terms of complete or almost complete clearance and probably reduces haemangioma volume more than placebo. We found no evidence of a difference in terms of short‐ or long‐term adverse events between the groups (low‐quality evidence). </p> </li> <li> <p>Low‐quality evidence indicates that topical timolol maleate may reduce IH redness more than placebo, with possibly no accompanying cardiovascular events, although no other safety data were assessed for this comparison. </p> </li> <li> <p>There was no evidence of a difference between oral propranolol and topical timolol maleate in their ability to generate a 50% or greater reduction in IH size, based on low‐quality evidence. We were unable to draw conclusions about adverse events for this comparison due to very low‐quality evidence. </p> </li> </ul> </p> <p>All outcomes reported for these comparisons were measured at 24 weeks’ follow‐up and were clinician assessed, except for the safety outcomes. We are unable to present evidence on the following key outcomes for our key comparisons because they were not reported. </p> <p> <ul id="CD006545-list-0017"> <li> <p>A subjective measure of improvement, as assessed by the parent or child.</p> </li> <li> <p>Proportion of parents who consider their child still has a problem.</p> </li> <li> <p>Proportion of children who consider they still have a problem.</p> </li> <li> <p>Aesthetic appearance as assessed by physician, child, or parent.</p> </li> </ul> </p> <p>As the evidence underlying our results for propranolol and timolol maleate was allocated a GRADE rating no higher than moderate, we cannot make qualitative statements with high certainty. However, propranolol remains the standard treatment for infantile haemangiomas, and clinicians should be aware that clinical management of haemangiomas depends on the following risk factors, amongst others: the grade of complication, presence of comorbidities, clinician experience, need for hospitalisation versus ambulatory care, and patient factors. </p> <p>A large number of interventions were not assessed by any included study: argon laser, carbon dioxide laser, erbium laser, excision, cryotherapy, imiquimod, interferon alpha, vincristine, and rapamycin. </p> </section> <h3 class="title" id="CD006545-sec-0384">Implications for research</h3> <section id="CD006545-sec-0384"> <p>Despite the fact that there was a considerable increase in the number of trials since the publication of the first version of this review (from 4 trials/271 children to 28 trials/1728 children), the certainty of the evidence was reduced due to issues such as the sample size of the included studies and risk of bias in, for example, blinding and selective reporting domains. Furthermore, scarce or non‐existent evidence for certain interventions and outcomes means that there is still a need for high‐quality randomised controlled trials (RCTs) to assess interventions for IH. </p> <section id="CD006545-sec-0385"> <h5 class="title">Participants</h5> <p>Randomised controlled trials are needed for all types of haemangiomas, especially complicated scenarios such as ulcerated or problematic IH, where evidence is lacking. It is important that the haemangioma subtype is clearly reported in trial publications. </p> </section> <section id="CD006545-sec-0386"> <h5 class="title">Interventions</h5> <p>There is a need for RCTs related to the efficacy and safety of the following interventions:</p> <p> <ul id="CD006545-list-0018"> <li> <p>oral propranolol and topical timolol maleate (assessed separately);</p> </li> <li> <p>combination of oral propranolol with other interventions (such as laser or corticosteroids);</p> </li> <li> <p>combination of topical timolol maleate with other interventions;</p> </li> <li> <p>other potential interventions, such as imiquimod, interferon alpha, excision, cryotherapy, vincristine, and rapamycin; and </p> </li> <li> <p>new interventions, such as beta blockers.</p> </li> </ul> </p> <p>The evaluation of different dosages and duration, which will vary according to treatment, should also be taken into account. </p> </section> <section id="CD006545-sec-0387"> <h5 class="title">Comparators</h5> <p>High‐quality trials should assess oral propranolol and topical timolol maleate against each other. Other interventions should also be compared against oral propranolol and topical timolol maleate, as beta blockers are currently approved as standard care both by the US Food and Drug Administration and the European Medicines Agency. </p> </section> <section id="CD006545-sec-0388"> <h5 class="title">Outcomes</h5> <p>Important outcomes to assess include the incidence and types of adverse events experienced by trial participants, as well as other patient‐reported outcomes, or those pertaining to parents and carers, such as the proportion of participants that feel they still have a problem (either reported by the child or the parent/carer), the requirement for surgical correction, and aesthetic appearance. These outcomes should ensure follow‐up in both the short term and the long term. Furthermore, objective outcomes such as resolution need further assessment. </p> </section> <section id="CD006545-sec-0389"> <h5 class="title">Methodology</h5> <p>A sufficient sample size to enable the detection of a clinically important effect size is crucial when conducting future trials; this could perhaps be achieved using a multicentre approach. Trials must be rigorously reported to help overcome methodological issues associated with poor RCTs in this field, such as selective reporting of outcomes and unclear blinding (outcomes, participants, and personnel). Furthermore, thorough reporting with regard to the nature of the interventions, the age of participants, and the type of haemangiomas included will ensure the applicability of future trial results. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006545-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006545-sec-0029"></div> <div class="table" id="CD006545-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral propranolol compared to placebo for infantile haemangiomas of the skin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral propranolol compared to placebo for infantile haemangiomas (strawberry birthmarks) of the skin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infantile haemangiomas (strawberry birthmarks) of the skin<br/> <b>Setting:</b> all settings (outpatient care)<br/> <b>Intervention:</b> oral propranolol<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral propranolol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance, as assessed by a clinician at any follow‐up ‐</b> 3 mg/kg/day </p> <p>24 weeks' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>604 per 1000<br/> (153 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 16.61</b><br/> (4.22 to 65.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>MODERATE</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>A subjective measure of improvement, as assessed by the parent or child, at any follow‐up</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events experienced at short or long term ‐</b> Serious adverse events </p> <p>24 weeks' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000<br/> (12 to 124) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b><br/> (0.33 to 3.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>509<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>LOW</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other measures of resolution, as assessed by a clinician, at any follow‐up ‐</b> percentage change in mean haemangioma volume at 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean: ‐14.1% (SD not reported)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean: ‐60% (SD not reported)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD</p> <p><b>45.9% lower</b> </p> <p>(80.2% lower to 11.6% lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean difference was reported by the study authors, but no SDs were reported for group means. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of parents who consider their child still has a problem, at any follow‐up ‐</b> not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of children who consider they still have a problem, at any follow‐up ‐</b> not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up ‐</b> not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group (the event rate in the single study or the mean event rate in the meta‐analysis) and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for imprecision (wide confidence interval around the estimate of the effect).<br/> <sup>2</sup>Downgraded by two levels for imprecision (wide confidence interval around the estimate of the effect and low number of events).<br/> <sup>3</sup>Downgraded by one level for risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006545-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical timolol compared to placebo for infantile haemangiomas of the skin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Topical timolol maleate compared to placebo for infantile haemangiomas (strawberry birthmarks) of the skin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infantile haemangiomas (strawberry birthmarks) of the skin<br/> <b>Setting:</b> all settings (outpatient care)<br/> <b>Intervention:</b> topical timolol maleate<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with topical timolol maleate</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance, as assessed by a clinician at any follow‐up</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>A subjective measure of improvement, as assessed by the parent or child, at any follow‐up</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events experienced at short or long term ‐</b> </p> <p>Serious cardiovascular adverse events ‐ bradycardia</p> <p>24 weeks' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events of bradycardia reported in <a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a>. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other measures of resolution, as assessed by a clinician, at any follow‐up ‐</b> no redness </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>369 per 1000<br/> (50 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 8.11</b><br/> (1.09 to 60.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of parents who consider their child still has a problem, at any follow‐up</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of children who consider they still have a problem, at any follow‐up ‐</b> not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up ‐</b> not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group (the event rate in the single study) and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by two levels for imprecision (low number of participants and events).<br/> <sup>2</sup>Downgraded by two levels for imprecision (wide confidence interval around the estimate of the effect and low number of participants and events). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006545-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oral propranolol compared to topical timolol for infantile haemangiomas of the skin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral propranolol compared to topical timolol maleate for infantile haemangiomas (strawberry birthmarks) of the skin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infantile haemangiomas (strawberry birthmarks) of the skin<br/> <b>Setting:</b> all settings (outpatient care)<br/> <b>Intervention:</b> oral propranolol<br/> <b>Comparison:</b> topical timolol maleate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with topical timolol maleate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral propranolol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance, as assessed by a clinician at any follow‐up</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>A subjective measure of improvement, as assessed by the parent or child, at any follow‐up</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events experienced at short or long term ‐</b> general adverse events </p> <p>24 weeks' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 7.00</b><br/> (0.40 to 123.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>VERY LOW</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were 3 events in the oral propranolol group and no events in the topical timolol maleate group. Due to no events in the control group, absolute events could not be calculated. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other measures of resolution, as assessed by a clinician, at any follow‐up ‐</b> size reduction ≥ 50% </p> <p>24 weeks' follow up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>615 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>695 per 1000<br/> (394 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b><br/> (0.64 to 1.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of parents who consider their child still has a problem, at any follow‐up</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of children who consider they still have a problem, at any follow‐up</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group (the event rate in the single study) and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by three levels: one level due to unclear risk of selection and performance bias and two levels for imprecision (wide confidence interval around the estimate of the effect and low number of participants and events).<br/> <sup>2</sup>Downgraded by two levels: one level due to unclear risk of selection and performance bias and one level for imprecision (small sample size). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006545-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006545-sec-0030"></div> <p>Please refer to the following website for definitions of technical terms: <a href="https://www.ncbi.nlm.nih.gov/mesh" target="_blank">www.ncbi.nlm.nih.gov/mesh</a>. </p> <section id="CD006545-sec-0031"> <h3 class="title" id="CD006545-sec-0031">Description of the condition</h3> <p>Infantile haemangiomas (IH) are the most common vascular tumours among children, occurring in 3% to 10% of infants (<a href="./references#CD006545-bbs2-0139" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine2015;372(8):735‐46. [PUBMED: 25693013] ">Léauté‐Labrèze 2015</a>). They were previously known as 'strawberry birthmarks' or 'strawberry naevi', or 'capillary haemangiomas', terms currently withdrawn by current classifications about vascular tumours (<a href="http://www.issva.org/classification" target="_blank">www.issva.org/classification</a>). They are benign and of endothelial cellular origin, characterised by a rapid pattern of propagation in the first months of life, then followed by a period of involution that can take several years (<a href="./references#CD006545-bbs2-0093" title="BrucknerAL , FriedenIJ . Infantile hemangiomas. Journal of the American Academy of Dermatology2006;55(4):671‐82. [PUBMED: 17010748] ">Bruckner 2006</a>). Sometimes the IH is characterised by a precursor lesion at birth. Infantile haemangiomas undergo a phase of rapid growth within the first few months of the first year (<a href="./references#CD006545-bbs2-0089" title="BaselgaE , RoeE , CoulieJ , MunozFZ , BoonLM , McCuaigC , et al. Risk factors for degree and type of sequelae after involution of untreated hemangiomas of infancy. JAMA Dermatology2016;152(11):1239‐43. [PUBMED: 27540637] ">Baselga 2016</a>; <a href="./references#CD006545-bbs2-0161" title="WangC , LiY , XiangB , XiongF , LiK , YangK , et al. Quality of life in children with infantile hemangioma: a case control study. Health and Quality of Life Outcomes2017;15(1):221. [PUBMED: 29145889] ">Wang 2017</a>). Regression is completed in 60% of patients by their fourth birthday, 76% by their seventh birthday, and approximately 90% by their ninth birthday (<a href="./references#CD006545-bbs2-0166" title="ZimmermannAP , WiegandS , WernerJA , EivaziB . Propranolol therapy for infantile haemangiomas: review of the literature. International Journal of Pediatric Otorhinolaryngology2010;74(4):338‐42. [PUBMED: 20117846] ">Zimmermann 2010</a>). However, it has been observed in some retrospective studies that the complete regression has been achieved at 3.5 years (<a href="./references#CD006545-bbs2-0089" title="BaselgaE , RoeE , CoulieJ , MunozFZ , BoonLM , McCuaigC , et al. Risk factors for degree and type of sequelae after involution of untreated hemangiomas of infancy. JAMA Dermatology2016;152(11):1239‐43. [PUBMED: 27540637] ">Baselga 2016</a>), and also at four years of follow‐up (<a href="./references#CD006545-bbs2-0103" title="DarrowDH , GreeneAK , ManciniAJ , NopperAJ . Diagnosis and management of infantile hemangioma. Pediatrics2015;136(4):e1060‐104. [PUBMED: 26416931] ">Darrow 2015</a>). While most lesions develop in a straightforward way, about 12% of cases result in clinically significant complications requiring referral (<a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>). In addition, IH can result in lifelong sequelae, which can cause psychological distress (<a href="./references#CD006545-bbs2-0139" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine2015;372(8):735‐46. [PUBMED: 25693013] ">Léauté‐Labrèze 2015</a>). More than 50% of untreated IH leave permanent sequelae that may cause disfigurement (<a href="./references#CD006545-bbs2-0089" title="BaselgaE , RoeE , CoulieJ , MunozFZ , BoonLM , McCuaigC , et al. Risk factors for degree and type of sequelae after involution of untreated hemangiomas of infancy. JAMA Dermatology2016;152(11):1239‐43. [PUBMED: 27540637] ">Baselga 2016</a>). Bauland and colleagues found residual lesions in 69% of 137 IH studied (<a href="./references#CD006545-bbs2-0090" title="BaulandCG , LuningTH , SmitJM , ZeebregtsCJ , SpauwenPH . Untreated hemangiomas: growth pattern and residual lesions. Plastic and Reconstructive Surgery2011;127(4):1643‐8. [PUBMED: 21460670] ">Bauland 2011</a>), and Baselga and colleagues in 54.9% out of 184 IH studied (<a href="./references#CD006545-bbs2-0089" title="BaselgaE , RoeE , CoulieJ , MunozFZ , BoonLM , McCuaigC , et al. Risk factors for degree and type of sequelae after involution of untreated hemangiomas of infancy. JAMA Dermatology2016;152(11):1239‐43. [PUBMED: 27540637] ">Baselga 2016</a>). </p> <p>Infantile haemangiomas appear more commonly among Caucasians (understood to be white individuals), being evident in up to 12% of all children (<a href="./references#CD006545-bbs2-0166" title="ZimmermannAP , WiegandS , WernerJA , EivaziB . Propranolol therapy for infantile haemangiomas: review of the literature. International Journal of Pediatric Otorhinolaryngology2010;74(4):338‐42. [PUBMED: 20117846] ">Zimmermann 2010</a>). Infantile haemangiomas affect females in a ratio of 3:1 (<a href="./references#CD006545-bbs2-0166" title="ZimmermannAP , WiegandS , WernerJA , EivaziB . Propranolol therapy for infantile haemangiomas: review of the literature. International Journal of Pediatric Otorhinolaryngology2010;74(4):338‐42. [PUBMED: 20117846] ">Zimmermann 2010</a>). Sixty per cent of IH are located in the head and neck area, whereas 25% occur on the trunk and 15% on the extremities (<a href="./references#CD006545-bbs2-0166" title="ZimmermannAP , WiegandS , WernerJA , EivaziB . Propranolol therapy for infantile haemangiomas: review of the literature. International Journal of Pediatric Otorhinolaryngology2010;74(4):338‐42. [PUBMED: 20117846] ">Zimmermann 2010</a>). Infantile haemangiomas can be divided by their morphology into superficial haemangiomas, subcutaneous (deep) haemangiomas, and mixed haemangiomas (<a href="http://www.issva.org/classification" target="_blank">www.issva.org/classification</a>) (<a href="./references#CD006545-bbs2-0152" title="SethuramanG , YenamandraVK , GuptaV . Management of infantile hemangiomas: current trends. Journal of cutaneous and aesthetic surgery2014;7(2):75‐85. [PUBMED: 25136206] ">Sethuraman 2014</a>). Superficial haemangiomas appear as a bright‐red vascular plaque with an irregular surface. Subcutaneous or deep haemangiomas present as protruding vascular swelling under normal or bluish skin. Mixed or combined haemangiomas show a combination of both superficial and deep characteristics. Infantile haemangiomas usually present as single lesions, although 20% of affected infants develop multiple tumours (<a href="./references#CD006545-bbs2-0158" title="van derKerkhofPCM , deRooijM , SteijlenPM . Spontaneous course of haemangiomas: facts and speculations. International Journal of Dermatology1998;37(2):101‐2. ">van de Kerkhof 1998</a>; <a href="./references#CD006545-bbs2-0166" title="ZimmermannAP , WiegandS , WernerJA , EivaziB . Propranolol therapy for infantile haemangiomas: review of the literature. International Journal of Pediatric Otorhinolaryngology2010;74(4):338‐42. [PUBMED: 20117846] ">Zimmermann 2010</a>). The skin covering haemangiomas may become ulcerated, exposing the underlying blood vessels and making them more liable to bleed from minor trauma and become infected, </p> <p>Infantile haemangiomas are not normally present at birth, or they are present only as a precursive mark, in the form of a pink macule, telangiectatic patches, or areas that appear bruised (<a href="./references#CD006545-bbs2-0159" title="Vega MataN , Lopez GutierrezJC , Vivanco AllendeB , Fernandez GarciaMS . Different clinical features of acral abortive hemangiomas. Case Reports in Dermatological Medicine2017;2017:2897617. [PUBMED: 28785492] ">Vega 2017</a>). Infantile haemangiomas generally proliferate during the first year of life, with most growth being completed by age six to nine months. Eighty per cent of haemangioma growth is completed by age three months, and 80% of haemangiomas have completed growth by age five months (<a href="./references#CD006545-bbs2-0157" title="TollefsonMM , FriedenIJ . Early growth of infantile hemangiomas: what parents' photographs tell us. Pediatrics2012;130(2):e314‐20. [PUBMED: 22826568] ">Tollefson 2012</a>). Despite the self limiting nature of most IH, several complications have been observed, including bleeding, ulceration and infection, deformation and disfigurement, impairment of vision, and airway obstruction (<a href="./references#CD006545-bbs2-0084" title="AchauerBM , ChangCJ , Vander KamVM . Management of hemangioma of infancy: review of 245 patients. Plastic &amp; Reconstructive Surgery1997;99(5):1301‐8. ">Achauer 1997</a>; <a href="./references#CD006545-bbs2-0156" title="SyedSB . Vascular birthmarks: update on presentation and management. Current Paediatrics1999;9(1):20‐6. ">Syed 1999</a>). Children under the age of three are seldom aware of their haemangiomas. Most IH resolve spontaneously; however, when they cause complications, they can be dangerous or present a risk to a person's life. </p> <p>The diagnosis of an IH is typically made clinically, based on its appearance and characteristic behaviour. When there is doubt in the diagnosis, additional studies such as Doppler ultrasound or skin biopsy may be performed (<a href="./references#CD006545-bbs2-0127" title="HollandKE , DroletBA . Approach to the patient with an infantile hemangioma. Dermatologic Clinics2013;31(2):289‐301. [PUBMED: 23557656] ">Holland 2013</a>). </p> <p>Studies have shown that blood vessel cells (positive for glucose transporter 1 (GLUT1)) in IH are similar to those found in the placenta (<a href="./references#CD006545-bbs2-0140" title="MaEH , RobertsonSJ , ChowCW , BekhorPS . Infantile hemangioma with minimal or arrested growth: further observations on clinical and histopathologic findings of this unique but underrecognized entity. Pediatric Dermatology2017;34(1):64‐71. [PUBMED: 27873347] ">Ma 2017</a>); this has raised the possibility that placental cells may become dislodged during pregnancy, travel into the foetus, and grow postnatally to form a haemangioma (<a href="./references#CD006545-bbs2-0140" title="MaEH , RobertsonSJ , ChowCW , BekhorPS . Infantile hemangioma with minimal or arrested growth: further observations on clinical and histopathologic findings of this unique but underrecognized entity. Pediatric Dermatology2017;34(1):64‐71. [PUBMED: 27873347] ">Ma 2017</a>). Some mechanisms have been studied in the pathogenesis of infantile haemangiomas such as tissue hypoxia and pathologic vasculogenesis leading to endothelial cell proliferation (<a href="./references#CD006545-bbs2-0140" title="MaEH , RobertsonSJ , ChowCW , BekhorPS . Infantile hemangioma with minimal or arrested growth: further observations on clinical and histopathologic findings of this unique but underrecognized entity. Pediatric Dermatology2017;34(1):64‐71. [PUBMED: 27873347] ">Ma 2017</a>). Predisposing factors have also been described in some studies, including low birth weight, advanced maternal age, multiple gestations, pre‐eclampsia, and gestational diabetes mellitus (<a href="./references#CD006545-bbs2-0094" title="CastrenE , SalminenP , GisslerM , StefanovicV , PitkarantaA , KlockarsT . Risk factors and morbidity of infantile haemangioma: preterm birth promotes ulceration. Acta Paediatrica2016;105(8):940‐5. [PUBMED: 27146410] ">Castren 2016</a>). Infantile haemangiomas have also been more frequently noted in children whose mothers had chorionic villus sampling (CVS) compared with the general population (<a href="./references#CD006545-bbs2-0133" title="KaplanP , NormandinJJr , WilsonGN , PlauchiH , LippmanA , VekemansM . Malformations and minor anomalies in children whose mothers had prenatal diagnosis: comparison between CVS and amniocentesis. American Journal of Medical Genetics1990;37(3):366‐70. [PUBMED: 2260567] ">Kaplan 1990</a>). </p> <p>Management of IH can be challenging. Each option involves significant drawbacks or side effects, or both. Although most haemangiomas are self limited and do not need treatment, some indications for treatment include the following: high‐output cardiac failure, bleeding, ulceration, risk of permanent disfigurement, or airway or visual obstruction. Location, age of the patient, risk of complications, and growth rate are all factors that physicians must consider in managing patients with IH (<a href="./references#CD006545-bbs2-0127" title="HollandKE , DroletBA . Approach to the patient with an infantile hemangioma. Dermatologic Clinics2013;31(2):289‐301. [PUBMED: 23557656] ">Holland 2013</a>). </p> <p>Recently, <a href="./references#CD006545-bbs2-0139" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine2015;372(8):735‐46. [PUBMED: 25693013] ">Léauté‐Labrèze 2015</a> described their chance observation of an antiproliferative effect of propranolol (PR) on IH. Since the introduction of propranolol in 2008, this drug has showed a highly effective profile with tolerable adverse events, in comparison with previous recommended interventions used for IH (e.g. steroids, interferon, chemotherapy) (<a href="./references#CD006545-bbs2-0167" title="ZouHX , JiaJ , ZhangWF , SunZJ , ZhaoYF . Propranolol inhibits endothelial progenitor cell homing: a possible treatment mechanism of infantile hemangioma. Cardiovascular Pathology2013;22(3):203‐10. [PUBMED: 23151525] ">Zou 2013</a>). Minimal or no side effects have been reported with propranolol, and the response rate has approached 100% (<a href="./references#CD006545-bbs2-0139" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine2015;372(8):735‐46. [PUBMED: 25693013] ">Léauté‐Labrèze 2015</a>). Propranolol is now the first‐line treatment for IH and has been approved for this indication (<a href="./references#CD006545-bbs2-0089" title="BaselgaE , RoeE , CoulieJ , MunozFZ , BoonLM , McCuaigC , et al. Risk factors for degree and type of sequelae after involution of untreated hemangiomas of infancy. JAMA Dermatology2016;152(11):1239‐43. [PUBMED: 27540637] ">Baselga 2016</a>; <a href="./references#CD006545-bbs2-0096" title="ChinnaduraiS , SatheNA , SurawiczT . Laser treatment of infantile hemangioma: A systematic review. Lasers in Surgery &amp; Medicine2016;48(3):221‐233. [PUBMED: 26711436] ">Chinnadurai 2016a</a>). </p> </section> <section id="CD006545-sec-0032"> <h3 class="title" id="CD006545-sec-0032">Description of the intervention</h3> <p>The diagnosis of an IH is typically made clinically, based on appearance and characteristic behaviour. When the diagnosis is uncertain, additional tests such as a Doppler ultrasound or skin biopsy may be performed (<a href="./references#CD006545-bbs2-0127" title="HollandKE , DroletBA . Approach to the patient with an infantile hemangioma. Dermatologic Clinics2013;31(2):289‐301. [PUBMED: 23557656] ">Holland 2013</a>). The vast majority of infantile haemangiomas will regress on their own and require no further treatment; therefore, an active monitoring approach is usually implemented (<a href="./references#CD006545-bbs2-0103" title="DarrowDH , GreeneAK , ManciniAJ , NopperAJ . Diagnosis and management of infantile hemangioma. Pediatrics2015;136(4):e1060‐104. [PUBMED: 26416931] ">Darrow 2015</a>). However, IH can occur in high‐risk areas, such as near the eyes, throat, and nose, impairing their function. If vision is obscured at a critical stage in brain development, complications such as failure to develop binocular vision can result (<a href="./references#CD006545-bbs2-0103" title="DarrowDH , GreeneAK , ManciniAJ , NopperAJ . Diagnosis and management of infantile hemangioma. Pediatrics2015;136(4):e1060‐104. [PUBMED: 26416931] ">Darrow 2015</a>). A large variety of treatments have been used historically, and many are still in use. </p> <p>Beta blockers, for example oral propranolol, are the current standard care, approved both by the US Food and Drug Administration and the European Medicines Agency, with complete regression without sequelae after six months of treatment in 60% of cases (<a href="./references#CD006545-bbs2-0103" title="DarrowDH , GreeneAK , ManciniAJ , NopperAJ . Diagnosis and management of infantile hemangioma. Pediatrics2015;136(4):e1060‐104. [PUBMED: 26416931] ">Darrow 2015</a>). Propranolol has also been assessed for intralesional and topical administration (<a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a>). The recommended dose of propranolol in oral administration is 3 mg/kg/day divided into two doses, for at least six months (<a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>). Reported adverse effects include hypoglycaemia, bradycardia, hypotension, bronchospasm, sleep disturbance, and gastrointestinal disorders (<a href="./references#CD006545-bbs2-0132" title="JiY , ChenS , XuC , LiL , XiangB . The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. British Journal of Dermatology2015;172(1):24‐32. [PUBMED: 25196392] ">Ji 2015</a>). Propranolol interacts with other medications such as insulin, non‐steroidal anti‐inflammatories, antiarrhythmics, and calcium channel blockers (<a href="./references#CD006545-bbs2-0127" title="HollandKE , DroletBA . Approach to the patient with an infantile hemangioma. Dermatologic Clinics2013;31(2):289‐301. [PUBMED: 23557656] ">Holland 2013</a>). In practice, when medication is warranted for infantile haemangioma, propranolol is the first‐choice drug. Parents and healthcare professionals must monitor infants closely for adverse effects (<a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>). </p> <p>In addition, topical timolol maleate, a non‐selective beta blocker, is available in a 0.25% and 0.5% solution, as well as an extended release 0.5% (5 mg/mL) gel‐forming solution. Frequency and method of application have varied from once daily under occlusion to twice daily without occlusion; 1 to 2 drops have typically been used and are usually given for 2 to 6 months (<a href="./references#CD006545-bbs2-0165" title="ZhengL , LiY . Effect of topical timolol on response rate and adverse events in infantile hemangioma: a meta‐analysis. Archives of Dermatological Research 2018 Jan 23 [Epub ahead of print]. [DOI: 10.1007/s00403‐018‐1815‐y] ">Zheng 2018</a>). Adverse effects of timolol maleate in the paediatric population, especially in high‐risk premature infants, include bradycardia and bronchospasm (<a href="./references#CD006545-bbs2-0127" title="HollandKE , DroletBA . Approach to the patient with an infantile hemangioma. Dermatologic Clinics2013;31(2):289‐301. [PUBMED: 23557656] ">Holland 2013</a>). </p> <p>The following other treatments besides oral propranolol and topical timolol maleate have been assessed and might still be in use (<a href="./references#CD006545-bbs2-0112" title="GlassbergE , LaskG , RabinowitzLG , TunnessenWWJr . Capillary hemangiomas: case study of novel laser treatment and a review of therapeutic options. Journal of Dermatologic Surgery &amp; Oncology1989;15(11):1214‐23. [PUBMED: 2808890] ">Glassberg 1989</a>). </p> <p> <ul id="CD006545-list-0001"> <li> <p><b>Atenolol</b> is a cardioselective beta blocker; it is a large, lipophobic molecule and has limited ability to cross the blood–brain barrier (<a href="./references#CD006545-bbs2-0091" title="BayartCB , TamburroJE , VidimosAT , WangL , GoldenAB . Atenolol Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase: A Retrospective Noninferiority Study. Pediatric dermatology2017;34(4):413‐21. [PUBMED: 28556385] ">Bayart 2017</a>). Its use may sometimes be preferred if patients experience side effects with propranolol. Treatment with atenolol is recommended in an oral dose of 1 mg/kg/day for three to six months, depending on the positive response or the presence of adverse events such as bradycardia, hypotension, dizziness, and lethargy (<a href="./references#CD006545-bbs2-0001" title="Abarzua‐ArayaA , Navarrete‐DechentCP , HeusserF , RetamalJ , Zegpi‐TruebaMS . Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. Journal of the American Academy of Dermatology2014;70(6):1045‐9. [CENTRAL: CN‐00993183; PUBMED: 24656727] ">Abarzua‐Araya 2014</a>; <a href="./references#CD006545-bbs2-0149" title="RaphaelMF , deGraafM , BreugemCC , PasmansSG , BreurJM . Atenolol: a promising alternative to propranolol for the treatment of hemangiomas. Journal of the American Academy of Dermatology2011; Vol. 65, issue 2:420‐1. [PUBMED: 21763565] ">Raphael 2011</a>). Some interactions with other medicaments have been suggested, including verapamil, clonidine, and ibuprofen (<a href="./references#CD006545-bbs2-0105" title="DoshanHD , RosenthalRR , BrownR , SlutskyA , ApplinWJ , CarusoFS . Celiprolol, atenolol and propranolol: a comparison of pulmonary effects in asthmatic patients. Journal of cardiovascular pharmacology1986;8 Suppl 4:S105‐8. [PUBMED: 2427836] ">Doshan 1986</a>; <a href="./references#CD006545-bbs2-0125" title="HanssonL , AbergH , KarlbergBE , WesterlundA . Controlled study of atenolol in treatment of hypertension. British medical journal1975;2(5967):367‐70. [PUBMED: 236810] ">Hansson 1975</a>). </p> </li> <li> <p><b>Bleomycin</b>, a well‐known anticancer and sclerosing agent, has been used to treat haemangiomas (<a href="./references#CD006545-bbs2-0138" title="LuoQF , ZhaoFY . The effects of Bleomycin A5 on infantile maxillofacial haemangioma. Head &amp; face medicine2011;7:11. [PUBMED: 21736714] ">Luo 2011</a>). Recommended dosage and duration of treatment depends on the age of the patient and the size of the lesion. Some clinicians have used a standard injection of bleomycin of 0.3 to 0.6 mg/kg per injection, and others have used a mixture of 5 mL 2% lidocaine, 5 mg dexamethasone, and 8 mg bleomycin A5 (<a href="./references#CD006545-bbs2-0146" title="PienaarC , GrahamR , GeldenhuysS , HudsonDA . Intralesional bleomycin for the treatment of hemangiomas. Plastic and reconstructive surgery2006;117(1):221‐6. [PUBMED: 16404271] ">Pienaar 2006</a>). Some documented adverse events for this agent include oedema and ulceration (<a href="./references#CD006545-bbs2-0138" title="LuoQF , ZhaoFY . The effects of Bleomycin A5 on infantile maxillofacial haemangioma. Head &amp; face medicine2011;7:11. [PUBMED: 21736714] ">Luo 2011</a>). No interactions with other drugs have been reported. </p> </li> <li> <p><b>Captopril</b>, an angiotensin‐converting enzyme inhibitor, has been suggested for potential use in the treatment of IH, due to its effects in inhibition of angiogenesis and vasculogenesis (<a href="./references#CD006545-bbs2-0098" title="ChristouEM , WargonO . Effect of captopril on infantile haemangiomas: a retrospective case series. The Australasian journal of dermatology2012;53(3):216‐8. [PUBMED: 22671578] ">Christou 2012</a>). Dosage and duration of administration have not yet been standardised; Zaher and colleagues used oral captopril at 0.5 to 1 mg/kg/day, in a titrating dose, while Tan and colleagues used a dose of 0.1 to 0.5 mg/kg under response (<a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>; <a href="./references#CD006545-bbs2-0025" title="ZaherH , RasheedH , El‐KomyMM , HegazyRA , GawdatHI , Abdel HalimDM , et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial. Journal of the American Academy of Dermatology2016;74(3):499‐505. [CENTRAL: CN‐01138323; PUBMED: 26685718] ">Zaher 2016</a>). Cardiac side effects requiring dose reduction or suspension have been documented for its use in IH (<a href="./references#CD006545-bbs2-0025" title="ZaherH , RasheedH , El‐KomyMM , HegazyRA , GawdatHI , Abdel HalimDM , et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial. Journal of the American Academy of Dermatology2016;74(3):499‐505. [CENTRAL: CN‐01138323; PUBMED: 26685718] ">Zaher 2016</a>). Treatments known to have interactions with captopril include aliskiren, everolimus, sirolimus, and lithium (<a href="./references#CD006545-bbs2-0143" title="Medicines.ie . Summary of product characteristics. www.medicines.ie/medicine/15865/SPC/Capoten+25mg+Tablets/#INTERACTIONS (accessed prior to 21 February 2018). ">Medicines.ie 2018</a>). </p> </li> <li> <p><b>High‐intensity focused ultrasound (HIFU)</b> is a non‐invasive surgical option with rapid evolvement in recent years that is mainly used in the management of solid tumours (<a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>). Documented side effects include damage in the focal point, endothelial cell loss, necrosis, and vascular discontinuity (<a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>). Different levels of energy have been used for different purposes, ranging from 2.6 to 4.5 W (<a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>). Lesions in the <a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a> studies were small‐ to medium‐sized (from 0.8 cm x 0.6 cm to 6.0 cm x 5.0 cm). No interactions have been reported. </p> </li> <li> <p><b>Interferon,</b> an inhibitor of angiogenesis, developed as an antiviral agent, has been suggested as a potential intervention for IH (<a href="./references#CD006545-bbs2-0107" title="EzekowitzRA , MullikenJB , FolkmanJ . Interferon alfa‐2a therapy for life‐threatening hemangiomas of infancy. The New England journal of medicine1992;326(22):1456‐63. [PUBMED: 1489383] ">Ezekowitz 1992</a>; <a href="./references#CD006545-bbs2-0115" title="GreinwaldJHJr , BurkeDK , BonthiusDJ , BaumanNM , SmithRJ . An update on the treatment of hemangiomas in children with interferon alfa‐2a. Archives of Otolaryngology ‐ Head and Neck Surgery1999;125(1):21‐7. [PUBMED: 9932582] ">Greinwald 1999</a>), especially for infants with life‐threatening haemangiomas unresponsive to corticosteroids. Some studies have suggested a dosage of interferon alpha‐2b of 3 million units/m² subcutaneously, from daily to 5 times per week for 6 to 24 months (<a href="./references#CD006545-bbs2-0107" title="EzekowitzRA , MullikenJB , FolkmanJ . Interferon alfa‐2a therapy for life‐threatening hemangiomas of infancy. The New England journal of medicine1992;326(22):1456‐63. [PUBMED: 1489383] ">Ezekowitz 1992</a>; <a href="./references#CD006545-bbs2-0115" title="GreinwaldJHJr , BurkeDK , BonthiusDJ , BaumanNM , SmithRJ . An update on the treatment of hemangiomas in children with interferon alfa‐2a. Archives of Otolaryngology ‐ Head and Neck Surgery1999;125(1):21‐7. [PUBMED: 9932582] ">Greinwald 1999</a>). Reported side effects include fever, malaise, transient neutropenia, and liver disease (<a href="./references#CD006545-bbs2-0127" title="HollandKE , DroletBA . Approach to the patient with an infantile hemangioma. Dermatologic Clinics2013;31(2):289‐301. [PUBMED: 23557656] ">Holland 2013</a>). Known interactions of interferon alpha‐2 include use of theophylline, acalabrutinib, and lamivudine, among others (<a href="./references#CD006545-bbs2-0106" title="EMC . Summary of product characteristics. www.medicines.org.uk/emc/medicine/1730/SPC/Roferon‐A+Pre‐Filled+Syringe/#INTERACTIONS (accessed prior to 21 February 2018). ">EMC 2018</a>). </p> </li> <li> <p><b>Methylene blue</b> is an inhibitor of nitric oxide synthase and guanylate cyclase and is used in the management of vasoplegia syndrome, septic shock, hepato‐pulmonary syndrome, and malaria, among others (<a href="./references#CD006545-bbs2-0110" title="GinimugePR , JyothiSD . Methylene blue: revisited. Journal of anaesthesiology, clinical pharmacology2010;26(4):517‐20. [PUBMED: 21547182] ">Ginimuge 2010</a>). This intervention has not been widely evaluated in the management of IH. The mechanism of action of methylene blue in photodynamic therapy has shown effects in the elimination of bacterial agents in superficial and deep excisional wounds, as well as the treatment of resistant plaque psoriasis. Reported adverse effects in high doses include cardiac arrhythmias, coronary vasoconstriction, decreased cardiac output, renal blood flow, and mesenteric blood flow (<a href="./references#CD006545-bbs2-0110" title="GinimugePR , JyothiSD . Methylene blue: revisited. Journal of anaesthesiology, clinical pharmacology2010;26(4):517‐20. [PUBMED: 21547182] ">Ginimuge 2010</a>). As methylene is a monoamine oxidase (MAO) inhibitor, it could interplay with MAO inhibitors as well as selective serotonin reuptake inhibitor (SSRI) to produce serious serotonin toxicity (<a href="./references#CD006545-bbs2-0110" title="GinimugePR , JyothiSD . Methylene blue: revisited. Journal of anaesthesiology, clinical pharmacology2010;26(4):517‐20. [PUBMED: 21547182] ">Ginimuge 2010</a>). </p> </li> <li> <p><b>Imiquimod</b> is an immune‐response modifier (a substance that changes the way the immune system works), which has been used in the management of condyloma, actinic keratoses, and basal cell carcinoma (<a href="./references#CD006545-bbs2-0051" title="McCuaigCC , DuboisJ , PowellJ , BellevilleC , DavidM , RousseauE , et al. A phase II, open‐label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatric Dermatology2009;26(2):203‐12. [PUBMED: 19419474] ">McCuaig 2009</a>). It has been suggested that imiquimod 5% cream, applied once daily for up to 16 weeks, can induce involution of superficial IH (<a href="./references#CD006545-bbs2-0051" title="McCuaigCC , DuboisJ , PowellJ , BellevilleC , DavidM , RousseauE , et al. A phase II, open‐label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatric Dermatology2009;26(2):203‐12. [PUBMED: 19419474] ">McCuaig 2009</a>). Reported side effects of imiquimod include local erythema, crusting, and contact dermatitis (<a href="./references#CD006545-bbs2-0051" title="McCuaigCC , DuboisJ , PowellJ , BellevilleC , DavidM , RousseauE , et al. A phase II, open‐label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatric Dermatology2009;26(2):203‐12. [PUBMED: 19419474] ">McCuaig 2009</a>). </p> </li> <li> <p><b>Laser treatments</b> (including pulsed dye, argon, carbon dioxide, neodymium‐doped yttrium aluminum garnet (Nd:YAG), sequential/concurrent dual‐wavelength laser and erbium) should be considered if there is a contraindication for systemic treatment, such as a history of sensitivity to beta blockers, asthma, renal disease, heart disease, or hypoglycaemia (<a href="./references#CD006545-bbs2-0096" title="ChinnaduraiS , SatheNA , SurawiczT . Laser treatment of infantile hemangioma: A systematic review. Lasers in Surgery &amp; Medicine2016;48(3):221‐233. [PUBMED: 26711436] ">Chinnadurai 2016a</a>; <a href="./references#CD006545-bbs2-0097" title="ChinnaduraiS , SnyderK , SatheN , FonnesbeckC , MoradA , LikisFE , et al. In: Agency for Healthcare Research and Quality, editor(s). Diagnosis and Management of Infantile Hemangioma. Vol. AHRQ Publication No.16‐EHC002‐EF, Rockville MD: Agency for Healthcare Research and Quality, 2016. ">Chinnadurai 2016b</a>). Some reported side effects of laser treatment include purpura, swelling, blisters, hypopigmentation, bleeding, infection, and atrophic or hypertrophic scarring (<a href="./references#CD006545-bbs2-0096" title="ChinnaduraiS , SatheNA , SurawiczT . Laser treatment of infantile hemangioma: A systematic review. Lasers in Surgery &amp; Medicine2016;48(3):221‐233. [PUBMED: 26711436] ">Chinnadurai 2016a</a>; <a href="./references#CD006545-bbs2-0097" title="ChinnaduraiS , SnyderK , SatheN , FonnesbeckC , MoradA , LikisFE , et al. In: Agency for Healthcare Research and Quality, editor(s). Diagnosis and Management of Infantile Hemangioma. Vol. AHRQ Publication No.16‐EHC002‐EF, Rockville MD: Agency for Healthcare Research and Quality, 2016. ">Chinnadurai 2016b</a>). Protocols of administrations are multiple and depend on the laser pulse width, age of the patient, IH anatomical location, cooling materials, and size of the tumour (<a href="./references#CD006545-bbs2-0096" title="ChinnaduraiS , SatheNA , SurawiczT . Laser treatment of infantile hemangioma: A systematic review. Lasers in Surgery &amp; Medicine2016;48(3):221‐233. [PUBMED: 26711436] ">Chinnadurai 2016a</a>; <a href="./references#CD006545-bbs2-0097" title="ChinnaduraiS , SnyderK , SatheN , FonnesbeckC , MoradA , LikisFE , et al. In: Agency for Healthcare Research and Quality, editor(s). Diagnosis and Management of Infantile Hemangioma. Vol. AHRQ Publication No.16‐EHC002‐EF, Rockville MD: Agency for Healthcare Research and Quality, 2016. ">Chinnadurai 2016b</a>). A study recently assessed the concurrent or sequential administration of laser with other potential interventions (<a href="./references#CD006545-bbs2-0017" title="LuJ , KuangX , ZhaoJ , XiangY , HuangJ , ZengQ , et al. Concurrent versus sequential combination of propranolol and dual‐wavelength laser (585 nm and 1064 nm) to treat complicated infantile hemangiomas. International Journal of Clinical and Experimental Medicine2016;9(8):16132‐16138. [EMBASE: 20160650632] ">Lu 2016</a>). Infants require a general anaesthetic for treatment because laser treatment can be painful. Early childhood anaesthesia carries the usual risks of complications associated with anaesthesia and as well as with neurocognitive impairment. </p> </li> <li> <p><b>Oral ibuprofen plus oral paracetamol</b>, as a combination of non‐steroidal anti‐inflammatory and analgesic drugs (NSAIDs), has a role in the management of ulcerated IH located in the head and neck region (<a href="./references#CD006545-bbs2-0022" title="TiwariP , PandeyV , GangopadhyayAN , SharmaSP , GuptaDK . Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. Oral &amp; Maxillofacial Surgery2016;20(1):73‐7. [PUBMED: 26481918] ">Tiwari 2016</a>). Recently, <a href="./references#CD006545-bbs2-0021" title="TawfikAA , AlsharnoubiJ . Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study. Pediatric dermatology2015;32(3):369‐76. [CENTRAL: CN‐01102313; PUBMED: 25740672] ">Tawfik 2015</a> assessed a combination of oral ibuprofen and paracetamol in doses of 10 and 16.2 mg/kg 8‐hourly versus oral propranolol for up to 6 months. </p> </li> <li> <p><b>Radiation therapy</b> has been conventionally used for treating life‐ or function‐threatening haemangiomas that have been unresponsive to treatment with corticosteroids. Side effects of using ionising radiation include blisters, infection, and ulcers, while possible lasting complications include pigmentation restricted to certain areas or hypopigmentation, the creation of scars, soft tissue dysplasia, and the retardation of bone growth (<a href="./references#CD006545-bbs2-0108" title="FraguP , Lemarchand‐VenencieF , BenhamouS , FrançoisP , JeannelD , BenhamouE , et al. Long‐term effects in skin and thyroid after radiotherapy for skin angiomas: a French retrospective cohort study. European Journal of Cancer1991;27(10):1215‐22. [PUBMED: 1835589] ">Fragu 1991</a>; <a href="./references#CD006545-bbs2-0147" title="ProbertJC , ParkerBR . The effects of radiation therapy on bone growth. Radiology1975;114(1):115‐62. [PUBMED: 813276] ">Probert 1975</a>). Radiation therapy for haemangiomas includes ⁹⁰SR‐⁹⁰Y radiation and soft X‐ray radiation. Adverse effects include radionecrosis (acute) and scarring and skin cancer (long term). </p> </li> <li> <p><b>Rapamycin</b> is a macrolide compound with immunosuppression and antiangiogenic activity (<a href="./references#CD006545-bbs2-0136" title="LiB , LiZ , WangP , HuangQ , XuL , HeR , et al. Mammalian target of rapamycin complex 1 signalling is essential for germinal centre reaction. Immunology2017;152(2):276‐86. [PUBMED: 28557002] ">Li 2017</a>). Oral and local administration have been assessed. Reported side effects include hyperlipidaemia, impaired glucose tolerance, anaemia, and acute renal toxicity (<a href="./references#CD006545-bbs2-0136" title="LiB , LiZ , WangP , HuangQ , XuL , HeR , et al. Mammalian target of rapamycin complex 1 signalling is essential for germinal centre reaction. Immunology2017;152(2):276‐86. [PUBMED: 28557002] ">Li 2017</a>). </p> </li> <li> <p><b>Steroids</b> (administered topically, intralesionally, or systemically). Intralesional corticosteroids may be used for the treatment of small haemangiomas, usually involving the facial area. However, many dermatologists prefer systemic corticosteroids for periocular lesions, since intralesional administration has resulted in serious side effects including retinal artery occlusion and eyelid necrosis (<a href="./references#CD006545-bbs2-0154" title="ShorrN , SeiffSR . Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile haemangioma. Ophthalmic Surgery1986;17(4):229‐31. [PUBMED: 3714192] ">Shorr 1986</a>). Prednisolone is the most frequent steroid assessed for management of IH (<a href="./references#CD006545-bbs2-0002" title="AlyMMD , HamzaAF , Abdel KaderHM , SaafanHA , GhazyMS , RagabIA . Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. European Journal of Pediatrics2015;174(11):1503‐9. [CENTRAL: CN‐01106020; PUBMED: 25982338] ">Aly 2015</a>), at a dosage of 2 mg/kg/day for six months. There is an interaction of steroids with concomitant administration of phenytoin, phenobarbital, ephedrine, estrogens, and diuretics (<a href="./references#CD006545-bbs2-0005" title="BaumanNM , McCarterRJ , GuzzettaPC , ShinJJ , OhAK , PreciadoDA , et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngology, Head &amp; Neck Surgery.2014;140(4):323‐30. [CENTRAL: CN‐00988156; PUBMED: 24526257] NCT00967226 . Propranolol versus prednisolone for treatment of symptomatic hemangiomas. clinicaltrials.gov/ct2/show/NCT00967226 (accessed 23 April 2010). ">Bauman 2014</a>). Steroid side effects include growth retardation, increased susceptibility to infectious disease, and hypertension (<a href="./references#CD006545-bbs2-0109" title="GeorgeME , SharmaV , JacobsonJ , SimonS , NopperAJ . Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Archives of Dermatology2004;140(8):963‐9. [PUBMED: 15313812] ">George 2004</a>). Other minor, reversible complications associated with the administration of steroids include haematomas, periocular calcification, and eyelid pigmentation. </p> </li> <li> <p><b>Surgery</b> is indicated for lesions that interfere with function if pharmacologic therapy fails or is contraindicated, as well as where ulceration or bleeding has occurred (<a href="./references#CD006545-bbs2-0137" title="LiangMG , FriedenIJ . Infantile and congenital hemangiomas. Seminars in pediatric surgery2014;23(4):162‐7. [PUBMED: 25241092] ">Liang 2014</a>). Surgical excision might also be used to improve the final cosmetic appearance if loose skin is left after IH regression (<a href="./references#CD006545-bbs2-0155" title="SmolinskiKN , YanAC . Hemangiomas of infancy: clinical and biological characteristics. Clinical Pediatrics2005;44(9):747‐66. [PUBMED: 16327961] ">Smolinski 2005</a>). In addition, cryotherapy can be used for small and flat haemangiomas, in order to accelerate haemangioma involution (shrinkage) (<a href="./references#CD006545-bbs2-0114" title="GrantzowR . [Differential therapy of hemangiomas‐‐when cryotherapy, laser therapy or operation?] [Differentialtherapie von Hamangiomen‐‐Wann Kryo, Laser oder Operation?]. Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress2001;118:521‐4. [PUBMED: 11824311] ">Grantzow 2001</a>). Surgical intervention is commonly used for the correction of scarring as well as removal of residual tissue, but it can be used also for excision of life‐threatening haemangiomas (<a href="./references#CD006545-bbs2-0127" title="HollandKE , DroletBA . Approach to the patient with an infantile hemangioma. Dermatologic Clinics2013;31(2):289‐301. [PUBMED: 23557656] ">Holland 2013</a>). </p> </li> <li> <p><b>Vincristine</b> is a vinca alkaloid that has been assessed in the treatment of IH, especially those IH unaffected by corticosteroids or in patients who cannot bear corticosteroids (<a href="./references#CD006545-bbs2-0111" title="GladeRS , VinsonK , BectonD , BhuttaS , BuckmillerLM . Management of complicated hemangiomas with vincristine/vinblastine: Quantitative response to therapy using MRI. International journal of pediatric otorhinolaryngology2010;74(11):1221‐5. [PUBMED: 20884067] ">Glade 2010</a>). Single weekly doses of 1 to 1.5 mg/m² have been assessed (median of three cycles). Potential serious adverse events included constipation, neuromyopathy,(<a href="./references#CD006545-bbs2-0111" title="GladeRS , VinsonK , BectonD , BhuttaS , BuckmillerLM . Management of complicated hemangiomas with vincristine/vinblastine: Quantitative response to therapy using MRI. International journal of pediatric otorhinolaryngology2010;74(11):1221‐5. [PUBMED: 20884067] ">Glade 2010</a>), and risk associated with placement of the central line (<a href="./references#CD006545-bbs2-0127" title="HollandKE , DroletBA . Approach to the patient with an infantile hemangioma. Dermatologic Clinics2013;31(2):289‐301. [PUBMED: 23557656] ">Holland 2013</a>). </p> </li> <li> <p><b>Active monitoring</b>. This approach has been shown to produce the best cosmetic outcomes for uncomplicated infantile haemangiomas (<a href="./references#CD006545-bbs2-0104" title="DinehartSM , KincannonJ , GeronemusR . Hemangiomas: evaluation and treatment. Dermatologic Surgery2001;27(5):475‐85. [PUBMED: 11359498] ">Dinehart 2001</a>). In general, most haemangiomas resolve spontaneously without significant sequelae and follow‐up can be the clinician's choice (<a href="./references#CD006545-bbs2-0137" title="LiangMG , FriedenIJ . Infantile and congenital hemangiomas. Seminars in pediatric surgery2014;23(4):162‐7. [PUBMED: 25241092] ">Liang 2014</a>). </p> </li> </ul> </p> </section> <section id="CD006545-sec-0033"> <h3 class="title" id="CD006545-sec-0033">How the intervention might work</h3> <section id="CD006545-sec-0034"> <h4 class="title">Propranolol</h4> <p>Propranolol has been to shown to restrict the haemangioma's capillaries, causing a subsequent decrease in blood flow within the tumour. In addition, it has been suggested that propranolol can hinder angiogenesis and encourage apoptosis in IH cells (<a href="./references#CD006545-bbs2-0162" title="WnekA , AndrzejewskaE , KobosJ , TaranK , PrzewratilP . Molecular and immunohistochemical expression of apoptotic proteins Bax, Bcl‐2 and Caspase 3 in infantile hemangioma tissues as an effect of propranolol treatment. Immunology Letters2017;185:27‐31. [PUBMED: 28279700] ">Wnek 2017</a>). Potential mechanisms of action of propranolol include the stimulation of apoptosis in haemangioma endothelial cells through GLUT1 receptor antagonism; the prevention of catecholamine‐induced angiogenesis; the constraint of the renin‐angiotensin axis; and the interruption of signalling pathways that regulate progenitor cells (<a href="./references#CD006545-bbs2-0162" title="WnekA , AndrzejewskaE , KobosJ , TaranK , PrzewratilP . Molecular and immunohistochemical expression of apoptotic proteins Bax, Bcl‐2 and Caspase 3 in infantile hemangioma tissues as an effect of propranolol treatment. Immunology Letters2017;185:27‐31. [PUBMED: 28279700] ">Wnek 2017</a>). In contrast with corticosteroids, propranolol is effective during the proliferative phase of growth. Studies have recently suggested that propranolol administration in IH therapy generates a biological response involving changes in the expression of chosen apoptosis‐regulating factors (<a href="./references#CD006545-bbs2-0162" title="WnekA , AndrzejewskaE , KobosJ , TaranK , PrzewratilP . Molecular and immunohistochemical expression of apoptotic proteins Bax, Bcl‐2 and Caspase 3 in infantile hemangioma tissues as an effect of propranolol treatment. Immunology Letters2017;185:27‐31. [PUBMED: 28279700] ">Wnek 2017</a>). </p> </section> <section id="CD006545-sec-0035"> <h4 class="title">Timolol maleate</h4> <p>Topical timolol hinders IH growth and encourages the regression of superficial IH, although some studies have raised concerns about the effect of systemic absorption, as well side effects such as sleep disturbance (<a href="./references#CD006545-bbs2-0101" title="DanartiR , AriwibowoL , RadionoS , BudiyantoA . Topical timolol maleate 0.5% for infantile hemangioma: its effectiveness compared to ultrapotent topical corticosteroids ‐ a single‐center experience of 278 cases. Dermatology (Basel, Switzerland)2016;232(5):566‐71. [PUBMED: 27592104] ">Danarti 2016</a>). </p> </section> <section id="CD006545-sec-0036"> <h4 class="title">Atenolol</h4> <p>The main effects of atenolol involve the beta‐1 receptors with minor beta‐2 effects (<a href="./references#CD006545-bbs2-0001" title="Abarzua‐ArayaA , Navarrete‐DechentCP , HeusserF , RetamalJ , Zegpi‐TruebaMS . Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. Journal of the American Academy of Dermatology2014;70(6):1045‐9. [CENTRAL: CN‐00993183; PUBMED: 24656727] ">Abarzua‐Araya 2014</a>). Because atenolol does not act on pulmonary beta‐2 receptors, it can be used in infants with pulmonary conditions, including reactive airway disease. Likewise, atenolol does not act on pancreatic beta‐2 receptors and thus does not interfere with regulation of gluconeogenesis, glycogenolysis, and lipolysis (<a href="./references#CD006545-bbs2-0091" title="BayartCB , TamburroJE , VidimosAT , WangL , GoldenAB . Atenolol Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase: A Retrospective Noninferiority Study. Pediatric dermatology2017;34(4):413‐21. [PUBMED: 28556385] ">Bayart 2017</a>). </p> </section> <section id="CD006545-sec-0037"> <h4 class="title">Bleomycin</h4> <p>The action of bleomycin involves a decrease in the production of vascular endothelial cells, as well as the tempering of angiogenesis of the infantile haemangiomas (<a href="./references#CD006545-bbs2-0138" title="LuoQF , ZhaoFY . The effects of Bleomycin A5 on infantile maxillofacial haemangioma. Head &amp; face medicine2011;7:11. [PUBMED: 21736714] ">Luo 2011</a>; <a href="./references#CD006545-bbs2-0148" title="QiuY , LinX , MaG , ChangL , JinY , ChenH , et al. Eighteen cases of soft tissue atrophy after intralesional bleomycin a5 injections for the treatment of infantile hemangiomas: a long‐term follow‐up. Pediatric Dermatology2015;32(2):188‐91. [PUBMED: 25640925] ">Qiu 2015</a>). In addition, its administration has an effect in the G2 and S phases of endothelial cells by inducing DNA deterioration and preventing its reconstruction, resulting in collapse, shrinkage, and fibrosis (<a href="./references#CD006545-bbs2-0138" title="LuoQF , ZhaoFY . The effects of Bleomycin A5 on infantile maxillofacial haemangioma. Head &amp; face medicine2011;7:11. [PUBMED: 21736714] ">Luo 2011</a>; <a href="./references#CD006545-bbs2-0148" title="QiuY , LinX , MaG , ChangL , JinY , ChenH , et al. Eighteen cases of soft tissue atrophy after intralesional bleomycin a5 injections for the treatment of infantile hemangiomas: a long‐term follow‐up. Pediatric Dermatology2015;32(2):188‐91. [PUBMED: 25640925] ">Qiu 2015</a>). </p> </section> <section id="CD006545-sec-0038"> <h4 class="title">Captopril</h4> <p>Because some components of the renin‐angiotensin system (RAS) are expressed in proliferating IH, modulation of downstream products of RAS, including angiotensin‐converting enzymes, could have a role in the treatment of IH (<a href="./references#CD006545-bbs2-0025" title="ZaherH , RasheedH , El‐KomyMM , HegazyRA , GawdatHI , Abdel HalimDM , et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial. Journal of the American Academy of Dermatology2016;74(3):499‐505. [CENTRAL: CN‐01138323; PUBMED: 26685718] ">Zaher 2016</a>). Similar to propranolol, captopril leads to a decrease in vascular endothelial growth factor production via downregulation of angiotensin II (<a href="./references#CD006545-bbs2-0130" title="ItinteangT , BraschHD , TanST , DayDJ . Expression of components of the renin‐angiotensin system in proliferating infantile haemangioma may account for the propranolol‐induced accelerated involution. Journal of plastic, reconstructive &amp; aesthetic surgery : JPRAS2011;64(6):759‐65. [PUBMED: 20870476] ">Itinteang 2011</a>). In addition, captopril can inhibit the effect of kininase II and increase the plasma bradykinin levels (<a href="./references#CD006545-bbs2-0160" title="WaeberB , BrunnerHR , BrunnerDB , CurtetAL , TuriniGA , GavrasH . Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension (Dallas, Tex. : 1979)1980;2(2):236‐42. [PUBMED: 6247269] ">Waeber 1980</a>). </p> </section> <section id="CD006545-sec-0039"> <h4 class="title">High‐intensity focused ultrasound (HIFU)</h4> <p>It has been suggested that the effectiveness of HIFU in the treatment of IH, as well as superficial skin lesions, could be similar to that shown in treating body parts and tumour (<a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>; <a href="./references#CD006545-bbs2-0145" title="OrsiF , ArnoneP , ChenW , ZhangL . High intensity focused ultrasound ablation: a new therapeutic option for solid tumors. Journal of cancer research and therapeutics2010;6(4):414‐20. [PUBMED: 21358073] ">Orsi 2010</a>). High‐intensity focused ultrasound produces coagulative necrosis in a focal point without effects in adjacent structures by means of ultrasonic tissue penetration. Biological effects of HIFU include coagulative necrosis, nuclei damage, membrane disruption, and apoptosis (<a href="./references#CD006545-bbs2-0134" title="KennedyJE . High‐intensity focused ultrasound in the treatment of solid tumours. Nature reviews. Cancer2005; Vol. 5, issue 4:321‐7. [PUBMED: 15776004] ">Kennedy 2005</a>). </p> </section> <section id="CD006545-sec-0040"> <h4 class="title">Interferon</h4> <p>Interferon therapy works by inhibiting locomotion of capillary endothelium in vitro (<a href="./references#CD006545-bbs2-0107" title="EzekowitzRA , MullikenJB , FolkmanJ . Interferon alfa‐2a therapy for life‐threatening hemangiomas of infancy. The New England journal of medicine1992;326(22):1456‐63. [PUBMED: 1489383] ">Ezekowitz 1992</a>). Although research from case series reports indicate similar results for interferon alpha‐2a and interferon alpha‐2b (<a href="./references#CD006545-bbs2-0095" title="ChangE , BoydA , NelsonCC , CrowleyD , LawT , KeoughKM , et al. Successful treatment of infant hemangiomas with interferon alpha‐2b. Journal of Pediatric Hematology/Oncology1997;19(3):237‐244. ">Chang 1997</a>), other research has indicated that the body may produce neutralising antibodies that reduce the efficacy of interferon alpha‐2a as compared to interferon alpha‐2b (<a href="./references#CD006545-bbs2-0087" title="AntonelliG , CurrentiM , TurrizianiO , DianzaniF . Neutralizing antibodies to interferon‐alpha: relative frequency in patients treated with different interferon preparations. Journal of Infectious Diseases1991;163(4):882‐885. ">Antonelli 1991</a>). Earlier research on interferon showed it to have an effect on vascular tumours such as Kaposi's sarcoma (<a href="./references#CD006545-bbs2-0107" title="EzekowitzRA , MullikenJB , FolkmanJ . Interferon alfa‐2a therapy for life‐threatening hemangiomas of infancy. The New England journal of medicine1992;326(22):1456‐63. [PUBMED: 1489383] ">Ezekowitz 1992</a>). </p> </section> <section id="CD006545-sec-0041"> <h4 class="title">Intralesional methylene blue</h4> <p>Feng and colleagues have suggested that methylene has a role in the management of IH due to its endothelial effects by induced thrombosis of the lesion, blocking the vascular supply and accelerating the necrosis of the haemangioma (<a href="./references#CD006545-bbs2-0008" title="FengLL , WangXJ , SunLQ , ZhangZR , MaCH . Clinical observation on efficacy of methylthionine chloride in the treatment of hemangiomas in children. Chinese Journal of Dermatology2000;33(4):284. [CENTRAL: CN‐00843680] ">Feng 2000</a>). </p> </section> <section id="CD006545-sec-0042"> <h4 class="title">Imiquimod</h4> <p>Imiquimod has a pro‐apoptotic and antiangiogenic activity. It activates the immune response system via the Toll‐like receptor‐7 on dendritic cells (<a href="./references#CD006545-bbs2-0129" title="HuL , HuangHZ , LiX , LinXX , LiW . Open‐label nonrandomized left‐right comparison of imiquimod 5% ointment and timolol maleate 0.5% eye drops in the treatment of proliferating superficial infantile hemangioma. Dermatology (Basel, Switzerland)2015;230(2):150‐5. [PUBMED: 25633200] ">Hu 2015</a>; <a href="./references#CD006545-bbs2-0051" title="McCuaigCC , DuboisJ , PowellJ , BellevilleC , DavidM , RousseauE , et al. A phase II, open‐label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatric Dermatology2009;26(2):203‐12. [PUBMED: 19419474] ">McCuaig 2009</a>), resulting in induction of cytokines and interferon‐gamma, as well as matrix metalloproteinase (<a href="./references#CD006545-bbs2-0051" title="McCuaigCC , DuboisJ , PowellJ , BellevilleC , DavidM , RousseauE , et al. A phase II, open‐label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatric Dermatology2009;26(2):203‐12. [PUBMED: 19419474] ">McCuaig 2009</a>). </p> </section> <section id="CD006545-sec-0043"> <h4 class="title">Laser</h4> <p>Lasers generally work by destroying blood vessels in the IH, with the equivalent wavelength of light absorbed by IH haemoglobin (<a href="./references#CD006545-bbs2-0086" title="AndersonRR , ParrishJA . The optics of human skin. Journal of Investigative Dermatology1981;77(1):9‐13. ">Anderson 1981</a>). The light from the laser is transformed into heat, and it is transmitted to the vessel wall, producing coagulation and vessel closure (<a href="./references#CD006545-bbs2-0021" title="TawfikAA , AlsharnoubiJ . Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study. Pediatric dermatology2015;32(3):369‐76. [CENTRAL: CN‐01102313; PUBMED: 25740672] ">Tawfik 2015</a>). Oxyhaemoglobin has been the classic target chromophore for vascular lesions, due to its absorption peaks at 418, 542, and 577 nm. Oxyhaemoglobin contained within vascular lumina absorb the light energy emitted from pulsed dye laser (PDL) devices, minimising collateral damage (<a href="./references#CD006545-bbs2-0151" title="RothfleischJE , KosannMK , LevineVJ , AshinoffR . Laser treatment of congenital and acquired vascular lesions. A review. Dermatologic Clinics2002;20(1):1‐18. [PUBMED: 11859585] ">Rothfleisch 2002</a>). </p> <p>In order to increase the tissue penetration of PDL, the original wavelength of 577 nm, which corresponds to the third absorption peak of oxyhaemoglobin, has been increased over the past decade to 585 nm, and the pulse duration has also been increased from 450 microseconds to 1.5 milliseconds. Cryogen‐cooling devices have been added in order to reduce pain and related adverse events (<a href="./references#CD006545-bbs2-0151" title="RothfleischJE , KosannMK , LevineVJ , AshinoffR . Laser treatment of congenital and acquired vascular lesions. A review. Dermatologic Clinics2002;20(1):1‐18. [PUBMED: 11859585] ">Rothfleisch 2002</a>). </p> <p>Argon laser devices radiate blue‐green light, with emissions between 488 to 514 nanometers on the electromagnetic spectrum (<a href="./references#CD006545-bbs2-0151" title="RothfleischJE , KosannMK , LevineVJ , AshinoffR . Laser treatment of congenital and acquired vascular lesions. A review. Dermatologic Clinics2002;20(1):1‐18. [PUBMED: 11859585] ">Rothfleisch 2002</a>). Argon laser energy is emitted by a continuous beam, which penetrates tissue at a depth of 1 mm to 2 mm. Emissions are absorbed mainly by oxyhaemoglobin, although epidermal and dermal melanin also have a degree of absorption (<a href="./references#CD006545-bbs2-0151" title="RothfleischJE , KosannMK , LevineVJ , AshinoffR . Laser treatment of congenital and acquired vascular lesions. A review. Dermatologic Clinics2002;20(1):1‐18. [PUBMED: 11859585] ">Rothfleisch 2002</a>). The popularity of the argon laser has markedly declined over the past decade because of its associated limitations and the development of the pulse dye laser (<a href="./references#CD006545-bbs2-0151" title="RothfleischJE , KosannMK , LevineVJ , AshinoffR . Laser treatment of congenital and acquired vascular lesions. A review. Dermatologic Clinics2002;20(1):1‐18. [PUBMED: 11859585] ">Rothfleisch 2002</a>). </p> <p>Carbon dioxide laser emits light in the infrared spectrum (10,600 nm), which is primarily absorbed by water molecules. Its action involves the excision or debulking of vascular tissue or actinically damaged facial skin (<a href="./references#CD006545-bbs2-0085" title="Al BuainianH , VerhaegheE , DierckxsensL , NaeyaertJM . Early treatment of hemangiomas with lasers. A review. Dermatology (Basel, Switzerland)2003;206(4):370‐3. [PUBMED: 12771489] ">Al 2003</a>; <a href="./references#CD006545-bbs2-0135" title="Krupa ShankarD , ChakravarthiM , ShilpakarR . Carbon dioxide laser guidelines. Journal of cutaneous and aesthetic surgery2009;2(2):72‐80. [PUBMED: 20808594] ">Krupa 2009</a>). </p> <p>Neodymium‐doped yttrium aluminum garnet (Nd:YAG) laser has been reported to have a weaker melanin absorption and a deeper effect on lesions (<a href="./references#CD006545-bbs2-0151" title="RothfleischJE , KosannMK , LevineVJ , AshinoffR . Laser treatment of congenital and acquired vascular lesions. A review. Dermatologic Clinics2002;20(1):1‐18. [PUBMED: 11859585] ">Rothfleisch 2002</a>). In addition, Nd:YAG has a high absorption coefficient of methaemoglobin and deoxyhaemoglobin, both of which are major parts of blue veins. Due to the long pulsed duration feature, Nd:YAG has a slower and more uniformed heat effect in the IH vessels, which generates coagulation without rupturing the vessel or causing purpura or hyperpigmentation (<a href="./references#CD006545-bbs2-0151" title="RothfleischJE , KosannMK , LevineVJ , AshinoffR . Laser treatment of congenital and acquired vascular lesions. A review. Dermatologic Clinics2002;20(1):1‐18. [PUBMED: 11859585] ">Rothfleisch 2002</a>). </p> <p>Dual‐wavelength laser combines PDL laser with YAG laser, allowing oxygenated haemoglobin to be transformed into methaemoglobin, and significantly increasing the Nd:YAG laser absorption rate. Local heat is reduced by a cooling system of ‐4 °C at the lesion site (<a href="./references#CD006545-bbs2-0017" title="LuJ , KuangX , ZhaoJ , XiangY , HuangJ , ZengQ , et al. Concurrent versus sequential combination of propranolol and dual‐wavelength laser (585 nm and 1064 nm) to treat complicated infantile hemangiomas. International Journal of Clinical and Experimental Medicine2016;9(8):16132‐16138. [EMBASE: 20160650632] ">Lu 2016</a>). </p> <p>The erbium laser (Er:YAG laser) produces a smaller zone of thermal injury, removing the epidermis in two or three passes, compared with the conventional CO<sub>2</sub> resurfacing lasers (<a href="./references#CD006545-bbs2-0142" title="McDanielDH , AshK , LordJ , NewmanJ , ZukowskiM . The erbium: YAG laser: a review and preliminary report on resurfacing of the face, neck, and hands. Aesthetic surgery journal1997;17(3):157‐64. [PUBMED: 19327707] ">McDaniel 1997</a>). The 2940‐nanometre wavelength of erbium produces a collagen absorption peak at 3030 nm (<a href="./references#CD006545-bbs2-0142" title="McDanielDH , AshK , LordJ , NewmanJ , ZukowskiM . The erbium: YAG laser: a review and preliminary report on resurfacing of the face, neck, and hands. Aesthetic surgery journal1997;17(3):157‐64. [PUBMED: 19327707] ">McDaniel 1997</a>). </p> </section> <section id="CD006545-sec-0044"> <h4 class="title">Oral ibuprofen plus oral paracetamol</h4> <p>In general, the mechanism of action of NSAIDs involves the inhibition of prostanoid biosynthesis (<a href="./references#CD006545-bbs2-0083" title="AbramsonS , WeissmannG . The mechanisms of action of nonsteroidal antiinflammatory drugs. Clinical and experimental rheumatology1989;7 Suppl 3:S163‐70. [PUBMED: 2557993] ">Abramson 1989</a>). NSAIDs in combination with analgesics can have a role in the management of ulcerated IH, especially for pain relief (<a href="./references#CD006545-bbs2-0022" title="TiwariP , PandeyV , GangopadhyayAN , SharmaSP , GuptaDK . Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. Oral &amp; Maxillofacial Surgery2016;20(1):73‐7. [PUBMED: 26481918] ">Tiwari 2016</a>). </p> </section> <section id="CD006545-sec-0045"> <h4 class="title">Radiation</h4> <p>Ionising radiation could be preferred due to its low chance of causing local scarring (<a href="./references#CD006545-bbs2-0028" title="ZhuHJ , LiuQ , DengXL , GuanYX . Efficacy of low‐dose 90Sr‐90Y therapy combined with topical application of 0.5% timolol maleate solution for the treatment of superficial infantile hemangiomas. Experimental and Therapeutic Medicine2015;10(3):1013‐8. [PUBMED: 26622431] ">Zhu 2015</a>). In general, the pathophysiology of radiation‐induced changes in the skin involves: 1) a transient early erythema, which remits after 24 to 48 hours; 2) a main erythematous reaction related to the severe loss of epidermal basal cells; 3) a subsequent phase of erythema combined with dermal ischaemia and possible necrosis; and 4) the appearance of dermal atrophy, telangiectasia, and necrosis (<a href="./references#CD006545-bbs2-0128" title="HopewellJW . The skin: its structure and response to ionizing radiation. International journal of radiation biology1990;57(4):751‐73. [PUBMED: 1969905] ">Hopewell 1990</a>). </p> </section> <section id="CD006545-sec-0046"> <h4 class="title">Rapamycin</h4> <p>Rapamycin has been reported to have a superior antihaemangioma activity due to its inhibition of the proliferation of haemangioma endothelial cells and vascular endothelial growth factor production (<a href="./references#CD006545-bbs2-0136" title="LiB , LiZ , WangP , HuangQ , XuL , HeR , et al. Mammalian target of rapamycin complex 1 signalling is essential for germinal centre reaction. Immunology2017;152(2):276‐86. [PUBMED: 28557002] ">Li 2017</a>). </p> </section> <section id="CD006545-sec-0047"> <h4 class="title">Steroids</h4> <p>High‐dose intralesional (injected directly into the lesion) or systemic (whole body) steroid therapies work by stopping the growth of the haemangioma through the promotion of stabilisation or regression, and possibly by softening the lesion (<a href="./references#CD006545-bbs2-0092" title="BennettML , FleischerABJr , ChamlinSL , FriedenIJ . Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence‐based evaluation. Archives of Dermatology2001;137(9):1208‐1213. ">Bennett 2001</a>). </p> </section> <section id="CD006545-sec-0048"> <h4 class="title">Surgery</h4> <p>Surgical management involves removing the haemangioma in order to restore normal facial features (<a href="./references#CD006545-bbs2-0137" title="LiangMG , FriedenIJ . Infantile and congenital hemangiomas. Seminars in pediatric surgery2014;23(4):162‐7. [PUBMED: 25241092] ">Liang 2014</a>). Several techniques have been proposed including circular excision with purse‐string closure (<a href="./references#CD006545-bbs2-0144" title="MullikenJB , RogersGF , MarlerJJ . Circular excision of hemangioma and purse‐string closure: the smallest possible scar. Plastic and reconstructive surgery2002;109(5):1544‐54; discussion 1555. [PUBMED: 11932595] ">Mulliken 2002</a>), as well as single‐stage resection (<a href="./references#CD006545-bbs2-0102" title="DaramolaOO , ChunRH , KerschnerJE . Surgical management of auricular infantile hemangiomas. Archives of otolaryngology‐‐head &amp; neck surgery2012;138(1):72‐5. [PUBMED: 22249633] ">Daramola 2012</a>). </p> </section> <section id="CD006545-sec-0049"> <h4 class="title">Vincristine</h4> <p>Vincristine is thought to act as an antiangiogenic through its effect on vascular endothelial growth factor (<a href="./references#CD006545-bbs2-0088" title="AzzopardiS , WrightTC . Novel strategies for managing infantile hemangiomas: a review. Annals of plastic surgery2012;68(2):226‐8. [PUBMED: 21629088] ">Azzopardi 2012</a>). In addition, vincristine works by reducing the creation of microtubules, triggering mitotic arrest during metaphase, which produces apoptosis of tumour cells in vitro (<a href="./references#CD006545-bbs2-0111" title="GladeRS , VinsonK , BectonD , BhuttaS , BuckmillerLM . Management of complicated hemangiomas with vincristine/vinblastine: Quantitative response to therapy using MRI. International journal of pediatric otorhinolaryngology2010;74(11):1221‐5. [PUBMED: 20884067] ">Glade 2010</a>). </p> </section> <section id="CD006545-sec-0050"> <h4 class="title">Active monitoring</h4> <p>Despite the fact that it is hypothesised that several growth factors (e.g. hormonal, mechanical) are involved in the abnormal proliferation of endothelial cells in IH, the mechanism of action behind haemangiogenesis remains unknown (<a href="./references#CD006545-bbs2-0141" title="MarchukDA . Pathogenesis of hemangioma. Journal of Clinical Investigation2001;107(6):665‐6. [PUBMED: 11254664] ">Marchuk 2001</a>). In addition, most infantile haemangiomas are reported to involute completely by four years of age (<a href="./references#CD006545-bbs2-0099" title="CoutoRA , MaclellanRA , ZurakowskiD , GreeneAK . Infantile hemangioma: clinical assessment of the involuting phase and implications for management. Plastic and reconstructive surgery2012;130(3):619‐24. [PUBMED: 22575857] ">Couto 2012</a>). </p> </section> </section> <section id="CD006545-sec-0051"> <h3 class="title" id="CD006545-sec-0051">Why it is important to do this review</h3> <p>A significant minority of babies (up to 1 in 10) develop infantile haemangiomas (<a href="./references#CD006545-bbs2-0139" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine2015;372(8):735‐46. [PUBMED: 25693013] ">Léauté‐Labrèze 2015</a>). While the majority of IH are non‐problematic and will regress and disappear in five to seven years, a few will become problematic or cause mental distress to children and their parents (<a href="./references#CD006545-bbs2-0100" title="CsomaZR , DalmadyS , AbrahamR , RozsaT , RaczK , KemenyL . Infantile haemangioma: clinical and demographic characteristics, experiences in the treatment [Infantilis haemangioma: klinikai es demografiai jellemzok, kezelesi‐gondozasi tapasztalatok.]. Orvosi Hetilap2017;158(39):1535‐44. [PUBMED: 28942665] ">Csoma 2017</a>). Some IH may also result in complications, including congestive heart failure, lifelong disfigurement, bleeding, ulceration, and visual and airway‐related obstruction (<a href="./references#CD006545-bbs2-0100" title="CsomaZR , DalmadyS , AbrahamR , RozsaT , RaczK , KemenyL . Infantile haemangioma: clinical and demographic characteristics, experiences in the treatment [Infantilis haemangioma: klinikai es demografiai jellemzok, kezelesi‐gondozasi tapasztalatok.]. Orvosi Hetilap2017;158(39):1535‐44. [PUBMED: 28942665] ">Csoma 2017</a>). In such cases, medical intervention with a variety of medical treatments may be necessary. Propranolol therapy has been recommended as the most effective way of treating IH, as it inhibits proliferation and incites regression of IH during the proliferative phase (<a href="./references#CD006545-bbs2-0164" title="ZhangL , WuHW , YuanW , ZhengJW . Propranolol therapy for infantile hemangioma: our experience. Drug Design, Development and Therapy2017;11:1401‐8. [PUBMED: 28507428] ">Zhang 2017</a>). However, other methods may still be in use. It was therefore necessary to review the efficacy and potential adverse events of these interventions for the management of IH. </p> <p>A first assessment of these interventions was published by Leonardi‐Bee in 2011 (<a href="./references#CD006545-bbs2-0168" title="Leonardi‐BeeJ , BattaK , O’BrienC , Bath‐HextallFJ . Interventions for infantile haemangiomas (strawberry birthmarks) of the skin. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD006545.pub2] ">Leonardi‐Bee 2011</a>), reporting information from four trials with limited evidence. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006545-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006545-sec-0052"></div> <p>To assess the effects of interventions for the management of infantile haemangiomas in children. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006545-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006545-sec-0053"></div> <section id="CD006545-sec-0054"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006545-sec-0055"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials.</p> </section> <section id="CD006545-sec-0056"> <h4 class="title">Types of participants</h4> <p>Any child (usually under 24 months) with single or multiple infantile haemangiomas located on the skin. We excluded participants above the age of 18 years. We excluded studies with a mixture of populations (including children and adults) that did not provide separate information for children. In addition, we excluded children with cases of very rare types of haemangiomas (including congenital haemangioma, haemangiomas associated with Kasabach‐Merritt syndrome, and eruptive neonatal haemangiomatosis) and internal haemangiomas. </p> </section> <section id="CD006545-sec-0057"> <h4 class="title">Types of interventions</h4> <p>We considered all types of interventions used in the treatment of infantile haemangiomas. Interventions could be given alone or in combination. The most commonly used interventions include the following. </p> <p> <ul id="CD006545-list-0002"> <li> <p>Beta blockers: propranolol, timolol maleate, and atenolol</p> </li> <li> <p>Lasers: pulsed dye, argon, carbon dioxide, Nd:YAG, and erbium</p> </li> <li> <p>Steroids: administered topically, intralesionally, or systemically</p> </li> <li> <p>Surgery: excision or cryotherapy</p> </li> <li> <p>Other treatments: imiquimod, interferon alpha‐2a, bleomycin, vincristine, and rapamycin (administered topically, intralesionally, orally, or systemically) </p> </li> </ul> </p> <p>Comparators included placebo, active monitoring (i.e. wait‐and‐see), or other interventions (e.g. systemic steroids versus laser therapy). Comparator interventions could be given alone or in combination. </p> </section> <section id="CD006545-sec-0058"> <h4 class="title">Types of outcome measures</h4> <section id="CD006545-sec-0059"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD006545-list-0003"> <li> <p>Clearance, as assessed by a clinician at any follow‐up: proportion of children with lesions completely cleared or with minimal residual signs (defined as faint macular erythema with no palpable component). </p> </li> <li> <p>A subjective measure of improvement, as assessed by the parent or child, at any follow‐up.</p> </li> <li> <p>Adverse events experienced at short (immediately after treatment until 48 hours after) or long term (more than 48 hours after treatment) related to each intervention. These included skin atrophy (scarring where the skin is thinned, with or without depression at the skin surface), skin hypopigmentation (loss of skin pigmentation), and complications (including bleeding, ulceration, infection, deformation, disfigurement, vision impairment, airway obstruction, pain associated with treatment or ulceration, and/or side effects of treatments). We also considered reports of number of adverse events in general, as well as serious/severe adverse events (as defined by trial authors). </p> </li> </ul> </p> </section> <section id="CD006545-sec-0060"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD006545-list-0004"> <li> <p>Other measures of resolution, as assessed by a clinician, at any follow‐up. These included surface area, height or volume of lesion, and redness of lesion, preferably using an objective measure of assessment, such as photographs. </p> </li> <li> <p>Proportion of parents who consider their child still has a problem, at any follow‐up.</p> </li> <li> <p>Proportion of children who consider they still have a problem, at any follow‐up.</p> </li> <li> <p>Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up.</p> </li> <li> <p>Requirement for surgical correction, as assessed by a physician, at any follow‐up.</p> </li> </ul> </p> <section id="CD006545-sec-0061"> <h6 class="title">Timing</h6> <p>We considered data recorded for six months or less from baseline to reflect short‐term benefit, and we analysed these data separately from data recorded after six months' follow‐up, apart from adverse events data, where we considered up to 48 hours from baseline short term. </p> </section> </section> </section> </section> <section id="CD006545-sec-0062"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant randomised controlled trials regardless of language or publication status (published, unpublished, in press, or ongoing). </p> <section id="CD006545-sec-0063"> <h4 class="title">Electronic searches</h4> <p>For this update, we revised our search strategies in line with current Cochrane Skin Group practices. Details of the previous search strategies are available in <a href="./references#CD006545-bbs2-0168" title="Leonardi‐BeeJ , BattaK , O’BrienC , Bath‐HextallFJ . Interventions for infantile haemangiomas (strawberry birthmarks) of the skin. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD006545.pub2] ">Leonardi‐Bee 2011</a>. </p> <p>We searched the following databases up to 22 February 2017:</p> <p> <ul id="CD006545-list-0005"> <li> <p>the Cochrane Skin Group Specialised Register using the search strategy in <a href="./appendices#CD006545-sec-0393">Appendix 1</a>; </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) 2017, Issue 1 in the Cochrane Library using the strategy in <a href="./appendices#CD006545-sec-0394">Appendix 2</a>; </p> </li> <li> <p>MEDLINE via Ovid (from 1946) using the strategy in <a href="./appendices#CD006545-sec-0395">Appendix 3</a>; </p> </li> <li> <p>Embase via Ovid (from 1974) using the strategy in <a href="./appendices#CD006545-sec-0396">Appendix 4</a>; </p> </li> <li> <p>AMED via Ovid (Allied and Complementary Medicine, from 1985) using the strategy in <a href="./appendices#CD006545-sec-0397">Appendix 5</a>; </p> </li> <li> <p>PsycINFO via Ovid (from 1806) using the strategy in <a href="./appendices#CD006545-sec-0398">Appendix 6</a>; </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database, from 1982) using the strategy in <a href="./appendices#CD006545-sec-0399">Appendix 7</a>; and </p> </li> <li> <p>CINAHL via EBSCO (Cumulative Index of Nursing and Allied Health Literature, from 1981) using the strategy in <a href="./appendices#CD006545-sec-0400">Appendix 8</a>. </p> </li> </ul> </p> </section> <section id="CD006545-sec-0064"> <h4 class="title">Searching other resources</h4> <section id="CD006545-sec-0065"> <h5 class="title">Trials registers</h5> <p>On 22 February 2017 we searched the following ongoing trials databases using the terms 'haemangioma', 'hemangioma', 'strawberry', 'naevi', or 'naevus': </p> <p> <ul id="CD006545-list-0006"> <li> <p>ISRCTN register (<a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au" target="_blank">www.anzctr.org.au</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>); and </p> </li> <li> <p>EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/" target="_blank">www.clinicaltrialsregister.eu</a>). </p> </li> </ul> </p> </section> <section id="CD006545-sec-0066"> <h5 class="title">Searching reference lists</h5> <p>We checked the bibliographies of included studies for additional references to relevant trials. </p> </section> <section id="CD006545-sec-0067"> <h5 class="title">Adverse effects</h5> <p>We did not perform a separate search for adverse effects of interventions used for the treatment of infantile haemangiomas. We considered adverse and side effects described in included studies only. </p> </section> </section> </section> <section id="CD006545-sec-0068"> <h3 class="title" id="CD006545-sec-0068">Data collection and analysis</h3> <section id="CD006545-sec-0069"> <h4 class="title">Selection of studies</h4> <p>Two review authors (LG and SB) independently selected eligible studies. Authors reviewed titles and abstracts of all articles identified by the search to assess whether they met the inclusion criteria. The full texts of selected studies were further assessed to confirm their relevance for inclusion in the review. An additional third review author was consulted when disagreements arose (IAR). At any stage of the review, review authors were not blinded to the authors’ names and institutions, journal of publication, or study results. All excluded studies and reasons for their exclusion are listed in the <a href="./references#CD006545-sec-0412" title="">Characteristics of excluded studies</a> tables. </p> </section> <section id="CD006545-sec-0070"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (LG and SB) independently performed data extraction using predesigned data collection spreadsheets. We extracted participant characteristics, methods of randomisation, blinding, comparisons of interest, number of children originally randomised by arm, and follow‐up losses and outcomes. A third review author was consulted when disagreements arose (MN or IAR). We entered extracted data into Review Manager 5 for further analysis (<a href="./references#CD006545-bbs2-0150" title="Nordic Cochrane Centre, The Cochrane Collaboration.. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration., 2014. ">Review Manager 5.3</a>). </p> </section> <section id="CD006545-sec-0071"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>As outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006545-bbs2-0126" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration, 2011. ">Higgins 2011</a>), two review authors (LG and SB) independently assessed risk of bias in included trials. We took six domains into consideration: random sequence generation, blinding of participants and personnel, blinding of outcome assessment, allocation concealment, selective reporting, and other biases. We assessed blinding of participants and blinding of personnel separately, as in most cases this information was partially reported (i.e. study authors reported blinding for participants or for personnel, but not both). We judged each domain to be at low, high, or unclear risk of bias. Disagreements were solved in consultation with a third review author (IAR). We assessed the direction and magnitude of bias, as well as its correlational impact on any findings (<a href="./references#CD006545-bbs2-0126" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration, 2011. ">Higgins 2011</a>). We summarised information in 'Risk of bias' tables in the <a href="./references#CD006545-sec-0411" title="">Characteristics of included studies</a>. </p> </section> <section id="CD006545-sec-0072"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed results as risk ratios (RR) with 95% confidence intervals (CI) for dichotomous outcomes, and difference in means (MD) with 95% CI for continuous outcomes. Transformation of data was not required. </p> </section> <section id="CD006545-sec-0073"> <h4 class="title">Unit of analysis issues</h4> <p>Where there were multiple intervention groups within a trial, we made pair‐wise comparisons of similar active interventions versus no treatment, placebo, or other active intervention. Although we did not find any randomised controlled trials that used cross‐over or internally controlled designs, we would have analysed the former using data only from the first phase pooled, where possible, with parallel‐design studies. For the latter, we would have used appropriate techniques for paired designs without pooling with studies of other designs. </p> </section> <section id="CD006545-sec-0074"> <h4 class="title">Dealing with missing data</h4> <p>In cases where participant dropout led to missing data, we conducted an intention‐to‐treat analysis. For dichotomous outcomes, we regarded children with missing outcome data as treatment failures and included them in the analysis. For continuous outcomes, we would have considered using the last recorded value carried forward for children with missing outcome data; however, these circumstances did not occur. If high levels of missing data were seen within the analyses, we planned to conduct sensitivity analyses to assess the robustness of the results from the approaches described above, by comparing the results with those excluding the missing data from the analyses. However, these circumstances did not occur. </p> </section> <section id="CD006545-sec-0075"> <h4 class="title">Assessment of heterogeneity</h4> <p>We investigated heterogeneity with close visual examination of the forest plots. Additionally, we assessed statistical heterogeneity of effect sizes by means of the I² statistic. The I² statistic is employed to describe the per cent of total variation across all contributing trials due to heterogeneity rather than sampling error (<a href="./references#CD006545-bbs2-0126" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration, 2011. ">Higgins 2011</a>). If we identified signs of heterogeneity (I² &gt; 30%), we performed further exploration by prespecified subgroup analysis; furthermore, if we identified considerable per cent of heterogeneity (I² &gt; 80%), we did not present pooled results. </p> </section> <section id="CD006545-sec-0076"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to use funnel plots, with respect to primary outcomes, to illustrate whether treatment estimates were related to study size or to determine variability among trials in an attempt to detect publication bias. If 10 or more trials are available, extrapolation based on asymmetry is plausible. However, due to scarcity of data in all comparisons, we were unable to perform a full analysis of reporting bias. </p> </section> <section id="CD006545-sec-0077"> <h4 class="title">Data synthesis</h4> <p>For studies with a similar type of active intervention, we performed a meta‐analysis to calculate a weighted treatment effect across trials using a random‐effects (DerSimonian and Laird) model. We planned and carried out statistical analyses using Review Manager 5 (<a href="./references#CD006545-bbs2-0150" title="Nordic Cochrane Centre, The Cochrane Collaboration.. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration., 2014. ">Review Manager 5.3</a>). When it was not possible to perform a meta‐analysis, we presented data narratively. </p> </section> <section id="CD006545-sec-0078"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform a subgroup analysis and to determine interaction tests to check for subgroup differences where meaningful. For the primary outcomes, we considered subgroup analyses for the following factors: </p> <p> <ul id="CD006545-list-0007"> <li> <p>dosage;</p> </li> <li> <p>duration of treatment;</p> </li> <li> <p>types of infantile haemangioma (superficial, deep, mixed, others);</p> </li> <li> <p>location of birthmark (low‐risk or high‐risk areas).</p> </li> </ul> </p> <p>Due to scarcity of data in all comparisons, we were unable to perform a full investigation of heterogeneity. </p> </section> <section id="CD006545-sec-0079"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct sensitivity analyses using trials classified as having low risk of bias in three core domains: allocation concealment, incomplete outcome data, and blinding of outcome assessment, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006545-bbs2-0126" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration, 2011. ">Higgins 2011</a>). However, due to scarcity of data in all comparisons, we were unable to perform a full sensitivity analysis. </p> <section id="CD006545-sec-0080"> <h5 class="title">'Summary of findings' tables</h5> <p>We assessed quality of the body of evidence (also known as certainty in the evidence) pertaining to primary and secondary outcomes using the principles of the GRADE system (<a href="./references#CD006545-bbs2-0116" title='GuyattGH , OxmanAD , KunzR , VistGE , Falck‐YtterY , SchunemannHJ . What is "quality of evidence" and why is it important to clinicians?. BMJ2008;336(7651):995‐8. [PUBMED: 18456631] '>Guyatt 2008</a>). We also constructed 'Summary of findings' tables. Factors taken into consideration in the evaluation of quality of the evidence are study risk of bias, heterogeneity of data, directness of the evidence, precision of effect estimates, and potential publication bias (<a href="./references#CD006545-bbs2-0116" title='GuyattGH , OxmanAD , KunzR , VistGE , Falck‐YtterY , SchunemannHJ . What is "quality of evidence" and why is it important to clinicians?. BMJ2008;336(7651):995‐8. [PUBMED: 18456631] '>Guyatt 2008</a>; <a href="./references#CD006545-bbs2-0117" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence‐‐inconsistency. Journal of Clinical Epidemiology2011;64(12):1294‐302. [PUBMED: 21803546] ">Guyatt 2011a</a>; <a href="./references#CD006545-bbs2-0118" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR , BrozekJ , et al. GRADE guidelines: 5. Rating the quality of evidence‐‐publication bias. Journal of Clinical Epidemiology2011;64(12):1277‐82. [PUBMED: 21802904] ">Guyatt 2011b</a>; <a href="./references#CD006545-bbs2-0119" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 8. Rating the quality of evidence‐‐indirectness. Journal of Clinical Epidemiology2011;64(12):1303‐10. [PUBMED: 21802903] ">Guyatt 2011c</a>; <a href="./references#CD006545-bbs2-0120" title="GuyattGH , OxmanAD , VistG , KunzR , BrozekJ , Alonso‐CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence‐‐study limitations (risk of bias). Journal of Clinical Epidemiology2011;64(4):407‐15. [PUBMED: 21247734] ">Guyatt 2011d</a>; <a href="./references#CD006545-bbs2-0121" title="GuyattGH , OxmanAD , SultanS , GlasziouP , AklEA , Alonso‐CoelloP , et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology2011;64(12):1311‐6. [PUBMED: 21802902] ">Guyatt 2011e</a>; <a href="./references#CD006545-bbs2-0122" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence‐‐imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. [PUBMED: 21839614] ">Guyatt 2011f</a>; <a href="./references#CD006545-bbs2-0123" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. [PUBMED: 21195583] ">Guyatt 2011g</a>; <a href="./references#CD006545-bbs2-0124" title="GuyattGH , OxmanAD , KunzR , AtkinsD , BrozekJ , VistG , et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology2011;64(4):395‐400. [PUBMED: 21194891] ">Guyatt 2011h</a>). We developed the 'Summary of findings' table using a web‐based version of the GRADEpro software (<a href="./references#CD006545-bbs2-0113" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed prior to 27/03/2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT</a>), according to the methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006545-bbs2-0126" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration, 2011. ">Higgins 2011</a>). We selected information about currently used treatments for these 'Summary of findings' tables. </p> <p>We developed 'Summary of findings' tables for the following comparisons:</p> <p> <ul id="CD006545-list-0008"> <li> <p>oral propranolol versus placebo;</p> </li> <li> <p>topical timolol maleate versus placebo;</p> </li> <li> <p>oral propranolol versus topical timolol maleate.</p> </li> </ul> </p> <p>We assessed the quality of the evidence for the following outcomes in these comparisons:</p> <p> <ul id="CD006545-list-0009"> <li> <p>clearance (as assessed by a clinician);</p> </li> <li> <p>subjective measurements of improvement;</p> </li> <li> <p>adverse events;</p> </li> <li> <p>other measures of resolution;</p> </li> <li> <p>proportion of parents who consider their child still has a problem;</p> </li> <li> <p>proportion of children who consider they still have a problem; and</p> </li> <li> <p>aesthetic appearance.</p> </li> </ul> </p> <p>For the outcome 'adverse events', we presented in the corresponding table the most frequent or the most important adverse event, or both, related to each intervention. When information about adverse events in general (including serious/severe adverse events) was available, we presented these results instead of individual findings. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006545-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006545-sec-0081"></div> <section id="CD006545-sec-0082"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD006545-sec-0411" title="">Characteristics of included studies</a> and <a href="./references#CD006545-sec-0412" title="">Characteristics of excluded studies</a>. </p> <section id="CD006545-sec-0083"> <h4 class="title">Results of the search</h4> <p>Our updated searches identified 932 new records in addition to the 128 identified in the first version of this review. From the combined total of 1060 records, we screened out 969 records based on titles and abstracts. We examined the remaining 91 records in full text. From these, we excluded 45 studies (16 identified in the previous version of this review and 29 from this update, see <a href="./references#CD006545-sec-0412" title="">Characteristics of excluded studies</a>). We included 28 studies reported in 37 references (see <a href="./references#CD006545-sec-0411" title="">Characteristics of included studies</a>). We classified seven studies as awaiting assessment (see <a href="./references#CD006545-sec-0413" title="">Characteristics of studies awaiting classification</a>) and two further studies as ongoing (see <a href="./references#CD006545-sec-0414" title="">Characteristics of ongoing studies</a>). For a further description of the screening process, see the study flow diagram (<a href="#CD006545-fig-0001">Figure 1</a>), </p> <div class="figure" id="CD006545-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006545-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD006545-sec-0084"> <h4 class="title">Included studies</h4> <p>Twenty‐eight studies (reported in 37 references) were eligible for inclusion in this updated review. All studies were published. The 28 studies enrolled and randomised a total of 1728 participants. Details of the included studies are provided in the <a href="./references#CD006545-sec-0411" title="">Characteristics of included studies</a> tables. Four of the 28 studies were included in the previous version of this review, with 24 new studies included in this update. </p> <section id="CD006545-sec-0085"> <h5 class="title">Design</h5> <p>A total of 21 studies used a two‐arm design; six used a three‐arm design; and one used a four‐arm, parallel‐group design. </p> </section> <section id="CD006545-sec-0086"> <h5 class="title">Sample sizes</h5> <p>Numbers of children in the studies ranged from 12 in <a href="./references#CD006545-bbs2-0026" title="ZhangL , MaiHM , ZhengJ , ZhengJW , ChenZG , WangYA , et al. Preliminary study on plasma RPN concentration of patients with infantile hemangioma treated with propranolol. International journal of clinical and experimental medicine2013;6(5):342‐5. [CENTRAL: CN‐00906420; PUBMED: 23724152] ">Zhang 2013</a> to 460 in <a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>. Only five studies reported a calculation of sample sizes prior to the beginning of the trial (<a href="./references#CD006545-bbs2-0005" title="BaumanNM , McCarterRJ , GuzzettaPC , ShinJJ , OhAK , PreciadoDA , et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngology, Head &amp; Neck Surgery.2014;140(4):323‐30. [CENTRAL: CN‐00988156; PUBMED: 24526257] NCT00967226 . Propranolol versus prednisolone for treatment of symptomatic hemangiomas. clinicaltrials.gov/ct2/show/NCT00967226 (accessed 23 April 2010). ">Bauman 2014</a>; <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0013" title="KesselsJP , HamersET , OstertagJU . Superficial hemangioma: pulsed dye laser versus wait‐and‐see. Dermatologic Surgery2013;39(3 Pt 1):414‐21. [CENTRAL: CN‐00966183; PUBMED: 23279058] ">Kessels 2013</a>; <a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>; <a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a>). </p> </section> <section id="CD006545-sec-0087"> <h5 class="title">Setting</h5> <p>Studies were conducted in Canada (<a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a>), China (<a href="./references#CD006545-bbs2-0008" title="FengLL , WangXJ , SunLQ , ZhangZR , MaCH . Clinical observation on efficacy of methylthionine chloride in the treatment of hemangiomas in children. Chinese Journal of Dermatology2000;33(4):284. [CENTRAL: CN‐00843680] ">Feng 2000</a>; <a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>; <a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a>; <a href="./references#CD006545-bbs2-0016" title="LiG , XuDP , TongS , XueL , SunNN , WangXK . Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions. Journal of Craniofacial Surgery2016;27(1):56‐60. [CENTRAL: CN‐01195472; PUBMED: 26716547] ">Li 2016</a>; <a href="./references#CD006545-bbs2-0017" title="LuJ , KuangX , ZhaoJ , XiangY , HuangJ , ZengQ , et al. Concurrent versus sequential combination of propranolol and dual‐wavelength laser (585 nm and 1064 nm) to treat complicated infantile hemangiomas. International Journal of Clinical and Experimental Medicine2016;9(8):16132‐16138. [EMBASE: 20160650632] ">Lu 2016</a>; <a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>; <a href="./references#CD006545-bbs2-0023" title="XuWL . The research of pingyangmycin emulsion on proliferation of tumor cell apoptosis in capillary hemangiomas [translation]. Shijiazhuang, Hebei, China: Hebei Medical University, 2003. XuWL , NiuAG , LiSL , LiZD . Pingyangmycin emulsion inducing apoptosis in infantile proliferating capillary hemangiomas. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2006;22(5):362‐4. [CENTRAL: CN‐00730309] XuWL , NiuAG , LiZD , LiSL , ShiBJ , ZhangYB , et al. Effect of pingyangmycin emulsion on the microenvironment of infantile proliferating capillary hemangioma. World Journal of Pediatrics2006;2(3):217‐22. ">Xu 2006</a>; <a href="./references#CD006545-bbs2-0026" title="ZhangL , MaiHM , ZhengJ , ZhengJW , ChenZG , WangYA , et al. Preliminary study on plasma RPN concentration of patients with infantile hemangioma treated with propranolol. International journal of clinical and experimental medicine2013;6(5):342‐5. [CENTRAL: CN‐00906420; PUBMED: 23724152] ">Zhang 2013</a>; <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a>; <a href="./references#CD006545-bbs2-0028" title="ZhuHJ , LiuQ , DengXL , GuanYX . Efficacy of low‐dose 90Sr‐90Y therapy combined with topical application of 0.5% timolol maleate solution for the treatment of superficial infantile hemangiomas. Experimental and Therapeutic Medicine2015;10(3):1013‐8. [PUBMED: 26622431] ">Zhu 2015</a>), Germany (<a href="./references#CD006545-bbs2-0012" title="JungEG . X‐ray therapy for hemangiomatas [Die strahlentherapie der hamangiome]. Dermatologica1976;153(2):86‐7. [CENTRAL: CN‐00784697] JungEG , KohlerU . Regression of haemangiomata in infants after x‐ray treatment and mock‐radiation [Rückbildung frühkindlicher hämangiome nach röntgen‐ und pseudobestrahlung]. Archives of Dermatological Research1977;259(1):21‐8. [CENTRAL: CN‐00614355] ">Jung 1977</a>), Chile (<a href="./references#CD006545-bbs2-0001" title="Abarzua‐ArayaA , Navarrete‐DechentCP , HeusserF , RetamalJ , Zegpi‐TruebaMS . Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. Journal of the American Academy of Dermatology2014;70(6):1045‐9. [CENTRAL: CN‐00993183; PUBMED: 24656727] ">Abarzua‐Araya 2014</a>), the UK (<a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a>), the USA (<a href="./references#CD006545-bbs2-0005" title="BaumanNM , McCarterRJ , GuzzettaPC , ShinJJ , OhAK , PreciadoDA , et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngology, Head &amp; Neck Surgery.2014;140(4):323‐30. [CENTRAL: CN‐00988156; PUBMED: 24526257] NCT00967226 . Propranolol versus prednisolone for treatment of symptomatic hemangiomas. clinicaltrials.gov/ct2/show/NCT00967226 (accessed 23 April 2010). ">Bauman 2014</a>), Australia (<a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a>; <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>), Iran (<a href="./references#CD006545-bbs2-0003" title="AsilianA , MokhtariF , KamaliAS , Abtahi‐NaeiniB , NilforoushzadehMA , MostafaieS . Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double‐blind randomized controlled trial. Advanced Biomedical Research.2015;4:257. [PUBMED: 26918239] ">Asilian 2015</a>; <a href="./references#CD006545-bbs2-0007" title="EhsaniAH , NoormohammadpoorP , AbdolrezaM , BalighiK , ArianianZ , DaklanS . Combination therapy of infantile hemangioma with pulsed dye laser with topical propranolol: a randomized clinical trial. Archives of Iranian Medicine2014;17(10):657‐60. [CENTRAL: CN‐01042472; PUBMED: 25305763] ">Ehsani 2014</a>), the Netherlands (<a href="./references#CD006545-bbs2-0013" title="KesselsJP , HamersET , OstertagJU . Superficial hemangioma: pulsed dye laser versus wait‐and‐see. Dermatologic Surgery2013;39(3 Pt 1):414‐21. [CENTRAL: CN‐00966183; PUBMED: 23279058] ">Kessels 2013</a>), France (<a href="./references#CD006545-bbs2-0014" title="Leaute‐LabrezeC , Dumas de la RoqueE , NackaF , AbouelfathA , GrenierN , RebolaM , et al. Double‐blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants &lt; 4 months of age. British Journal of Dermatology2013;169(1):181‐3. [CENTRAL: CN‐00977604; PUBMED: 23301692] ">Leaute‐Labreze 2013</a>; <a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>), India (<a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>; <a href="./references#CD006545-bbs2-0022" title="TiwariP , PandeyV , GangopadhyayAN , SharmaSP , GuptaDK . Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. Oral &amp; Maxillofacial Surgery2016;20(1):73‐7. [PUBMED: 26481918] ">Tiwari 2016</a>), and Egypt (<a href="./references#CD006545-bbs2-0002" title="AlyMMD , HamzaAF , Abdel KaderHM , SaafanHA , GhazyMS , RagabIA . Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. European Journal of Pediatrics2015;174(11):1503‐9. [CENTRAL: CN‐01106020; PUBMED: 25982338] ">Aly 2015</a>; <a href="./references#CD006545-bbs2-0021" title="TawfikAA , AlsharnoubiJ . Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study. Pediatric dermatology2015;32(3):369‐76. [CENTRAL: CN‐01102313; PUBMED: 25740672] ">Tawfik 2015</a>; <a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a>; <a href="./references#CD006545-bbs2-0025" title="ZaherH , RasheedH , El‐KomyMM , HegazyRA , GawdatHI , Abdel HalimDM , et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial. Journal of the American Academy of Dermatology2016;74(3):499‐505. [CENTRAL: CN‐01138323; PUBMED: 26685718] ">Zaher 2016</a>). </p> </section> <section id="CD006545-sec-0088"> <h5 class="title">Participants</h5> <p>Baseline data were reported in 17 trials (<a href="./references#CD006545-bbs2-0001" title="Abarzua‐ArayaA , Navarrete‐DechentCP , HeusserF , RetamalJ , Zegpi‐TruebaMS . Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. Journal of the American Academy of Dermatology2014;70(6):1045‐9. [CENTRAL: CN‐00993183; PUBMED: 24656727] ">Abarzua‐Araya 2014</a>; <a href="./references#CD006545-bbs2-0003" title="AsilianA , MokhtariF , KamaliAS , Abtahi‐NaeiniB , NilforoushzadehMA , MostafaieS . Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double‐blind randomized controlled trial. Advanced Biomedical Research.2015;4:257. [PUBMED: 26918239] ">Asilian 2015</a>; <a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a>; <a href="./references#CD006545-bbs2-0005" title="BaumanNM , McCarterRJ , GuzzettaPC , ShinJJ , OhAK , PreciadoDA , et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngology, Head &amp; Neck Surgery.2014;140(4):323‐30. [CENTRAL: CN‐00988156; PUBMED: 24526257] NCT00967226 . Propranolol versus prednisolone for treatment of symptomatic hemangiomas. clinicaltrials.gov/ct2/show/NCT00967226 (accessed 23 April 2010). ">Bauman 2014</a>; <a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a>; <a href="./references#CD006545-bbs2-0007" title="EhsaniAH , NoormohammadpoorP , AbdolrezaM , BalighiK , ArianianZ , DaklanS . Combination therapy of infantile hemangioma with pulsed dye laser with topical propranolol: a randomized clinical trial. Archives of Iranian Medicine2014;17(10):657‐60. [CENTRAL: CN‐01042472; PUBMED: 25305763] ">Ehsani 2014</a>; <a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a>; <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0012" title="JungEG . X‐ray therapy for hemangiomatas [Die strahlentherapie der hamangiome]. Dermatologica1976;153(2):86‐7. [CENTRAL: CN‐00784697] JungEG , KohlerU . Regression of haemangiomata in infants after x‐ray treatment and mock‐radiation [Rückbildung frühkindlicher hämangiome nach röntgen‐ und pseudobestrahlung]. Archives of Dermatological Research1977;259(1):21‐8. [CENTRAL: CN‐00614355] ">Jung 1977</a>; <a href="./references#CD006545-bbs2-0013" title="KesselsJP , HamersET , OstertagJU . Superficial hemangioma: pulsed dye laser versus wait‐and‐see. Dermatologic Surgery2013;39(3 Pt 1):414‐21. [CENTRAL: CN‐00966183; PUBMED: 23279058] ">Kessels 2013</a>; <a href="./references#CD006545-bbs2-0014" title="Leaute‐LabrezeC , Dumas de la RoqueE , NackaF , AbouelfathA , GrenierN , RebolaM , et al. Double‐blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants &lt; 4 months of age. British Journal of Dermatology2013;169(1):181‐3. [CENTRAL: CN‐00977604; PUBMED: 23301692] ">Leaute‐Labreze 2013</a>; <a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>; <a href="./references#CD006545-bbs2-0016" title="LiG , XuDP , TongS , XueL , SunNN , WangXK . Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions. Journal of Craniofacial Surgery2016;27(1):56‐60. [CENTRAL: CN‐01195472; PUBMED: 26716547] ">Li 2016</a>; <a href="./references#CD006545-bbs2-0017" title="LuJ , KuangX , ZhaoJ , XiangY , HuangJ , ZengQ , et al. Concurrent versus sequential combination of propranolol and dual‐wavelength laser (585 nm and 1064 nm) to treat complicated infantile hemangiomas. International Journal of Clinical and Experimental Medicine2016;9(8):16132‐16138. [EMBASE: 20160650632] ">Lu 2016</a>; <a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a>; <a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a>; <a href="./references#CD006545-bbs2-0025" title="ZaherH , RasheedH , El‐KomyMM , HegazyRA , GawdatHI , Abdel HalimDM , et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial. Journal of the American Academy of Dermatology2016;74(3):499‐505. [CENTRAL: CN‐01138323; PUBMED: 26685718] ">Zaher 2016</a>). Four trials did not report the number of males and females included (<a href="./references#CD006545-bbs2-0002" title="AlyMMD , HamzaAF , Abdel KaderHM , SaafanHA , GhazyMS , RagabIA . Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. European Journal of Pediatrics2015;174(11):1503‐9. [CENTRAL: CN‐01106020; PUBMED: 25982338] ">Aly 2015</a>; <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>; <a href="./references#CD006545-bbs2-0022" title="TiwariP , PandeyV , GangopadhyayAN , SharmaSP , GuptaDK . Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. Oral &amp; Maxillofacial Surgery2016;20(1):73‐7. [PUBMED: 26481918] ">Tiwari 2016</a>; <a href="./references#CD006545-bbs2-0023" title="XuWL . The research of pingyangmycin emulsion on proliferation of tumor cell apoptosis in capillary hemangiomas [translation]. Shijiazhuang, Hebei, China: Hebei Medical University, 2003. XuWL , NiuAG , LiSL , LiZD . Pingyangmycin emulsion inducing apoptosis in infantile proliferating capillary hemangiomas. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2006;22(5):362‐4. [CENTRAL: CN‐00730309] XuWL , NiuAG , LiZD , LiSL , ShiBJ , ZhangYB , et al. Effect of pingyangmycin emulsion on the microenvironment of infantile proliferating capillary hemangioma. World Journal of Pediatrics2006;2(3):217‐22. ">Xu 2006</a>). One trial had equal numbers of males and females (<a href="./references#CD006545-bbs2-0026" title="ZhangL , MaiHM , ZhengJ , ZhengJW , ChenZG , WangYA , et al. Preliminary study on plasma RPN concentration of patients with infantile hemangioma treated with propranolol. International journal of clinical and experimental medicine2013;6(5):342‐5. [CENTRAL: CN‐00906420; PUBMED: 23724152] ">Zhang 2013</a>). The remaining 23 trials had a greater number of females than males, ranging from 58% in <a href="./references#CD006545-bbs2-0016" title="LiG , XuDP , TongS , XueL , SunNN , WangXK . Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions. Journal of Craniofacial Surgery2016;27(1):56‐60. [CENTRAL: CN‐01195472; PUBMED: 26716547] ">Li 2016</a> to 86% in <a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a>. The maximum age of enrolment at the beginning of the trial, as an inclusion criterion, ranged from 14 weeks in <a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a> to five years in <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; four studies did not clearly state this information (<a href="./references#CD006545-bbs2-0017" title="LuJ , KuangX , ZhaoJ , XiangY , HuangJ , ZengQ , et al. Concurrent versus sequential combination of propranolol and dual‐wavelength laser (585 nm and 1064 nm) to treat complicated infantile hemangiomas. International Journal of Clinical and Experimental Medicine2016;9(8):16132‐16138. [EMBASE: 20160650632] ">Lu 2016</a>; <a href="./references#CD006545-bbs2-0021" title="TawfikAA , AlsharnoubiJ . Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study. Pediatric dermatology2015;32(3):369‐76. [CENTRAL: CN‐01102313; PUBMED: 25740672] ">Tawfik 2015</a>; <a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a>; <a href="./references#CD006545-bbs2-0025" title="ZaherH , RasheedH , El‐KomyMM , HegazyRA , GawdatHI , Abdel HalimDM , et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial. Journal of the American Academy of Dermatology2016;74(3):499‐505. [CENTRAL: CN‐01138323; PUBMED: 26685718] ">Zaher 2016</a>). Age was heterogeneously reported in the included studies (mean, medians, ranges for total, or subgroups were reported). In 19 studies reporting mean age, this ranged from 12 weeks in <a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a> to 13.4 years in <a href="./references#CD006545-bbs2-0021" title="TawfikAA , AlsharnoubiJ . Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study. Pediatric dermatology2015;32(3):369‐76. [CENTRAL: CN‐01102313; PUBMED: 25740672] ">Tawfik 2015</a>. </p> </section> <section id="CD006545-sec-0089"> <h5 class="title">Subtypes of haemangiomas</h5> <p>Different subtypes of infantile haemangiomas were assessed, including children with mixed or deep IH (<a href="./references#CD006545-bbs2-0016" title="LiG , XuDP , TongS , XueL , SunNN , WangXK . Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions. Journal of Craniofacial Surgery2016;27(1):56‐60. [CENTRAL: CN‐01195472; PUBMED: 26716547] ">Li 2016</a>; <a href="./references#CD006545-bbs2-0017" title="LuJ , KuangX , ZhaoJ , XiangY , HuangJ , ZengQ , et al. Concurrent versus sequential combination of propranolol and dual‐wavelength laser (585 nm and 1064 nm) to treat complicated infantile hemangiomas. International Journal of Clinical and Experimental Medicine2016;9(8):16132‐16138. [EMBASE: 20160650632] ">Lu 2016</a>; <a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a>; <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a>), ulcerated or problematic IH (<a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>; <a href="./references#CD006545-bbs2-0022" title="TiwariP , PandeyV , GangopadhyayAN , SharmaSP , GuptaDK . Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. Oral &amp; Maxillofacial Surgery2016;20(1):73‐7. [PUBMED: 26481918] ">Tiwari 2016</a>; <a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a>; <a href="./references#CD006545-bbs2-0025" title="ZaherH , RasheedH , El‐KomyMM , HegazyRA , GawdatHI , Abdel HalimDM , et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial. Journal of the American Academy of Dermatology2016;74(3):499‐505. [CENTRAL: CN‐01138323; PUBMED: 26685718] ">Zaher 2016</a>), or high‐risk haemangiomas (<a href="./references#CD006545-bbs2-0001" title="Abarzua‐ArayaA , Navarrete‐DechentCP , HeusserF , RetamalJ , Zegpi‐TruebaMS . Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. Journal of the American Academy of Dermatology2014;70(6):1045‐9. [CENTRAL: CN‐00993183; PUBMED: 24656727] ">Abarzua‐Araya 2014</a>; <a href="./references#CD006545-bbs2-0002" title="AlyMMD , HamzaAF , Abdel KaderHM , SaafanHA , GhazyMS , RagabIA . Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. European Journal of Pediatrics2015;174(11):1503‐9. [CENTRAL: CN‐01106020; PUBMED: 25982338] ">Aly 2015</a>; <a href="./references#CD006545-bbs2-0003" title="AsilianA , MokhtariF , KamaliAS , Abtahi‐NaeiniB , NilforoushzadehMA , MostafaieS . Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double‐blind randomized controlled trial. Advanced Biomedical Research.2015;4:257. [PUBMED: 26918239] ">Asilian 2015</a>; <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0017" title="LuJ , KuangX , ZhaoJ , XiangY , HuangJ , ZengQ , et al. Concurrent versus sequential combination of propranolol and dual‐wavelength laser (585 nm and 1064 nm) to treat complicated infantile hemangiomas. International Journal of Clinical and Experimental Medicine2016;9(8):16132‐16138. [EMBASE: 20160650632] ">Lu 2016</a>; <a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a>; <a href="./references#CD006545-bbs2-0025" title="ZaherH , RasheedH , El‐KomyMM , HegazyRA , GawdatHI , Abdel HalimDM , et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial. Journal of the American Academy of Dermatology2016;74(3):499‐505. [CENTRAL: CN‐01138323; PUBMED: 26685718] ">Zaher 2016</a>; <a href="./references#CD006545-bbs2-0028" title="ZhuHJ , LiuQ , DengXL , GuanYX . Efficacy of low‐dose 90Sr‐90Y therapy combined with topical application of 0.5% timolol maleate solution for the treatment of superficial infantile hemangiomas. Experimental and Therapeutic Medicine2015;10(3):1013‐8. [PUBMED: 26622431] ">Zhu 2015</a>). One study assessed facial haemangiomas (defined as "periorbital/orbital tumours with visual impairment and/or large size/disfiguring haemangiomas") (<a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a>). Six studies exclusively assessed superficial haemangiomas (<a href="./references#CD006545-bbs2-0003" title="AsilianA , MokhtariF , KamaliAS , Abtahi‐NaeiniB , NilforoushzadehMA , MostafaieS . Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double‐blind randomized controlled trial. Advanced Biomedical Research.2015;4:257. [PUBMED: 26918239] ">Asilian 2015</a>; <a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a>; <a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a>; <a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a>; <a href="./references#CD006545-bbs2-0013" title="KesselsJP , HamersET , OstertagJU . Superficial hemangioma: pulsed dye laser versus wait‐and‐see. Dermatologic Surgery2013;39(3 Pt 1):414‐21. [CENTRAL: CN‐00966183; PUBMED: 23279058] ">Kessels 2013</a>; <a href="./references#CD006545-bbs2-0028" title="ZhuHJ , LiuQ , DengXL , GuanYX . Efficacy of low‐dose 90Sr‐90Y therapy combined with topical application of 0.5% timolol maleate solution for the treatment of superficial infantile hemangiomas. Experimental and Therapeutic Medicine2015;10(3):1013‐8. [PUBMED: 26622431] ">Zhu 2015</a>), while one trial evaluated mixed haemangiomas only (<a href="./references#CD006545-bbs2-0016" title="LiG , XuDP , TongS , XueL , SunNN , WangXK . Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions. Journal of Craniofacial Surgery2016;27(1):56‐60. [CENTRAL: CN‐01195472; PUBMED: 26716547] ">Li 2016</a>). <a href="./references#CD006545-bbs2-0012" title="JungEG . X‐ray therapy for hemangiomatas [Die strahlentherapie der hamangiome]. Dermatologica1976;153(2):86‐7. [CENTRAL: CN‐00784697] JungEG , KohlerU . Regression of haemangiomata in infants after x‐ray treatment and mock‐radiation [Rückbildung frühkindlicher hämangiome nach röntgen‐ und pseudobestrahlung]. Archives of Dermatological Research1977;259(1):21‐8. [CENTRAL: CN‐00614355] ">Jung 1977</a> assessed planotuberous or tuberocavernous haemangiomas. The remaining trials did not provide additional information about the type of IH included or included a mixture of subtypes (<a href="./references#CD006545-bbs2-0005" title="BaumanNM , McCarterRJ , GuzzettaPC , ShinJJ , OhAK , PreciadoDA , et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngology, Head &amp; Neck Surgery.2014;140(4):323‐30. [CENTRAL: CN‐00988156; PUBMED: 24526257] NCT00967226 . Propranolol versus prednisolone for treatment of symptomatic hemangiomas. clinicaltrials.gov/ct2/show/NCT00967226 (accessed 23 April 2010). ">Bauman 2014</a>; <a href="./references#CD006545-bbs2-0007" title="EhsaniAH , NoormohammadpoorP , AbdolrezaM , BalighiK , ArianianZ , DaklanS . Combination therapy of infantile hemangioma with pulsed dye laser with topical propranolol: a randomized clinical trial. Archives of Iranian Medicine2014;17(10):657‐60. [CENTRAL: CN‐01042472; PUBMED: 25305763] ">Ehsani 2014</a>; <a href="./references#CD006545-bbs2-0008" title="FengLL , WangXJ , SunLQ , ZhangZR , MaCH . Clinical observation on efficacy of methylthionine chloride in the treatment of hemangiomas in children. Chinese Journal of Dermatology2000;33(4):284. [CENTRAL: CN‐00843680] ">Feng 2000</a>; <a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>; <a href="./references#CD006545-bbs2-0014" title="Leaute‐LabrezeC , Dumas de la RoqueE , NackaF , AbouelfathA , GrenierN , RebolaM , et al. Double‐blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants &lt; 4 months of age. British Journal of Dermatology2013;169(1):181‐3. [CENTRAL: CN‐00977604; PUBMED: 23301692] ">Leaute‐Labreze 2013</a>; <a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>; <a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>; <a href="./references#CD006545-bbs2-0021" title="TawfikAA , AlsharnoubiJ . Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study. Pediatric dermatology2015;32(3):369‐76. [CENTRAL: CN‐01102313; PUBMED: 25740672] ">Tawfik 2015</a>; <a href="./references#CD006545-bbs2-0023" title="XuWL . The research of pingyangmycin emulsion on proliferation of tumor cell apoptosis in capillary hemangiomas [translation]. Shijiazhuang, Hebei, China: Hebei Medical University, 2003. XuWL , NiuAG , LiSL , LiZD . Pingyangmycin emulsion inducing apoptosis in infantile proliferating capillary hemangiomas. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2006;22(5):362‐4. [CENTRAL: CN‐00730309] XuWL , NiuAG , LiZD , LiSL , ShiBJ , ZhangYB , et al. Effect of pingyangmycin emulsion on the microenvironment of infantile proliferating capillary hemangioma. World Journal of Pediatrics2006;2(3):217‐22. ">Xu 2006</a>; <a href="./references#CD006545-bbs2-0026" title="ZhangL , MaiHM , ZhengJ , ZhengJW , ChenZG , WangYA , et al. Preliminary study on plasma RPN concentration of patients with infantile hemangioma treated with propranolol. International journal of clinical and experimental medicine2013;6(5):342‐5. [CENTRAL: CN‐00906420; PUBMED: 23724152] ">Zhang 2013</a>). </p> </section> <section id="CD006545-sec-0090"> <h5 class="title">Interventions</h5> <p>The included trials assessed the following interventions for treating infantile haemangiomas.</p> <p> <ul id="CD006545-list-0010"> <li> <p>Lasers: pulsed dye laser (PDL), Nd:YAG laser, sequential/concurrent dual‐wavelength laser. </p> </li> <li> <p>Beta blockers: oral/topical propranolol, topical timolol maleate.</p> </li> <li> <p>Steroids: oral prednisolone.</p> </li> <li> <p>Other treatments: topical bleomycin, intralesional methylene blue.</p> </li> <li> <p>High‐intensity focused ultrasound (HIFU).</p> </li> <li> <p>Radiation therapy: soft X‐ray radiation, ⁹⁰SR‐⁹⁰Y radiation.</p> </li> </ul> </p> <p>Some treatments were used in combination.</p> <p>Comparators included active monitoring (observation), placebo, sham radiation, and the following interventions (single or in combination with another intervention). </p> <p> <ul id="CD006545-list-0011"> <li> <p>Beta blockers: intralesional/oral/topical propranolol, topical timolol maleate, oral atenolol. </p> </li> <li> <p>Oral ibuprofen plus oral paracetamol, oral captopril.</p> </li> <li> <p>Lasers: concurrent dual‐wavelength laser, PDL alone, Nd:YAG laser.</p> </li> <li> <p>Steroids: oral prednisolone, intralesional triamcinolone, methylprednisolone (infusion).</p> </li> <li> <p>HIFU.</p> </li> <li> <p>Radiation therapy: ⁹⁰SR‐⁹⁰Y radiation.</p> </li> </ul> </p> <p>We identified no evidence for argon laser, carbon dioxide laser, erbium laser, excision, cryotherapy, imiquimod, interferon alpha, vincristine, or rapamycin. We found the following treatment comparisons. </p> <p> <ul id="CD006545-list-0012"> <li> <p>PDL versus wait‐and‐see (i.e active monitoring) (<a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a>; <a href="./references#CD006545-bbs2-0013" title="KesselsJP , HamersET , OstertagJU . Superficial hemangioma: pulsed dye laser versus wait‐and‐see. Dermatologic Surgery2013;39(3 Pt 1):414‐21. [CENTRAL: CN‐00966183; PUBMED: 23279058] ">Kessels 2013</a>). </p> </li> <li> <p>Oral propranolol versus placebo (<a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0014" title="Leaute‐LabrezeC , Dumas de la RoqueE , NackaF , AbouelfathA , GrenierN , RebolaM , et al. Double‐blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants &lt; 4 months of age. British Journal of Dermatology2013;169(1):181‐3. [CENTRAL: CN‐00977604; PUBMED: 23301692] ">Leaute‐Labreze 2013</a>; <a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>). </p> </li> <li> <p>Topical timolol maleate versus placebo (<a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a>). </p> </li> <li> <p>Topical bleomycin versus placebo (<a href="./references#CD006545-bbs2-0023" title="XuWL . The research of pingyangmycin emulsion on proliferation of tumor cell apoptosis in capillary hemangiomas [translation]. Shijiazhuang, Hebei, China: Hebei Medical University, 2003. XuWL , NiuAG , LiSL , LiZD . Pingyangmycin emulsion inducing apoptosis in infantile proliferating capillary hemangiomas. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2006;22(5):362‐4. [CENTRAL: CN‐00730309] XuWL , NiuAG , LiZD , LiSL , ShiBJ , ZhangYB , et al. Effect of pingyangmycin emulsion on the microenvironment of infantile proliferating capillary hemangioma. World Journal of Pediatrics2006;2(3):217‐22. ">Xu 2006</a>). </p> </li> <li> <p>X‐ray radiation versus sham radiation (<a href="./references#CD006545-bbs2-0012" title="JungEG . X‐ray therapy for hemangiomatas [Die strahlentherapie der hamangiome]. Dermatologica1976;153(2):86‐7. [CENTRAL: CN‐00784697] JungEG , KohlerU . Regression of haemangiomata in infants after x‐ray treatment and mock‐radiation [Rückbildung frühkindlicher hämangiome nach röntgen‐ und pseudobestrahlung]. Archives of Dermatological Research1977;259(1):21‐8. [CENTRAL: CN‐00614355] ">Jung 1977</a>). </p> </li> <li> <p>Nd:YAG laser versus topical timolol maleate (<a href="./references#CD006545-bbs2-0021" title="TawfikAA , AlsharnoubiJ . Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study. Pediatric dermatology2015;32(3):369‐76. [CENTRAL: CN‐01102313; PUBMED: 25740672] ">Tawfik 2015</a>). </p> </li> <li> <p>Nd:YAG laser versus oral propranolol (<a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>; <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a>). </p> </li> <li> <p>PDL + topical propranolol versus PDL alone (<a href="./references#CD006545-bbs2-0007" title="EhsaniAH , NoormohammadpoorP , AbdolrezaM , BalighiK , ArianianZ , DaklanS . Combination therapy of infantile hemangioma with pulsed dye laser with topical propranolol: a randomized clinical trial. Archives of Iranian Medicine2014;17(10):657‐60. [CENTRAL: CN‐01042472; PUBMED: 25305763] ">Ehsani 2014</a>). </p> </li> <li> <p>PDL + topical timolol maleate versus PDL alone (<a href="./references#CD006545-bbs2-0003" title="AsilianA , MokhtariF , KamaliAS , Abtahi‐NaeiniB , NilforoushzadehMA , MostafaieS . Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double‐blind randomized controlled trial. Advanced Biomedical Research.2015;4:257. [PUBMED: 26918239] ">Asilian 2015</a>). </p> </li> <li> <p>Nd:YAG laser + oral propranolol versus Nd:YAG laser (<a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>; <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a>). </p> </li> <li> <p>Nd:YAG laser + oral propranolol versus oral propranolol (<a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>; <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a>). </p> </li> <li> <p>⁹⁰SR‐⁹⁰Y radiation + topical timolol maleate versus ⁹⁰SR‐⁹⁰Y radiation (<a href="./references#CD006545-bbs2-0028" title="ZhuHJ , LiuQ , DengXL , GuanYX . Efficacy of low‐dose 90Sr‐90Y therapy combined with topical application of 0.5% timolol maleate solution for the treatment of superficial infantile hemangiomas. Experimental and Therapeutic Medicine2015;10(3):1013‐8. [PUBMED: 26622431] ">Zhu 2015</a>). </p> </li> <li> <p>Sequential dual‐wavelength laser + oral propranolol versus concurrent dual‐wavelength laser + oral propranolol (<a href="./references#CD006545-bbs2-0017" title="LuJ , KuangX , ZhaoJ , XiangY , HuangJ , ZengQ , et al. Concurrent versus sequential combination of propranolol and dual‐wavelength laser (585 nm and 1064 nm) to treat complicated infantile hemangiomas. International Journal of Clinical and Experimental Medicine2016;9(8):16132‐16138. [EMBASE: 20160650632] ">Lu 2016</a>). </p> </li> <li> <p>Oral propranolol versus topical propranolol (<a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a>). </p> </li> <li> <p>Oral propranolol versus intralesional propranolol (<a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a>). </p> </li> <li> <p>Topical propranolol versus intralesional propranolol (<a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a>). </p> </li> <li> <p>Oral propranolol versus oral atenolol (<a href="./references#CD006545-bbs2-0001" title="Abarzua‐ArayaA , Navarrete‐DechentCP , HeusserF , RetamalJ , Zegpi‐TruebaMS . Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. Journal of the American Academy of Dermatology2014;70(6):1045‐9. [CENTRAL: CN‐00993183; PUBMED: 24656727] ">Abarzua‐Araya 2014</a>). </p> </li> <li> <p>Oral propranolol versus oral prednisolone (<a href="./references#CD006545-bbs2-0005" title="BaumanNM , McCarterRJ , GuzzettaPC , ShinJJ , OhAK , PreciadoDA , et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngology, Head &amp; Neck Surgery.2014;140(4):323‐30. [CENTRAL: CN‐00988156; PUBMED: 24526257] NCT00967226 . Propranolol versus prednisolone for treatment of symptomatic hemangiomas. clinicaltrials.gov/ct2/show/NCT00967226 (accessed 23 April 2010). ">Bauman 2014</a>; <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>). </p> </li> <li> <p>Oral propranolol versus oral captopril (<a href="./references#CD006545-bbs2-0025" title="ZaherH , RasheedH , El‐KomyMM , HegazyRA , GawdatHI , Abdel HalimDM , et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial. Journal of the American Academy of Dermatology2016;74(3):499‐505. [CENTRAL: CN‐01138323; PUBMED: 26685718] ">Zaher 2016</a>). </p> </li> <li> <p>Oral propranolol versus topical timolol maleate (<a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a>). </p> </li> <li> <p>Oral propranolol versus oral propranolol + oral prednisolone (<a href="./references#CD006545-bbs2-0002" title="AlyMMD , HamzaAF , Abdel KaderHM , SaafanHA , GhazyMS , RagabIA . Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. European Journal of Pediatrics2015;174(11):1503‐9. [CENTRAL: CN‐01106020; PUBMED: 25982338] ">Aly 2015</a>; <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>). </p> </li> <li> <p>Oral propranolol versus oral ibuprofen + oral paracetamol (<a href="./references#CD006545-bbs2-0022" title="TiwariP , PandeyV , GangopadhyayAN , SharmaSP , GuptaDK . Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. Oral &amp; Maxillofacial Surgery2016;20(1):73‐7. [PUBMED: 26481918] ">Tiwari 2016</a>). </p> </li> <li> <p>Oral propranolol + topical timolol maleate versus oral propranolol (<a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a>; <a href="./references#CD006545-bbs2-0016" title="LiG , XuDP , TongS , XueL , SunNN , WangXK . Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions. Journal of Craniofacial Surgery2016;27(1):56‐60. [CENTRAL: CN‐01195472; PUBMED: 26716547] ">Li 2016</a>). </p> </li> <li> <p>Oral propranolol + topical timolol maleate versus topical timolol maleate (<a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a>). </p> </li> <li> <p>Oral propranolol + oral prednisolone versus oral prednisolone (<a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>). </p> </li> <li> <p>Intralesional methylene blue versus intralesional triamcinolone (<a href="./references#CD006545-bbs2-0008" title="FengLL , WangXJ , SunLQ , ZhangZR , MaCH . Clinical observation on efficacy of methylthionine chloride in the treatment of hemangiomas in children. Chinese Journal of Dermatology2000;33(4):284. [CENTRAL: CN‐00843680] ">Feng 2000</a>). </p> </li> <li> <p>Oral prednisolone versus oral methylprednisolone (<a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a>). </p> </li> <li> <p>HIFU at 3.5 W versus HIFU at 4.5 W (<a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>). </p> </li> <li> <p>HIFU at 3.5 W versus HIFU at 4.0 W (<a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>). </p> </li> <li> <p>HIFU at 4.0 W versus HIFU at 4.5 W (<a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>). </p> </li> </ul> </p> <section id="CD006545-sec-0091"> <h6 class="title">Duration of treatment and follow‐up</h6> <p>The most common duration of treatment was 24 weeks, found in five trials (<a href="./references#CD006545-bbs2-0001" title="Abarzua‐ArayaA , Navarrete‐DechentCP , HeusserF , RetamalJ , Zegpi‐TruebaMS . Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. Journal of the American Academy of Dermatology2014;70(6):1045‐9. [CENTRAL: CN‐00993183; PUBMED: 24656727] ">Abarzua‐Araya 2014</a>; <a href="./references#CD006545-bbs2-0002" title="AlyMMD , HamzaAF , Abdel KaderHM , SaafanHA , GhazyMS , RagabIA . Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. European Journal of Pediatrics2015;174(11):1503‐9. [CENTRAL: CN‐01106020; PUBMED: 25982338] ">Aly 2015</a>; <a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a>; <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>). In six trials, there was no fixed length of intervention for all children; the intervention was stopped for the following reasons: when the lesion was cleared; there was no clear improvement; in the presence of important side effects; or for parent's/clinician request, among other reasons (<a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a>; <a href="./references#CD006545-bbs2-0005" title="BaumanNM , McCarterRJ , GuzzettaPC , ShinJJ , OhAK , PreciadoDA , et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngology, Head &amp; Neck Surgery.2014;140(4):323‐30. [CENTRAL: CN‐00988156; PUBMED: 24526257] NCT00967226 . Propranolol versus prednisolone for treatment of symptomatic hemangiomas. clinicaltrials.gov/ct2/show/NCT00967226 (accessed 23 April 2010). ">Bauman 2014</a>; <a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a>; <a href="./references#CD006545-bbs2-0013" title="KesselsJP , HamersET , OstertagJU . Superficial hemangioma: pulsed dye laser versus wait‐and‐see. Dermatologic Surgery2013;39(3 Pt 1):414‐21. [CENTRAL: CN‐00966183; PUBMED: 23279058] ">Kessels 2013</a>; <a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a>; <a href="./references#CD006545-bbs2-0025" title="ZaherH , RasheedH , El‐KomyMM , HegazyRA , GawdatHI , Abdel HalimDM , et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial. Journal of the American Academy of Dermatology2016;74(3):499‐505. [CENTRAL: CN‐01138323; PUBMED: 26685718] ">Zaher 2016</a>). In 11 trials, this information was unclear or poorly reported (<a href="./references#CD006545-bbs2-0003" title="AsilianA , MokhtariF , KamaliAS , Abtahi‐NaeiniB , NilforoushzadehMA , MostafaieS . Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double‐blind randomized controlled trial. Advanced Biomedical Research.2015;4:257. [PUBMED: 26918239] ">Asilian 2015</a>; <a href="./references#CD006545-bbs2-0007" title="EhsaniAH , NoormohammadpoorP , AbdolrezaM , BalighiK , ArianianZ , DaklanS . Combination therapy of infantile hemangioma with pulsed dye laser with topical propranolol: a randomized clinical trial. Archives of Iranian Medicine2014;17(10):657‐60. [CENTRAL: CN‐01042472; PUBMED: 25305763] ">Ehsani 2014</a>; <a href="./references#CD006545-bbs2-0008" title="FengLL , WangXJ , SunLQ , ZhangZR , MaCH . Clinical observation on efficacy of methylthionine chloride in the treatment of hemangiomas in children. Chinese Journal of Dermatology2000;33(4):284. [CENTRAL: CN‐00843680] ">Feng 2000</a>; <a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>; <a href="./references#CD006545-bbs2-0016" title="LiG , XuDP , TongS , XueL , SunNN , WangXK . Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions. Journal of Craniofacial Surgery2016;27(1):56‐60. [CENTRAL: CN‐01195472; PUBMED: 26716547] ">Li 2016</a>; <a href="./references#CD006545-bbs2-0017" title="LuJ , KuangX , ZhaoJ , XiangY , HuangJ , ZengQ , et al. Concurrent versus sequential combination of propranolol and dual‐wavelength laser (585 nm and 1064 nm) to treat complicated infantile hemangiomas. International Journal of Clinical and Experimental Medicine2016;9(8):16132‐16138. [EMBASE: 20160650632] ">Lu 2016</a>; <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>; <a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a>; <a href="./references#CD006545-bbs2-0021" title="TawfikAA , AlsharnoubiJ . Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study. Pediatric dermatology2015;32(3):369‐76. [CENTRAL: CN‐01102313; PUBMED: 25740672] ">Tawfik 2015</a>; <a href="./references#CD006545-bbs2-0022" title="TiwariP , PandeyV , GangopadhyayAN , SharmaSP , GuptaDK . Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. Oral &amp; Maxillofacial Surgery2016;20(1):73‐7. [PUBMED: 26481918] ">Tiwari 2016</a>; <a href="./references#CD006545-bbs2-0026" title="ZhangL , MaiHM , ZhengJ , ZhengJW , ChenZG , WangYA , et al. Preliminary study on plasma RPN concentration of patients with infantile hemangioma treated with propranolol. International journal of clinical and experimental medicine2013;6(5):342‐5. [CENTRAL: CN‐00906420; PUBMED: 23724152] ">Zhang 2013</a>). </p> <p>Duration of follow‐up ranged from 7 days in <a href="./references#CD006545-bbs2-0023" title="XuWL . The research of pingyangmycin emulsion on proliferation of tumor cell apoptosis in capillary hemangiomas [translation]. Shijiazhuang, Hebei, China: Hebei Medical University, 2003. XuWL , NiuAG , LiSL , LiZD . Pingyangmycin emulsion inducing apoptosis in infantile proliferating capillary hemangiomas. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2006;22(5):362‐4. [CENTRAL: CN‐00730309] XuWL , NiuAG , LiZD , LiSL , ShiBJ , ZhangYB , et al. Effect of pingyangmycin emulsion on the microenvironment of infantile proliferating capillary hemangioma. World Journal of Pediatrics2006;2(3):217‐22. ">Xu 2006</a> to 72 months in <a href="./references#CD006545-bbs2-0012" title="JungEG . X‐ray therapy for hemangiomatas [Die strahlentherapie der hamangiome]. Dermatologica1976;153(2):86‐7. [CENTRAL: CN‐00784697] JungEG , KohlerU . Regression of haemangiomata in infants after x‐ray treatment and mock‐radiation [Rückbildung frühkindlicher hämangiome nach röntgen‐ und pseudobestrahlung]. Archives of Dermatological Research1977;259(1):21‐8. [CENTRAL: CN‐00614355] ">Jung 1977</a>. The most frequent duration of follow‐up was six months, found in nine trials (<a href="./references#CD006545-bbs2-0001" title="Abarzua‐ArayaA , Navarrete‐DechentCP , HeusserF , RetamalJ , Zegpi‐TruebaMS . Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. Journal of the American Academy of Dermatology2014;70(6):1045‐9. [CENTRAL: CN‐00993183; PUBMED: 24656727] ">Abarzua‐Araya 2014</a>; <a href="./references#CD006545-bbs2-0003" title="AsilianA , MokhtariF , KamaliAS , Abtahi‐NaeiniB , NilforoushzadehMA , MostafaieS . Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double‐blind randomized controlled trial. Advanced Biomedical Research.2015;4:257. [PUBMED: 26918239] ">Asilian 2015</a>; <a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a>; <a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>; <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>; <a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a>; <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a>; <a href="./references#CD006545-bbs2-0028" title="ZhuHJ , LiuQ , DengXL , GuanYX . Efficacy of low‐dose 90Sr‐90Y therapy combined with topical application of 0.5% timolol maleate solution for the treatment of superficial infantile hemangiomas. Experimental and Therapeutic Medicine2015;10(3):1013‐8. [PUBMED: 26622431] ">Zhu 2015</a>). In three trials this information was unclear (<a href="./references#CD006545-bbs2-0008" title="FengLL , WangXJ , SunLQ , ZhangZR , MaCH . Clinical observation on efficacy of methylthionine chloride in the treatment of hemangiomas in children. Chinese Journal of Dermatology2000;33(4):284. [CENTRAL: CN‐00843680] ">Feng 2000</a>; <a href="./references#CD006545-bbs2-0017" title="LuJ , KuangX , ZhaoJ , XiangY , HuangJ , ZengQ , et al. Concurrent versus sequential combination of propranolol and dual‐wavelength laser (585 nm and 1064 nm) to treat complicated infantile hemangiomas. International Journal of Clinical and Experimental Medicine2016;9(8):16132‐16138. [EMBASE: 20160650632] ">Lu 2016</a>; <a href="./references#CD006545-bbs2-0026" title="ZhangL , MaiHM , ZhengJ , ZhengJW , ChenZG , WangYA , et al. Preliminary study on plasma RPN concentration of patients with infantile hemangioma treated with propranolol. International journal of clinical and experimental medicine2013;6(5):342‐5. [CENTRAL: CN‐00906420; PUBMED: 23724152] ">Zhang 2013</a>). </p> </section> </section> <section id="CD006545-sec-0092"> <h5 class="title">Outcomes</h5> <p>Fourteen trials assessed our primary outcome measure of clearance (<a href="./references#CD006545-bbs2-0001" title="Abarzua‐ArayaA , Navarrete‐DechentCP , HeusserF , RetamalJ , Zegpi‐TruebaMS . Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. Journal of the American Academy of Dermatology2014;70(6):1045‐9. [CENTRAL: CN‐00993183; PUBMED: 24656727] ">Abarzua‐Araya 2014</a>; <a href="./references#CD006545-bbs2-0003" title="AsilianA , MokhtariF , KamaliAS , Abtahi‐NaeiniB , NilforoushzadehMA , MostafaieS . Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double‐blind randomized controlled trial. Advanced Biomedical Research.2015;4:257. [PUBMED: 26918239] ">Asilian 2015</a>; <a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a>; <a href="./references#CD006545-bbs2-0007" title="EhsaniAH , NoormohammadpoorP , AbdolrezaM , BalighiK , ArianianZ , DaklanS . Combination therapy of infantile hemangioma with pulsed dye laser with topical propranolol: a randomized clinical trial. Archives of Iranian Medicine2014;17(10):657‐60. [CENTRAL: CN‐01042472; PUBMED: 25305763] ">Ehsani 2014</a>; <a href="./references#CD006545-bbs2-0008" title="FengLL , WangXJ , SunLQ , ZhangZR , MaCH . Clinical observation on efficacy of methylthionine chloride in the treatment of hemangiomas in children. Chinese Journal of Dermatology2000;33(4):284. [CENTRAL: CN‐00843680] ">Feng 2000</a>; <a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>; <a href="./references#CD006545-bbs2-0012" title="JungEG . X‐ray therapy for hemangiomatas [Die strahlentherapie der hamangiome]. Dermatologica1976;153(2):86‐7. [CENTRAL: CN‐00784697] JungEG , KohlerU . Regression of haemangiomata in infants after x‐ray treatment and mock‐radiation [Rückbildung frühkindlicher hämangiome nach röntgen‐ und pseudobestrahlung]. Archives of Dermatological Research1977;259(1):21‐8. [CENTRAL: CN‐00614355] ">Jung 1977</a>; <a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>; <a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>; <a href="./references#CD006545-bbs2-0021" title="TawfikAA , AlsharnoubiJ . Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study. Pediatric dermatology2015;32(3):369‐76. [CENTRAL: CN‐01102313; PUBMED: 25740672] ">Tawfik 2015</a>; <a href="./references#CD006545-bbs2-0022" title="TiwariP , PandeyV , GangopadhyayAN , SharmaSP , GuptaDK . Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. Oral &amp; Maxillofacial Surgery2016;20(1):73‐7. [PUBMED: 26481918] ">Tiwari 2016</a>; <a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a>; <a href="./references#CD006545-bbs2-0025" title="ZaherH , RasheedH , El‐KomyMM , HegazyRA , GawdatHI , Abdel HalimDM , et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial. Journal of the American Academy of Dermatology2016;74(3):499‐505. [CENTRAL: CN‐01138323; PUBMED: 26685718] ">Zaher 2016</a>; <a href="./references#CD006545-bbs2-0028" title="ZhuHJ , LiuQ , DengXL , GuanYX . Efficacy of low‐dose 90Sr‐90Y therapy combined with topical application of 0.5% timolol maleate solution for the treatment of superficial infantile hemangiomas. Experimental and Therapeutic Medicine2015;10(3):1013‐8. [PUBMED: 26622431] ">Zhu 2015</a>). One trial reported a subjective measure of improvement (<a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a>). Adverse events were fully reported in 20 trials (<a href="./references#CD006545-bbs2-0001" title="Abarzua‐ArayaA , Navarrete‐DechentCP , HeusserF , RetamalJ , Zegpi‐TruebaMS . Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. Journal of the American Academy of Dermatology2014;70(6):1045‐9. [CENTRAL: CN‐00993183; PUBMED: 24656727] ">Abarzua‐Araya 2014</a>; <a href="./references#CD006545-bbs2-0002" title="AlyMMD , HamzaAF , Abdel KaderHM , SaafanHA , GhazyMS , RagabIA . Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. European Journal of Pediatrics2015;174(11):1503‐9. [CENTRAL: CN‐01106020; PUBMED: 25982338] ">Aly 2015</a>; <a href="./references#CD006545-bbs2-0003" title="AsilianA , MokhtariF , KamaliAS , Abtahi‐NaeiniB , NilforoushzadehMA , MostafaieS . Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double‐blind randomized controlled trial. Advanced Biomedical Research.2015;4:257. [PUBMED: 26918239] ">Asilian 2015</a>; <a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a>; <a href="./references#CD006545-bbs2-0005" title="BaumanNM , McCarterRJ , GuzzettaPC , ShinJJ , OhAK , PreciadoDA , et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngology, Head &amp; Neck Surgery.2014;140(4):323‐30. [CENTRAL: CN‐00988156; PUBMED: 24526257] NCT00967226 . Propranolol versus prednisolone for treatment of symptomatic hemangiomas. clinicaltrials.gov/ct2/show/NCT00967226 (accessed 23 April 2010). ">Bauman 2014</a>; <a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a>; <a href="./references#CD006545-bbs2-0007" title="EhsaniAH , NoormohammadpoorP , AbdolrezaM , BalighiK , ArianianZ , DaklanS . Combination therapy of infantile hemangioma with pulsed dye laser with topical propranolol: a randomized clinical trial. Archives of Iranian Medicine2014;17(10):657‐60. [CENTRAL: CN‐01042472; PUBMED: 25305763] ">Ehsani 2014</a>; <a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>; <a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a>; <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0013" title="KesselsJP , HamersET , OstertagJU . Superficial hemangioma: pulsed dye laser versus wait‐and‐see. Dermatologic Surgery2013;39(3 Pt 1):414‐21. [CENTRAL: CN‐00966183; PUBMED: 23279058] ">Kessels 2013</a>; <a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>; <a href="./references#CD006545-bbs2-0016" title="LiG , XuDP , TongS , XueL , SunNN , WangXK . Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions. Journal of Craniofacial Surgery2016;27(1):56‐60. [CENTRAL: CN‐01195472; PUBMED: 26716547] ">Li 2016</a>; <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>; <a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>; <a href="./references#CD006545-bbs2-0022" title="TiwariP , PandeyV , GangopadhyayAN , SharmaSP , GuptaDK . Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. Oral &amp; Maxillofacial Surgery2016;20(1):73‐7. [PUBMED: 26481918] ">Tiwari 2016</a>; <a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a>; <a href="./references#CD006545-bbs2-0025" title="ZaherH , RasheedH , El‐KomyMM , HegazyRA , GawdatHI , Abdel HalimDM , et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial. Journal of the American Academy of Dermatology2016;74(3):499‐505. [CENTRAL: CN‐01138323; PUBMED: 26685718] ">Zaher 2016</a>; <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a>; <a href="./references#CD006545-bbs2-0028" title="ZhuHJ , LiuQ , DengXL , GuanYX . Efficacy of low‐dose 90Sr‐90Y therapy combined with topical application of 0.5% timolol maleate solution for the treatment of superficial infantile hemangiomas. Experimental and Therapeutic Medicine2015;10(3):1013‐8. [PUBMED: 26622431] ">Zhu 2015</a>). Other measures of resolution such as redness, reduction of volume, colour fading, haemoglobin levels, or mean size reduction were assessed in 16 trials (<a href="./references#CD006545-bbs2-0002" title="AlyMMD , HamzaAF , Abdel KaderHM , SaafanHA , GhazyMS , RagabIA . Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. European Journal of Pediatrics2015;174(11):1503‐9. [CENTRAL: CN‐01106020; PUBMED: 25982338] ">Aly 2015</a>; <a href="./references#CD006545-bbs2-0003" title="AsilianA , MokhtariF , KamaliAS , Abtahi‐NaeiniB , NilforoushzadehMA , MostafaieS . Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double‐blind randomized controlled trial. Advanced Biomedical Research.2015;4:257. [PUBMED: 26918239] ">Asilian 2015</a>; <a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a>; <a href="./references#CD006545-bbs2-0005" title="BaumanNM , McCarterRJ , GuzzettaPC , ShinJJ , OhAK , PreciadoDA , et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngology, Head &amp; Neck Surgery.2014;140(4):323‐30. [CENTRAL: CN‐00988156; PUBMED: 24526257] NCT00967226 . Propranolol versus prednisolone for treatment of symptomatic hemangiomas. clinicaltrials.gov/ct2/show/NCT00967226 (accessed 23 April 2010). ">Bauman 2014</a>; <a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a>; <a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a>; <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0013" title="KesselsJP , HamersET , OstertagJU . Superficial hemangioma: pulsed dye laser versus wait‐and‐see. Dermatologic Surgery2013;39(3 Pt 1):414‐21. [CENTRAL: CN‐00966183; PUBMED: 23279058] ">Kessels 2013</a>; <a href="./references#CD006545-bbs2-0016" title="LiG , XuDP , TongS , XueL , SunNN , WangXK . Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions. Journal of Craniofacial Surgery2016;27(1):56‐60. [CENTRAL: CN‐01195472; PUBMED: 26716547] ">Li 2016</a>; <a href="./references#CD006545-bbs2-0017" title="LuJ , KuangX , ZhaoJ , XiangY , HuangJ , ZengQ , et al. Concurrent versus sequential combination of propranolol and dual‐wavelength laser (585 nm and 1064 nm) to treat complicated infantile hemangiomas. International Journal of Clinical and Experimental Medicine2016;9(8):16132‐16138. [EMBASE: 20160650632] ">Lu 2016</a>; <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>; <a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a>; <a href="./references#CD006545-bbs2-0021" title="TawfikAA , AlsharnoubiJ . Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study. Pediatric dermatology2015;32(3):369‐76. [CENTRAL: CN‐01102313; PUBMED: 25740672] ">Tawfik 2015</a>; <a href="./references#CD006545-bbs2-0022" title="TiwariP , PandeyV , GangopadhyayAN , SharmaSP , GuptaDK . Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. Oral &amp; Maxillofacial Surgery2016;20(1):73‐7. [PUBMED: 26481918] ">Tiwari 2016</a>; <a href="./references#CD006545-bbs2-0023" title="XuWL . The research of pingyangmycin emulsion on proliferation of tumor cell apoptosis in capillary hemangiomas [translation]. Shijiazhuang, Hebei, China: Hebei Medical University, 2003. XuWL , NiuAG , LiSL , LiZD . Pingyangmycin emulsion inducing apoptosis in infantile proliferating capillary hemangiomas. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2006;22(5):362‐4. [CENTRAL: CN‐00730309] XuWL , NiuAG , LiZD , LiSL , ShiBJ , ZhangYB , et al. Effect of pingyangmycin emulsion on the microenvironment of infantile proliferating capillary hemangioma. World Journal of Pediatrics2006;2(3):217‐22. ">Xu 2006</a>; <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a>). One trial reported the proportion of parents who consider their child still has a problem (<a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a>); the same trial also reported on requirement for surgical correction. No trials reported the proportion of children who consider they still have a problem. In addition, one trial reported findings related to aesthetic appearance (<a href="./references#CD006545-bbs2-0013" title="KesselsJP , HamersET , OstertagJU . Superficial hemangioma: pulsed dye laser versus wait‐and‐see. Dermatologic Surgery2013;39(3 Pt 1):414‐21. [CENTRAL: CN‐00966183; PUBMED: 23279058] ">Kessels 2013</a>). </p> </section> </section> <section id="CD006545-sec-0093"> <h4 class="title">Excluded studies</h4> <p>Among the 45 studies excluded after full‐text assessment, six were excluded due to ineligible population or other diseases (<a href="./references#CD006545-bbs2-0050" title="LiuXJ , QuinZP , TaiMZ . Angiographic classification and sclerotic therapy of maxillofacial cavernous haemangiomas: a report of 204 cases. Journal of International Medical Research2009;37(5):1285‐92. [PUBMED: 19930833] ">Liu 2009</a>; <a href="./references#CD006545-bbs2-0054" title="MidenaE , PilottoE , RadinPP , deBelvisV . Bolus vs standard photodynamic therapy in the treatment of circumscribed choroidal hemangioma: a randomized, masked study. Investigative Ophthalmology &amp; Visual Science2004;45:3154. [CENTRAL: CN‐00598352] UrbanF , PilottoE , ParrozzaniR , MidenaE . Photodynamic therapy of circumscribed choroidal hemangioma: comparison of dosage and timing. Acta Ophthalmologica2008;86:s243. ">Midena 2008</a>; <a href="./references#CD006545-bbs2-0057" title="PancarGS , AydinF , SenturkN , BekY , CanturkMT , TuranliAY . Comparison of the 532‐nm KTP and 1064‐nm Nd:YAG lasers for the treatment of cherry angiomas. Journal of Cosmetic and Laser Therapy2011;13(4):138‐41. [CENTRAL: CN‐00811208] ">Pancar 2011</a>; <a href="./references#CD006545-bbs2-0060" title="RouvasAA , PapakostasTD , VavvasD , VergadosI , MoschosMM , KotsolisA , et al. Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study. Retina2009;29(4):536‐44. [CENTRAL: CN‐00704491] ">Rouvas 2009</a>; <a href="./references#CD006545-bbs2-0066" title="TierneyE , BarkerA , AhdoutJ , HankeCW , MoyRL , KoubaDJ . Photodynamic therapy for the treatment of cutaneous neoplasia, inflammatory disorders, and photoaging. Dermatologic Surgery2009;35(5):725‐46. [PUBMED: 19309338] ">Tierney 2009</a>; <a href="./references#CD006545-bbs2-0072" title="ZhouK , LiangC , YangK , WangL . A randomised controlled study on the efficacy of modified sclerotherapy in treating angioma of ear, nose and throat. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2002;16(12):681‐3. [CENTRAL: CN‐00436296] ">Zhou 2002</a>), and one for being developed in animals (<a href="./references#CD006545-bbs2-0073" title="ZhouW , HeS , YangY , JianD , ChenX , DingJ . Formulation, characterization and clinical evaluation of propranolol hydrochloride gel for transdermal treatment of superficial infantile hemangioma. Drug Development &amp; Industrial Pharmacy2015;41(7):1109‐19. [CENTRAL: CN‐01254273] ">Zhou 2015</a>). The remaining 38 excluded studies were not randomised trials. Details of these studies and reasons for exclusion are listed in the <a href="./references#CD006545-sec-0412" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD006545-sec-0094"> <h5 class="title">Studies awaiting classification</h5> <p>We assessed seven studies as awaiting classification because only partial information was available for these references (from abstracts, conference proceedings, or registration entries in trial platforms, among other reasons) (<a href="./references#CD006545-bbs2-0074" title="KuangX , LuJ . Concurrent versus sequential combination therapy of propranolol and dual‐wavelength laser (585nm and 1064nm) to treat refractory infantile hemangiomas. Journal of Dermatology2014;41:100. [CENTRAL: CN‐01055093] ">Kuang 2014</a>; <a href="./references#CD006545-bbs2-0075" title="MaierH , WankaA , SchmalwieserAW , MaierB , DaniT , NeumannR , et al. Prospective, randomized, investigator‐blind, controlled therapy study on treatment of haemangioma of infancy: Pulsed dye laser versus cryotherapy versus observation. Experimental Dermatology2012;21(3):e15. [EMBASE: 70792062] ">Maier 2012</a>; <a href="./references#CD006545-bbs2-0076" title="NCT00004436 . Randomized study of hormonal regulation of infantile hemangioma. clinicaltrials.gov/ct2/show/NCT00004436 (accessed 23 April 2010). ">NCT00004436</a>; <a href="./references#CD006545-bbs2-0077" title="NCT00555464 . Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas. clinicaltrials.gov/ct2/show/NCT00555464 (accessed 23 April 2010). ">NCT00555464</a>; <a href="./references#CD006545-bbs2-0078" title="NCT00744185 . Propranolol on capillary hemangiomas. clinicaltrials.gov/ct2/show/NCT00744185 (accessed 23 April 2010). ">NCT00744185</a>; <a href="./references#CD006545-bbs2-0079" title="NCT01072045 . Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Infantile Hemangioma. clinicaltrials.gov/ct2/show/NCT01072045 (accessed 23 April 2010). ">NCT01072045</a>; <a href="./references#CD006545-bbs2-0080" title="PandeyA , GangopadhyayAN , SharmaSP , KumarV , GuptaDK , GopalSC . Evaluation of topical steroids in the treatment of superficial hemangioma. SKINmed2010;8(1):9‐11. [CENTRAL: CN‐00760496] ">Pandey 2010</a>). Preliminary details are reported in the <a href="./references#CD006545-sec-0413" title="">Characteristics of studies awaiting classification</a> tables. </p> </section> <section id="CD006545-sec-0095"> <h5 class="title">Ongoing studies</h5> <p>We identified two ongoing trials from the updated searches (<a href="./references#CD006545-bbs2-0081" title="NCT01147601 . Topical Timolol 0.5% solution for proliferating infantile haemangiomas. clinicaltrials.gov/ct2/show/NCT01147601?term=NCT01147601 (accessed 25 March 2011). ">NCT01147601</a>; <a href="./references#CD006545-bbs2-0082" title="NCT02913612 . Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) (TIM01). clinicaltrials.gov/ct2/show/NCT02913612 Date first received: 12 August 2016. ">NCT02913612</a>). The designs of the trials are listed below. </p> <p> <ul id="CD006545-list-0013"> <li> <p><a href="./references#CD006545-bbs2-0081" title="NCT01147601 . Topical Timolol 0.5% solution for proliferating infantile haemangiomas. clinicaltrials.gov/ct2/show/NCT01147601?term=NCT01147601 (accessed 25 March 2011). ">NCT01147601</a>: topical 0.5% timolol maleate versus placebo, 2 to 3 drops to cover the haemangioma, twice daily. </p> </li> <li> <p><a href="./references#CD006545-bbs2-0082" title="NCT02913612 . Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) (TIM01). clinicaltrials.gov/ct2/show/NCT02913612 Date first received: 12 August 2016. ">NCT02913612</a>: timolol maleate gel forming solution drug versus wait‐and‐see (i.e. active monitoring). </p> </li> </ul> </p> </section> </section> </section> <section id="CD006545-sec-0096"> <h3 class="title">Risk of bias in included studies</h3> <p>We summarised the risk of bias of all the studies in the <a href="./references#CD006545-sec-0411" title="">Characteristics of included studies</a> section. The 'Risk of bias' graph (review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies) is presented in <a href="#CD006545-fig-0002">Figure 2</a>. The 'Risk of bias' summary (review authors' judgements about each 'Risk of bias' item for each included study) is presented in <a href="#CD006545-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD006545-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD006545-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD006545-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD006545-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> </div> <section id="CD006545-sec-0097"> <h4 class="title">Allocation</h4> <p>Seventeen trials used an adequate method of randomisation and were hence rated as at low risk of bias (<a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a>; <a href="./references#CD006545-bbs2-0005" title="BaumanNM , McCarterRJ , GuzzettaPC , ShinJJ , OhAK , PreciadoDA , et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngology, Head &amp; Neck Surgery.2014;140(4):323‐30. [CENTRAL: CN‐00988156; PUBMED: 24526257] NCT00967226 . Propranolol versus prednisolone for treatment of symptomatic hemangiomas. clinicaltrials.gov/ct2/show/NCT00967226 (accessed 23 April 2010). ">Bauman 2014</a>; <a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a>; <a href="./references#CD006545-bbs2-0007" title="EhsaniAH , NoormohammadpoorP , AbdolrezaM , BalighiK , ArianianZ , DaklanS . Combination therapy of infantile hemangioma with pulsed dye laser with topical propranolol: a randomized clinical trial. Archives of Iranian Medicine2014;17(10):657‐60. [CENTRAL: CN‐01042472; PUBMED: 25305763] ">Ehsani 2014</a>; <a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a>; <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0012" title="JungEG . X‐ray therapy for hemangiomatas [Die strahlentherapie der hamangiome]. Dermatologica1976;153(2):86‐7. [CENTRAL: CN‐00784697] JungEG , KohlerU . Regression of haemangiomata in infants after x‐ray treatment and mock‐radiation [Rückbildung frühkindlicher hämangiome nach röntgen‐ und pseudobestrahlung]. Archives of Dermatological Research1977;259(1):21‐8. [CENTRAL: CN‐00614355] ">Jung 1977</a>; <a href="./references#CD006545-bbs2-0013" title="KesselsJP , HamersET , OstertagJU . Superficial hemangioma: pulsed dye laser versus wait‐and‐see. Dermatologic Surgery2013;39(3 Pt 1):414‐21. [CENTRAL: CN‐00966183; PUBMED: 23279058] ">Kessels 2013</a>; <a href="./references#CD006545-bbs2-0014" title="Leaute‐LabrezeC , Dumas de la RoqueE , NackaF , AbouelfathA , GrenierN , RebolaM , et al. Double‐blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants &lt; 4 months of age. British Journal of Dermatology2013;169(1):181‐3. [CENTRAL: CN‐00977604; PUBMED: 23301692] ">Leaute‐Labreze 2013</a>; <a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>; <a href="./references#CD006545-bbs2-0016" title="LiG , XuDP , TongS , XueL , SunNN , WangXK . Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions. Journal of Craniofacial Surgery2016;27(1):56‐60. [CENTRAL: CN‐01195472; PUBMED: 26716547] ">Li 2016</a>; <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>; <a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a>; <a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>; <a href="./references#CD006545-bbs2-0021" title="TawfikAA , AlsharnoubiJ . Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study. Pediatric dermatology2015;32(3):369‐76. [CENTRAL: CN‐01102313; PUBMED: 25740672] ">Tawfik 2015</a>; <a href="./references#CD006545-bbs2-0022" title="TiwariP , PandeyV , GangopadhyayAN , SharmaSP , GuptaDK . Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. Oral &amp; Maxillofacial Surgery2016;20(1):73‐7. [PUBMED: 26481918] ">Tiwari 2016</a>; <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a>), while the other 11 did not provide sufficient information about the sequence generation process to permit judgement (unclear risk of bias) (<a href="./references#CD006545-bbs2-0001" title="Abarzua‐ArayaA , Navarrete‐DechentCP , HeusserF , RetamalJ , Zegpi‐TruebaMS . Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. Journal of the American Academy of Dermatology2014;70(6):1045‐9. [CENTRAL: CN‐00993183; PUBMED: 24656727] ">Abarzua‐Araya 2014</a>; <a href="./references#CD006545-bbs2-0002" title="AlyMMD , HamzaAF , Abdel KaderHM , SaafanHA , GhazyMS , RagabIA . Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. European Journal of Pediatrics2015;174(11):1503‐9. [CENTRAL: CN‐01106020; PUBMED: 25982338] ">Aly 2015</a>; <a href="./references#CD006545-bbs2-0003" title="AsilianA , MokhtariF , KamaliAS , Abtahi‐NaeiniB , NilforoushzadehMA , MostafaieS . Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double‐blind randomized controlled trial. Advanced Biomedical Research.2015;4:257. [PUBMED: 26918239] ">Asilian 2015</a>; <a href="./references#CD006545-bbs2-0008" title="FengLL , WangXJ , SunLQ , ZhangZR , MaCH . Clinical observation on efficacy of methylthionine chloride in the treatment of hemangiomas in children. Chinese Journal of Dermatology2000;33(4):284. [CENTRAL: CN‐00843680] ">Feng 2000</a>; <a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>; <a href="./references#CD006545-bbs2-0017" title="LuJ , KuangX , ZhaoJ , XiangY , HuangJ , ZengQ , et al. Concurrent versus sequential combination of propranolol and dual‐wavelength laser (585 nm and 1064 nm) to treat complicated infantile hemangiomas. International Journal of Clinical and Experimental Medicine2016;9(8):16132‐16138. [EMBASE: 20160650632] ">Lu 2016</a>; <a href="./references#CD006545-bbs2-0023" title="XuWL . The research of pingyangmycin emulsion on proliferation of tumor cell apoptosis in capillary hemangiomas [translation]. Shijiazhuang, Hebei, China: Hebei Medical University, 2003. XuWL , NiuAG , LiSL , LiZD . Pingyangmycin emulsion inducing apoptosis in infantile proliferating capillary hemangiomas. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2006;22(5):362‐4. [CENTRAL: CN‐00730309] XuWL , NiuAG , LiZD , LiSL , ShiBJ , ZhangYB , et al. Effect of pingyangmycin emulsion on the microenvironment of infantile proliferating capillary hemangioma. World Journal of Pediatrics2006;2(3):217‐22. ">Xu 2006</a>; <a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a>; <a href="./references#CD006545-bbs2-0025" title="ZaherH , RasheedH , El‐KomyMM , HegazyRA , GawdatHI , Abdel HalimDM , et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial. Journal of the American Academy of Dermatology2016;74(3):499‐505. [CENTRAL: CN‐01138323; PUBMED: 26685718] ">Zaher 2016</a>; <a href="./references#CD006545-bbs2-0026" title="ZhangL , MaiHM , ZhengJ , ZhengJW , ChenZG , WangYA , et al. Preliminary study on plasma RPN concentration of patients with infantile hemangioma treated with propranolol. International journal of clinical and experimental medicine2013;6(5):342‐5. [CENTRAL: CN‐00906420; PUBMED: 23724152] ">Zhang 2013</a>; <a href="./references#CD006545-bbs2-0028" title="ZhuHJ , LiuQ , DengXL , GuanYX . Efficacy of low‐dose 90Sr‐90Y therapy combined with topical application of 0.5% timolol maleate solution for the treatment of superficial infantile hemangiomas. Experimental and Therapeutic Medicine2015;10(3):1013‐8. [PUBMED: 26622431] ">Zhu 2015</a>). </p> <p>Nine studies specified adequate methods of allocation concealment and were hence rated as at low risk of bias (<a href="./references#CD006545-bbs2-0001" title="Abarzua‐ArayaA , Navarrete‐DechentCP , HeusserF , RetamalJ , Zegpi‐TruebaMS . Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. Journal of the American Academy of Dermatology2014;70(6):1045‐9. [CENTRAL: CN‐00993183; PUBMED: 24656727] ">Abarzua‐Araya 2014</a>; <a href="./references#CD006545-bbs2-0002" title="AlyMMD , HamzaAF , Abdel KaderHM , SaafanHA , GhazyMS , RagabIA . Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. European Journal of Pediatrics2015;174(11):1503‐9. [CENTRAL: CN‐01106020; PUBMED: 25982338] ">Aly 2015</a>; <a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a>; <a href="./references#CD006545-bbs2-0005" title="BaumanNM , McCarterRJ , GuzzettaPC , ShinJJ , OhAK , PreciadoDA , et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngology, Head &amp; Neck Surgery.2014;140(4):323‐30. [CENTRAL: CN‐00988156; PUBMED: 24526257] NCT00967226 . Propranolol versus prednisolone for treatment of symptomatic hemangiomas. clinicaltrials.gov/ct2/show/NCT00967226 (accessed 23 April 2010). ">Bauman 2014</a>; <a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a>; <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>; <a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a>; <a href="./references#CD006545-bbs2-0025" title="ZaherH , RasheedH , El‐KomyMM , HegazyRA , GawdatHI , Abdel HalimDM , et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial. Journal of the American Academy of Dermatology2016;74(3):499‐505. [CENTRAL: CN‐01138323; PUBMED: 26685718] ">Zaher 2016</a>). The remaining trials (n = 19) did not specify allocation concealment methods and so were assessed as at unclear risk of bias. </p> </section> <section id="CD006545-sec-0098"> <h4 class="title">Blinding</h4> <p>Eight trials reported blinding of participants (<a href="./references#CD006545-bbs2-0001" title="Abarzua‐ArayaA , Navarrete‐DechentCP , HeusserF , RetamalJ , Zegpi‐TruebaMS . Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. Journal of the American Academy of Dermatology2014;70(6):1045‐9. [CENTRAL: CN‐00993183; PUBMED: 24656727] ">Abarzua‐Araya 2014</a>; <a href="./references#CD006545-bbs2-0003" title="AsilianA , MokhtariF , KamaliAS , Abtahi‐NaeiniB , NilforoushzadehMA , MostafaieS . Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double‐blind randomized controlled trial. Advanced Biomedical Research.2015;4:257. [PUBMED: 26918239] ">Asilian 2015</a>; <a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a>; <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0012" title="JungEG . X‐ray therapy for hemangiomatas [Die strahlentherapie der hamangiome]. Dermatologica1976;153(2):86‐7. [CENTRAL: CN‐00784697] JungEG , KohlerU . Regression of haemangiomata in infants after x‐ray treatment and mock‐radiation [Rückbildung frühkindlicher hämangiome nach röntgen‐ und pseudobestrahlung]. Archives of Dermatological Research1977;259(1):21‐8. [CENTRAL: CN‐00614355] ">Jung 1977</a>; <a href="./references#CD006545-bbs2-0014" title="Leaute‐LabrezeC , Dumas de la RoqueE , NackaF , AbouelfathA , GrenierN , RebolaM , et al. Double‐blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants &lt; 4 months of age. British Journal of Dermatology2013;169(1):181‐3. [CENTRAL: CN‐00977604; PUBMED: 23301692] ">Leaute‐Labreze 2013</a>; <a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>; <a href="./references#CD006545-bbs2-0028" title="ZhuHJ , LiuQ , DengXL , GuanYX . Efficacy of low‐dose 90Sr‐90Y therapy combined with topical application of 0.5% timolol maleate solution for the treatment of superficial infantile hemangiomas. Experimental and Therapeutic Medicine2015;10(3):1013‐8. [PUBMED: 26622431] ">Zhu 2015</a>), and we judged these trials to be at a low risk of performance bias. The remaining studies (n = 20) did not report this information clearly and so were judged to be at unclear risk of performance bias in relation to participants. </p> <p>Five trials reported blinding of study personnel and so were rated as at low risk of performance bias (<a href="./references#CD006545-bbs2-0001" title="Abarzua‐ArayaA , Navarrete‐DechentCP , HeusserF , RetamalJ , Zegpi‐TruebaMS . Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. Journal of the American Academy of Dermatology2014;70(6):1045‐9. [CENTRAL: CN‐00993183; PUBMED: 24656727] ">Abarzua‐Araya 2014</a>; <a href="./references#CD006545-bbs2-0005" title="BaumanNM , McCarterRJ , GuzzettaPC , ShinJJ , OhAK , PreciadoDA , et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngology, Head &amp; Neck Surgery.2014;140(4):323‐30. [CENTRAL: CN‐00988156; PUBMED: 24526257] NCT00967226 . Propranolol versus prednisolone for treatment of symptomatic hemangiomas. clinicaltrials.gov/ct2/show/NCT00967226 (accessed 23 April 2010). ">Bauman 2014</a>; <a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a>; <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0014" title="Leaute‐LabrezeC , Dumas de la RoqueE , NackaF , AbouelfathA , GrenierN , RebolaM , et al. Double‐blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants &lt; 4 months of age. British Journal of Dermatology2013;169(1):181‐3. [CENTRAL: CN‐00977604; PUBMED: 23301692] ">Leaute‐Labreze 2013</a>). We rated the remaining 23 trials as at unclear risk of performance bias in relation to personnel. </p> <p>Fifteen trials reported blinding of outcome assessment and so were rated as at low risk of bias (<a href="./references#CD006545-bbs2-0002" title="AlyMMD , HamzaAF , Abdel KaderHM , SaafanHA , GhazyMS , RagabIA . Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. European Journal of Pediatrics2015;174(11):1503‐9. [CENTRAL: CN‐01106020; PUBMED: 25982338] ">Aly 2015</a>; <a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a>; <a href="./references#CD006545-bbs2-0007" title="EhsaniAH , NoormohammadpoorP , AbdolrezaM , BalighiK , ArianianZ , DaklanS . Combination therapy of infantile hemangioma with pulsed dye laser with topical propranolol: a randomized clinical trial. Archives of Iranian Medicine2014;17(10):657‐60. [CENTRAL: CN‐01042472; PUBMED: 25305763] ">Ehsani 2014</a>; <a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a>; <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0013" title="KesselsJP , HamersET , OstertagJU . Superficial hemangioma: pulsed dye laser versus wait‐and‐see. Dermatologic Surgery2013;39(3 Pt 1):414‐21. [CENTRAL: CN‐00966183; PUBMED: 23279058] ">Kessels 2013</a>; <a href="./references#CD006545-bbs2-0014" title="Leaute‐LabrezeC , Dumas de la RoqueE , NackaF , AbouelfathA , GrenierN , RebolaM , et al. Double‐blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants &lt; 4 months of age. British Journal of Dermatology2013;169(1):181‐3. [CENTRAL: CN‐00977604; PUBMED: 23301692] ">Leaute‐Labreze 2013</a>; <a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>; <a href="./references#CD006545-bbs2-0016" title="LiG , XuDP , TongS , XueL , SunNN , WangXK . Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions. Journal of Craniofacial Surgery2016;27(1):56‐60. [CENTRAL: CN‐01195472; PUBMED: 26716547] ">Li 2016</a>; <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>; <a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a>; <a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>; <a href="./references#CD006545-bbs2-0021" title="TawfikAA , AlsharnoubiJ . Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study. Pediatric dermatology2015;32(3):369‐76. [CENTRAL: CN‐01102313; PUBMED: 25740672] ">Tawfik 2015</a>; <a href="./references#CD006545-bbs2-0025" title="ZaherH , RasheedH , El‐KomyMM , HegazyRA , GawdatHI , Abdel HalimDM , et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial. Journal of the American Academy of Dermatology2016;74(3):499‐505. [CENTRAL: CN‐01138323; PUBMED: 26685718] ">Zaher 2016</a>; <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a>). The remaining trials (n = 13) did not report this information explicitly and so were rated as at unclear risk of bias. </p> <p>We rated only three trials as at low risk of bias for all three of the blinding items assessed (<a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a>; <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0014" title="Leaute‐LabrezeC , Dumas de la RoqueE , NackaF , AbouelfathA , GrenierN , RebolaM , et al. Double‐blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants &lt; 4 months of age. British Journal of Dermatology2013;169(1):181‐3. [CENTRAL: CN‐00977604; PUBMED: 23301692] ">Leaute‐Labreze 2013</a>). </p> </section> <section id="CD006545-sec-0099"> <h4 class="title">Incomplete outcome data</h4> <p>Risk of attrition bias was high in <a href="./references#CD006545-bbs2-0012" title="JungEG . X‐ray therapy for hemangiomatas [Die strahlentherapie der hamangiome]. Dermatologica1976;153(2):86‐7. [CENTRAL: CN‐00784697] JungEG , KohlerU . Regression of haemangiomata in infants after x‐ray treatment and mock‐radiation [Rückbildung frühkindlicher hämangiome nach röntgen‐ und pseudobestrahlung]. Archives of Dermatological Research1977;259(1):21‐8. [CENTRAL: CN‐00614355] ">Jung 1977</a> because of a high dropout rate (47% in the intervention group and 44% in the control group) with no reasons given. We assessed two trials as at unclear risk of bias (<a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>; <a href="./references#CD006545-bbs2-0022" title="TiwariP , PandeyV , GangopadhyayAN , SharmaSP , GuptaDK . Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. Oral &amp; Maxillofacial Surgery2016;20(1):73‐7. [PUBMED: 26481918] ">Tiwari 2016</a>). The risk of attrition bias was low in the remaining 25 trials due to a low or null dropout rate. </p> </section> <section id="CD006545-sec-0100"> <h4 class="title">Selective reporting</h4> <p>There was evidence of selective omissions of outcomes or critical information from the publications of seven trials (<a href="./references#CD006545-bbs2-0008" title="FengLL , WangXJ , SunLQ , ZhangZR , MaCH . Clinical observation on efficacy of methylthionine chloride in the treatment of hemangiomas in children. Chinese Journal of Dermatology2000;33(4):284. [CENTRAL: CN‐00843680] ">Feng 2000</a>; <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0012" title="JungEG . X‐ray therapy for hemangiomatas [Die strahlentherapie der hamangiome]. Dermatologica1976;153(2):86‐7. [CENTRAL: CN‐00784697] JungEG , KohlerU . Regression of haemangiomata in infants after x‐ray treatment and mock‐radiation [Rückbildung frühkindlicher hämangiome nach röntgen‐ und pseudobestrahlung]. Archives of Dermatological Research1977;259(1):21‐8. [CENTRAL: CN‐00614355] ">Jung 1977</a>; <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>; <a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a>; <a href="./references#CD006545-bbs2-0023" title="XuWL . The research of pingyangmycin emulsion on proliferation of tumor cell apoptosis in capillary hemangiomas [translation]. Shijiazhuang, Hebei, China: Hebei Medical University, 2003. XuWL , NiuAG , LiSL , LiZD . Pingyangmycin emulsion inducing apoptosis in infantile proliferating capillary hemangiomas. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2006;22(5):362‐4. [CENTRAL: CN‐00730309] XuWL , NiuAG , LiZD , LiSL , ShiBJ , ZhangYB , et al. Effect of pingyangmycin emulsion on the microenvironment of infantile proliferating capillary hemangioma. World Journal of Pediatrics2006;2(3):217‐22. ">Xu 2006</a>; <a href="./references#CD006545-bbs2-0026" title="ZhangL , MaiHM , ZhengJ , ZhengJW , ChenZG , WangYA , et al. Preliminary study on plasma RPN concentration of patients with infantile hemangioma treated with propranolol. International journal of clinical and experimental medicine2013;6(5):342‐5. [CENTRAL: CN‐00906420; PUBMED: 23724152] ">Zhang 2013</a>). In the <a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a> trial, the scores for a subjective measure of improvement as rated by the parents were not presented; the authors instead presented the correlation between the scores of the parents and the scores of the outcome assessors (intraclass correlation coefficient: 0.92). The choice of selective omission of the outcome did not appear to be based on outcome result, since highly significant findings were seen for the reported outcomes. We judged <a href="./references#CD006545-bbs2-0007" title="EhsaniAH , NoormohammadpoorP , AbdolrezaM , BalighiK , ArianianZ , DaklanS . Combination therapy of infantile hemangioma with pulsed dye laser with topical propranolol: a randomized clinical trial. Archives of Iranian Medicine2014;17(10):657‐60. [CENTRAL: CN‐01042472; PUBMED: 25305763] ">Ehsani 2014</a> to be at unclear risk of selective reporting because an outcome in their protocol was not included in their study report. We judged the remaining trials (n = 20) as at low risk of reporting bias. </p> </section> <section id="CD006545-sec-0101"> <h4 class="title">Other potential sources of bias</h4> <p>There may be other sources of bias in one study related to the role of the sponsors in the development of the research (<a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>); hence we rated this trial as at unclear risk of bias for this domain. We found <a href="./references#CD006545-bbs2-0005" title="BaumanNM , McCarterRJ , GuzzettaPC , ShinJJ , OhAK , PreciadoDA , et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngology, Head &amp; Neck Surgery.2014;140(4):323‐30. [CENTRAL: CN‐00988156; PUBMED: 24526257] NCT00967226 . Propranolol versus prednisolone for treatment of symptomatic hemangiomas. clinicaltrials.gov/ct2/show/NCT00967226 (accessed 23 April 2010). ">Bauman 2014</a> to be at unclear risk of other potential sources of bias due to the termination of the trial, which might generate biases in the results. We identified no additional sources of bias in the remaining studies (n = 26). </p> </section> </section> <section id="CD006545-sec-0102"> <h3 class="title" id="CD006545-sec-0102">Effects of interventions</h3> <p>See: <a href="./full#CD006545-tbl-0001"><b>Summary of findings for the main comparison</b> Oral propranolol compared to placebo for infantile haemangiomas of the skin</a>; <a href="./full#CD006545-tbl-0002"><b>Summary of findings 2</b> Topical timolol compared to placebo for infantile haemangiomas of the skin</a>; <a href="./full#CD006545-tbl-0003"><b>Summary of findings 3</b> Oral propranolol compared to topical timolol for infantile haemangiomas of the skin</a> </p> <section id="CD006545-sec-0103"> <h4 class="title">Comparison 1. Interventions versus placebo: PDL versus wait‐and‐see (i.e. active monitoring)</h4> <p>For this comparison, we included the information from two trials with a total of 143 children (<a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a>; <a href="./references#CD006545-bbs2-0013" title="KesselsJP , HamersET , OstertagJU . Superficial hemangioma: pulsed dye laser versus wait‐and‐see. Dermatologic Surgery2013;39(3 Pt 1):414‐21. [CENTRAL: CN‐00966183; PUBMED: 23279058] ">Kessels 2013</a>). Both authors included children with superficial early haemangiomas in the preproliferative or early proliferative growth phase. <a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a> used Chromos 585 nm wavelength venous flash‐lamp pulsed dye laser without epidermal cooling (SLS Biophile, Dyfed, Wales, UK) at a pulse duration of 0.45 ms, with spot diameter of 3 to 5 mm, and energy fluence of 6.0 to 7.5 J/cm², and the treatment was repeated every 2 to 4 weeks. Duration of treatment was until the lesion cleared, stopped proliferating, stopped responding, or if the parents discontinued treatment (treatment maximum of one year), and children were followed until six months. <a href="./references#CD006545-bbs2-0013" title="KesselsJP , HamersET , OstertagJU . Superficial hemangioma: pulsed dye laser versus wait‐and‐see. Dermatologic Surgery2013;39(3 Pt 1):414‐21. [CENTRAL: CN‐00966183; PUBMED: 23279058] ">Kessels 2013</a> used 595 nm PDL (Vbeam, Syneron Candela, Wayland, MA, USA) with 7‐millimetre spot diameter, 30/10 to 40/10 epidermal cooling, at fluence range of 7 to 15 J/cm² and a pulse duration of 0.45 to 40.0 ms. The treatment was repeated every two to six weeks. The intervention ended when the child had complete remission, stop of proliferation, or no response of the haemangioma. Children were followed until 12 months. </p> <section id="CD006545-sec-0104"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p>One trial provided information about this outcome and reported a total of 52 cases of clearance (121 children; percentage of clearance: 42.9%) (<a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a>): 25 children out of 60 (41.6%) in the PDL group and 27 out of 61 (44.2%) in the wait‐and‐see group reached clearance of lesions. This study found no differences in terms of clearance when comparing PDL with wait‐and‐see (risk ratio (RR) 0.94, 95% confidence interval (CI) 0.62 to 1.42; <a href="./references#CD006545-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD006545-sec-0105"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0106"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p>Two trials provided information for four different adverse events. <a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a> provided information about 22 cases of skin atrophy (121 children; percentage of skin atrophy: 18.1%) and 36 cases of skin hypopigmentation (121 children; percentage of skin hypopigmentation: 29.7%). Seventeen children out of 60 (28.3%) in the PDL group and 5 out of 61 (8.1%) in the wait‐and‐see group had skin atrophy. The risk of skin atrophy after PDL was 3.46 times that after wait‐and‐see (RR 3.46, 95% CI 1.36 to 8.77; <a href="./references#CD006545-fig-0005" title="">Analysis 1.2</a>). In addition, 27 children out of 60 (45%) in the PDL group and 9 out of 61 (14.7%) in the wait‐and‐see group had skin hypopigmentation. The risk of skin hypopigmentation after PDL was 3.05 times that after wait‐and‐see (RR 3.05, 95% CI 1.57 to 5.93; <a href="./references#CD006545-fig-0006" title="">Analysis 1.3</a>). </p> <p>Likewise, <a href="./references#CD006545-bbs2-0013" title="KesselsJP , HamersET , OstertagJU . Superficial hemangioma: pulsed dye laser versus wait‐and‐see. Dermatologic Surgery2013;39(3 Pt 1):414‐21. [CENTRAL: CN‐00966183; PUBMED: 23279058] ">Kessels 2013</a> provided information about two cases of minimal crusting (22 children; percentage of minimal crusting: 9.09%) and two cases of pain (22 children; percentage of skin hypopigmentation: 9.09%). Two children out of 11 (18%) in the PDL group and 0 out of 11 (0%) in the wait‐and‐see group had minimal crusting. This study found no clear differences in terms of these adverse events when comparing PDL with wait‐and‐see, due to imprecision (RR 5.00, 95% CI 0.27 to 93.5; <a href="./references#CD006545-fig-0007" title="">Analysis 1.4</a>; and RR 5.00, 95% CI 0.27 to 93.5; <a href="./references#CD006545-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD006545-sec-0107"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p><a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a> provided information about 23 cases of no‐redness (121 children; percentage of no‐redness: 19%). Nineteen children out of 60 (31.6%) in the PDL group and 4 out of 61 (6.5%) in the wait‐and‐see group had no‐redness. The risk of absence of redness after PDL was 4.83 times that after wait‐and‐see (RR 4.83, 95% CI 1.75 to 13.36; <a href="./references#CD006545-fig-0009" title="">Analysis 1.6</a>). <a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a> provided information about surface area after follow‐up, reporting a median of 113 mm² (range 0 to 150) for the PDL group and a median of 146 mm² (range 0 to 2403) for the group under observation. <a href="./references#CD006545-bbs2-0013" title="KesselsJP , HamersET , OstertagJU . Superficial hemangioma: pulsed dye laser versus wait‐and‐see. Dermatologic Surgery2013;39(3 Pt 1):414‐21. [CENTRAL: CN‐00966183; PUBMED: 23279058] ">Kessels 2013</a> provided information about median change in surface area at the age of 1 year, reporting a median of 0.20 cm² (interquartile range (IQR) ‐0.10 to 0.58) for the group receiving PDL versus a median of 0.00 cm² (IQR ‐0.10 to 0.4) for the group under observation. </p> </section> <section id="CD006545-sec-0108"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>One trial provided information for this outcome with 20 cases (121 participants; percentage of parents: 16.5%) (<a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a>). Eleven participants out of 60 (18.3%) in the PDL group and 9 out of 61 (14.7%) in the wait‐and‐see group considered their child still has a problem. This study found no clear differences for this outcome when comparing PDL with wait‐and‐see (RR 1.24, 95% CI 0.56 to 2.78; <a href="./references#CD006545-fig-0010" title="">Analysis 1.7</a>). </p> </section> <section id="CD006545-sec-0109"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0110"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>One trial provided information for this outcome with nine cases (22 children; percentage of aesthetic appearance: 40.9%) (<a href="./references#CD006545-bbs2-0013" title="KesselsJP , HamersET , OstertagJU . Superficial hemangioma: pulsed dye laser versus wait‐and‐see. Dermatologic Surgery2013;39(3 Pt 1):414‐21. [CENTRAL: CN‐00966183; PUBMED: 23279058] ">Kessels 2013</a>). A better cosmetic outcome was reported for 7 children out of 11 (63%) in the PDL group and 4 out of 11 (36%) in the wait‐and‐see group. This study found no clear differences for this outcome when comparing PDL with wait‐and‐see (RR 1.75, 95% CI 0.71 to 4.31; <a href="./references#CD006545-fig-0011" title="">Analysis 1.8</a>). </p> </section> <section id="CD006545-sec-0111"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>In <a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a>, 7 out of 60 children in the PDL group compared with 3 out of 61 children in the wait‐and‐see group required surgical correction at 5 years' follow‐up. There was no significant difference between groups for this outcome (RR 2.37, 95% CI 0.64 to 8.75; <a href="./references#CD006545-fig-0012" title="">Analysis 1.9</a>). </p> </section> </section> <section id="CD006545-sec-0112"> <h4 class="title">Comparison 2. Interventions versus placebo: oral propranolol versus placebo</h4> <p>For this comparison, we included information from three trials (312 children) (<a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0014" title="Leaute‐LabrezeC , Dumas de la RoqueE , NackaF , AbouelfathA , GrenierN , RebolaM , et al. Double‐blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants &lt; 4 months of age. British Journal of Dermatology2013;169(1):181‐3. [CENTRAL: CN‐00977604; PUBMED: 23301692] ">Leaute‐Labreze 2013</a>; <a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>). <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a> enrolled 40 children between the ages of 9 weeks and 5 years with facial infantile haemangioma or infantile haemangiomas in sites with potential for disfigurement. Children were randomly assigned to receive propranolol or placebo. Administration was initiated at a dosage of 1 mg/kg per day divided 3 times daily and then increased to 2 mg/kg per day divided 3 times daily from weeks 2 to 24. The children were followed up at weeks 0, 4, 8, 12, 16, 20, and 24. Duration of treatment and follow‐up was 24 weeks in both cases. <a href="./references#CD006545-bbs2-0014" title="Leaute‐LabrezeC , Dumas de la RoqueE , NackaF , AbouelfathA , GrenierN , RebolaM , et al. Double‐blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants &lt; 4 months of age. British Journal of Dermatology2013;169(1):181‐3. [CENTRAL: CN‐00977604; PUBMED: 23301692] ">Leaute‐Labreze 2013</a> enrolled 14 children younger than 16 weeks with one or more non‐threatening infantile haemangiomas of more than 1 cm in diameter, without vital or functional impairment. Children were randomly assigned to receive placebo or propranolol 3 mg/kg daily for 15 days, then 4 mg/kg daily for 15 additional days. Duration of treatment and follow‐up was one month in both cases. Finally, <a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a> enrolled 456 infants between 35 and 150 days old with proliferating infantile haemangioma requiring systemic therapy. Children were randomly assigned to receive propranolol 1 mg/kg per day, 3 mg/kg per day, or placebo for 3 or 6 months. We reported data for the groups followed for six months in this analysis. </p> <section id="CD006545-sec-0113"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p>One trial provided information for this outcome (<a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>). Fifty children out of 102 (49%) in the oral propranolol group (1 mg/kg/day) and 2 out of 55 (3.6%) in the placebo group reached clearance of lesions. The risk of clearance after oral propranolol 1 mg/kg/day was 13.48 times that after placebo (RR 13.48, 95% CI 3.41 to 53.30; <a href="./references#CD006545-fig-0013" title="">Analysis 2.1</a>). Likewise, 61 children out of 101 (60.3%) in the oral propranolol group (3 mg/kg/day) and 2 out of 55 (3.6%) in the placebo group reached clearance of lesions. The risk of clearance after oral propranolol 3 mg/kg/day was 16.61 times that after placebo (RR 16.61, 95% CI 4.22 to 65.34; <a href="./references#CD006545-fig-0013" title="">Analysis 2.1</a>). We downgraded the quality of the evidence from high to moderate due to imprecision (see <a href="./full#CD006545-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD006545-sec-0114"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0115"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p>Three trials reported information about 26 cases of serious adverse events in general, but this was based only on information from a single trial (<a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>; percentage of cases: 5.1%), as the other two trials had zero events in both arms (<a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0014" title="Leaute‐LabrezeC , Dumas de la RoqueE , NackaF , AbouelfathA , GrenierN , RebolaM , et al. Double‐blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants &lt; 4 months of age. British Journal of Dermatology2013;169(1):181‐3. [CENTRAL: CN‐00977604; PUBMED: 23301692] ">Leaute‐Labreze 2013</a>). Twenty‐three children out of 427 (5.3%) in the oral propranolol group and 3 out of 82 (3.6%) in the placebo group had serious adverse events. This study found no differences in terms of adverse events when comparing oral propranolol with placebo (RR 1.05, 95% CI 0.33 to 3.39; <a href="./references#CD006545-fig-0014" title="">Analysis 2.2</a>). We downgraded the quality of the evidence from high to low due to imprecision (see <a href="./full#CD006545-tbl-0001">summary of findings Table for the main comparison</a>). Likewise, we did not find a significant difference between oral propranolol and placebo at any doses, in terms of serious cardiovascular adverse events (<a href="./references#CD006545-fig-0015" title="">Analysis 2.3</a>) and other adverse events, including bronchospasm and hypoglycaemia (<a href="./references#CD006545-fig-0016" title="">Analysis 2.4</a>). </p> </section> <section id="CD006545-sec-0116"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p><a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a> provided information about other measures of resolution, including per cent change in volume at 24 weeks and redness. For change in volume, the authors reported a reduction of mean haemangioma volume at 24 weeks of 45.9% (95% CI 11.60% to 80.20%) comparing oral propranolol with placebo (<a href="./references#CD006545-fig-0017" title="">Analysis 2.5</a>). We downgraded the quality of the evidence from high to moderate due to imprecision (See <a href="./full#CD006545-tbl-0001">summary of findings Table for the main comparison</a>). Likewise, <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a> reported improvement in redness at week 24 in 4 children out of 20 (20%) in the oral propranolol group and 0 out of 20 (0%) in the placebo group. This study found no clear difference in terms of redness improvement when comparing oral propranolol with placebo due to imprecision (RR 9.00, 95% CI 0.52 to 156.9; <a href="./references#CD006545-fig-0018" title="">Analysis 2.6</a>). </p> </section> <section id="CD006545-sec-0117"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0118"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0119"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0120"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0121"> <h4 class="title">Comparison 3. Interventions versus placebo: topical timolol maleate versus placebo</h4> <p>For this comparison, we included the information from one trial (<a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a>), with 41 children between the ages of 5 weeks and 24 weeks with small, focal superficial infantile haemangiomas. Children were randomly assigned to receive placebo or timolol maleate 0.5% gel. Administration was initiated by applying, with a fingertip, part of one drop of the gel onto the surface of the IH twice a day. Duration of treatment and follow‐up was six months in both cases. </p> <section id="CD006545-sec-0122"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0123"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0124"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a> provided information about serious cardiovascular events, reporting zero events of bradycardia and zero of hypotension (41 children). We downgraded the quality of the evidence from high to low due to imprecision (see <a href="./full#CD006545-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD006545-sec-0125"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p><a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a> provided information about absence of redness at the end of follow‐up, reporting eight cases (41 children; percentage of absence of redness: 19.5%). Seven children out of 19 (36.8%) in the topical timolol maleate group and 1 out of 22 (4.5%) in the placebo group reached clearance of lesions. The absence of redness after topical timolol maleate was 8.11 times that after placebo (RR 8.11, 95% CI 1.09 to 60.09; <a href="./references#CD006545-fig-0019" title="">Analysis 3.1</a>). We downgraded the quality of the evidence from high to low due to imprecision (see <a href="./full#CD006545-tbl-0002">summary of findings Table 2</a>). <a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a> also provided information about cases of volume reduction (equal to or more than 5%), reporting 11 cases (41 children; percentage of volume reduction: 26.8%). Nine children out of 19 (47.3%) in the topical timolol maleate group and 2 out of 22 (9%) in the placebo group reached clearance of lesions. Volume reduction after topical timolol maleate was 5.21 times that after placebo (RR 5.21, 95% CI 1.28 to 21.21; <a href="./references#CD006545-fig-0019" title="">Analysis 3.1</a>). We downgraded the quality of the evidence from high to low due to imprecision (see <a href="./full#CD006545-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD006545-sec-0126"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0127"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0128"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0129"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0130"> <h4 class="title">Comparison 4. Interventions versus placebo: topical bleomycin versus placebo</h4> <p>For this comparison, we included information from one trial with 30 children (<a href="./references#CD006545-bbs2-0023" title="XuWL . The research of pingyangmycin emulsion on proliferation of tumor cell apoptosis in capillary hemangiomas [translation]. Shijiazhuang, Hebei, China: Hebei Medical University, 2003. XuWL , NiuAG , LiSL , LiZD . Pingyangmycin emulsion inducing apoptosis in infantile proliferating capillary hemangiomas. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2006;22(5):362‐4. [CENTRAL: CN‐00730309] XuWL , NiuAG , LiZD , LiSL , ShiBJ , ZhangYB , et al. Effect of pingyangmycin emulsion on the microenvironment of infantile proliferating capillary hemangioma. World Journal of Pediatrics2006;2(3):217‐22. ">Xu 2006</a>). Thirty infants with "capillary hemangioma" at body surface aged less than six months were enrolled in this study. Children were randomly assigned to receive placebo or bleomycin emulsion 2 mg/dL by the ultrasound‐atomised technique three times per day for one week and made a biopsy. Duration of treatment and follow‐up was seven days in both cases. </p> <section id="CD006545-sec-0131"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0132"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0133"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0134"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p>In <a href="./references#CD006545-bbs2-0023" title="XuWL . The research of pingyangmycin emulsion on proliferation of tumor cell apoptosis in capillary hemangiomas [translation]. Shijiazhuang, Hebei, China: Hebei Medical University, 2003. XuWL , NiuAG , LiSL , LiZD . Pingyangmycin emulsion inducing apoptosis in infantile proliferating capillary hemangiomas. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2006;22(5):362‐4. [CENTRAL: CN‐00730309] XuWL , NiuAG , LiZD , LiSL , ShiBJ , ZhangYB , et al. Effect of pingyangmycin emulsion on the microenvironment of infantile proliferating capillary hemangioma. World Journal of Pediatrics2006;2(3):217‐22. ">Xu 2006</a>, two‐thirds of the 15 haemangiomas treated with bleomycin, a very toxic agent, became deep red and their surfaces began to shrink slightly at day 7 (10 cases; 30 children). Ten children out of 15 (66%) in the topical bleomycin group and 0 out of 15 (0%) in the placebo group reached clearance of lesions. The shrink of lesions after topical bleomycin was 21 times greater than after placebo, but the 95% CI was wide, showing imprecision (RR 21.00, 95% CI 1.34 to 328.86; <a href="./references#CD006545-fig-0020" title="">Analysis 4.1</a>). </p> </section> <section id="CD006545-sec-0135"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0136"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0137"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0138"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0139"> <h4 class="title">Comparison 5. Interventions versus placebo: X‐ray radiation versus sham radiation</h4> <p>For this comparison, we included the information from one trial with 100 children (<a href="./references#CD006545-bbs2-0012" title="JungEG . X‐ray therapy for hemangiomatas [Die strahlentherapie der hamangiome]. Dermatologica1976;153(2):86‐7. [CENTRAL: CN‐00784697] JungEG , KohlerU . Regression of haemangiomata in infants after x‐ray treatment and mock‐radiation [Rückbildung frühkindlicher hämangiome nach röntgen‐ und pseudobestrahlung]. Archives of Dermatological Research1977;259(1):21‐8. [CENTRAL: CN‐00614355] ">Jung 1977</a>). The infantile haemangiomas were irradiated 2 or 3 times with 400 rad (rad = unit of absorbed radiation dose) at intervals of 4 to 8 weeks. For more than 4 cm of diameter, the 400 rad was dissolved in 3 x 200 rad at weekly intervals. Follow‐up was performed at the end of each month, then monitored on an outpatient basis in six‐month intervals. Duration of treatment ranged from 4 to 7 weeks; children were followed until 72 months. </p> <section id="CD006545-sec-0140"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p><a href="./references#CD006545-bbs2-0012" title="JungEG . X‐ray therapy for hemangiomatas [Die strahlentherapie der hamangiome]. Dermatologica1976;153(2):86‐7. [CENTRAL: CN‐00784697] JungEG , KohlerU . Regression of haemangiomata in infants after x‐ray treatment and mock‐radiation [Rückbildung frühkindlicher hämangiome nach röntgen‐ und pseudobestrahlung]. Archives of Dermatological Research1977;259(1):21‐8. [CENTRAL: CN‐00614355] ">Jung 1977</a> provided information on this outcome, reporting a total of 34 cases of clearance (100 children; percentage of clearance: 34%). Eighteen children out of 51 (35.2%) in the X‐ray radiation group and 16 out of 49 (32.6%) in the sham radiation group reached clearance of lesions. This study found no differences in terms of clearance when comparing X‐ray radiation with sham radiation (RR 1.08, 95% CI 0.63 to 1.87; <a href="./references#CD006545-fig-0021" title="">Analysis 5.1</a>). </p> </section> <section id="CD006545-sec-0141"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0142"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0143"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0144"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0145"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0146"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0147"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0148"> <h4 class="title">Comparison 6. Laser comparisons: Nd:YAG laser versus topical timolol maleate</h4> <p>For this comparison, we included information from one trial with 60 children (<a href="./references#CD006545-bbs2-0021" title="TawfikAA , AlsharnoubiJ . Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study. Pediatric dermatology2015;32(3):369‐76. [CENTRAL: CN‐01102313; PUBMED: 25740672] ">Tawfik 2015</a>). Children were randomly allocated into two groups. Group 1 was assigned to receive timolol maleate 0.5% drops (5 mg/mL) to apply twice a day. Group 2 was treated using combined sequential dual‐wavelength 585 nm PDL and 1064 nm Nd:YAG laser (Synergy Multiplex, Cynosure, Westford, MA, USA) to flat superficial haemangiomas. The parameters were: PDL with a 7‐millimetre spot size, 6‐millisecond pulse duration, and fluence of 4.5 to 6 J/cm². After a 1‐second delay, Nd:YAG laser was administered at 15‐millisecond pulse duration and fluence of 25 to 35 J/cm². Parameters for children with mixed haemangiomas were: PDL with a 7‐millimetre spot size, 10‐millisecond pulse duration, and fluence of 6 to 7.5 J/cm². After a 1‐second delay, Nd:YAG laser was administered at 15‐millisecond pulse duration and fluence of 30 to 40 J/cm². Interventions were administered in a maximum of six sessions; children were followed until three months. </p> <section id="CD006545-sec-0149"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0150"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0151"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0021" title="TawfikAA , AlsharnoubiJ . Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study. Pediatric dermatology2015;32(3):369‐76. [CENTRAL: CN‐01102313; PUBMED: 25740672] ">Tawfik 2015</a> narratively reported four cases of crusts and hyperpigmentation in the laser group after the first session. One child in the timolol maleate group reported shortness of breath and insomnia. </p> </section> <section id="CD006545-sec-0152"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p><a href="./references#CD006545-bbs2-0021" title="TawfikAA , AlsharnoubiJ . Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study. Pediatric dermatology2015;32(3):369‐76. [CENTRAL: CN‐01102313; PUBMED: 25740672] ">Tawfik 2015</a> provided information on mean haemoglobin level after treatment with timolol maleate or laser, reporting a mean of 1.67 (standard deviation (SD) = 0.54) for the timolol maleate group versus a mean of 2.58 (SD = 0.86) for the laser group. Mean haemoglobin levels after topical timolol maleate were 0.91 units smaller than after Nd:YAG laser treatment (mean difference (MD) ‐0.91, 95% CI ‐1.27 to ‐0.55; <a href="./references#CD006545-fig-0022" title="">Analysis 6.1</a>). </p> <p><a href="./references#CD006545-bbs2-0021" title="TawfikAA , AlsharnoubiJ . Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study. Pediatric dermatology2015;32(3):369‐76. [CENTRAL: CN‐01102313; PUBMED: 25740672] ">Tawfik 2015</a> also provided information on children with an improvement between 76% and 100% (excellent improvement), reporting 12 cases (60 children; 20%). Nine children out of 30 (30%) in the Nd:YAG laser group and 3 out of 30 (10%) in the topical timolol maleate group reported excellent improvement. No clear differences in terms of this score were found when comparing Nd:YAG laser with topical timolol maleate due to imprecision (RR 3.00, 95% CI 0.90 to 10.01; <a href="./references#CD006545-fig-0023" title="">Analysis 6.2</a>). </p> </section> <section id="CD006545-sec-0153"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0154"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0155"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0156"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0157"> <h4 class="title">Comparison 7. Laser comparisons: Nd:YAG laser versus oral propranolol</h4> <p>For this comparison, we included information from two trials with a total of 105 children (<a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>; <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a>). In <a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>, Group B received Nd:YAG laser with spot diameter of 1.5‐ to 3.0‐millimetre handle; energy density at 170 to 240 J/cm² range; width from 20 to 50 each session every 6 weeks. Group C received only twice‐daily dose of 0.5 mg/kg oral propranolol, increased two weeks later to 0.8 mg/kg, and four weeks later to 1.0 mg/kg. Duration of treatment and follow‐up were six months in both cases. In <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a>, Group C received Nd:YAG once, with parameters adjusted according to lesion depth. Group B received propranolol 1.5 mg/kg over 3 divided doses per day for a total of 6 months. Treatment ranged from three to six months. Follow‐up was six months. </p> <section id="CD006545-sec-0158"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p><a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a> provided information on this outcome, reporting a total of 4 cases of clearance out of 65 children (percentage of clearance: 6.1%). Three children out of 35 (8.5%) in the Nd:YAG laser group and 1 out of 30 (3.3%) in the oral propranolol group reached complete clearance of lesions. This study found no clear differences in terms of clearance when comparing Nd:YAG laser with oral propranolol due to imprecision (RR 2.57, 95% CI 0.28 to 23.44; <a href="./references#CD006545-fig-0024" title="">Analysis 7.1</a>). </p> </section> <section id="CD006545-sec-0159"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0160"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a> provided information about cases of hyperpigmentation, reporting a total of 4 cases out of 65 children (6.1%). Three children out of 35 (8.5%) in the Nd:YAG laser group and 1 out of 30 (3.3%) in the oral propranolol group reported hyperpigmentation. This study found no clear differences in terms of hyperpigmentation when comparing Nd:YAG laser with oral propranolol (RR 2.57, 95% CI 0.28 to 23.44; <a href="./references#CD006545-fig-0025" title="">Analysis 7.2</a>). <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a> also provided information about cases of pigmentation and thinning, reporting a total of 12 cases (40 children, 30%). Three children out of 20 (15%) in the Nd:YAG laser group and 9 out of 20 (45%) in the oral propranolol group reported this combined outcome. This study found no clear differences in terms of pigmentation and thinning when comparing Nd:YAG laser with oral propranolol (RR 0.33, 95% CI 0.11 to 1.05; <a href="./references#CD006545-fig-0026" title="">Analysis 7.3</a>). </p> <p>Both studies provided information about cases of superficial scar, reporting a total of 11 cases out of 105 children (10.4%). Seven children out of 55 (12.2%) in the Nd:YAG laser group and 4 out of 50 (8%) in the oral propranolol group reported superficial scars. These studies found no clear differences in terms of superficial scars when comparing Nd:YAG laser with oral propranolol (RR 1.52, 95% CI 0.24 to 9.58; I² = 48%; <a href="./references#CD006545-fig-0027" title="">Analysis 7.4</a>). <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a> also reported that no cases of severe hypoglycaemia, hypotension, or Reynauld’s syndrome (extremity coldness) were found. </p> </section> <section id="CD006545-sec-0161"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p><a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a> provided information about "excellent response", defined as an improvement equal or superior to 95% performed by two clinicians, reporting a total of eight cases (40 children; 20%). Two children out of 20 (10%) in the Nd:YAG laser group and 6 out of 20 (30%) in the oral propranolol group reported this response. This study found no clear differences when comparing Nd:YAG laser with oral propranolol (RR 0.33, 95% CI 0.08 to 1.46; <a href="./references#CD006545-fig-0028" title="">Analysis 7.5</a>). </p> </section> <section id="CD006545-sec-0162"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0163"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0164"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0165"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0166"> <h4 class="title">Comparison 8. Laser comparisons: PDL + topical propranolol versus PDL alone</h4> <p>For this comparison, we included information from one trial with 19 children (<a href="./references#CD006545-bbs2-0007" title="EhsaniAH , NoormohammadpoorP , AbdolrezaM , BalighiK , ArianianZ , DaklanS . Combination therapy of infantile hemangioma with pulsed dye laser with topical propranolol: a randomized clinical trial. Archives of Iranian Medicine2014;17(10):657‐60. [CENTRAL: CN‐01042472; PUBMED: 25305763] ">Ehsani 2014</a>). Children were randomly divided into two groups: the first group (nine children) were treated with PDL (spot size 7 mm, fluence 12 J/cm², pulse duration 1.5 ms, dynamic cooling device 40/40), while second group (10 children) were treated with the same PDL sessions together with topical ointment of propranolol hydrochloride 1% applied twice a day for at least 12 weeks. Duration of treatment was at least 12 weeks; children were followed until four months. </p> <section id="CD006545-sec-0167"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p><a href="./references#CD006545-bbs2-0007" title="EhsaniAH , NoormohammadpoorP , AbdolrezaM , BalighiK , ArianianZ , DaklanS . Combination therapy of infantile hemangioma with pulsed dye laser with topical propranolol: a randomized clinical trial. Archives of Iranian Medicine2014;17(10):657‐60. [CENTRAL: CN‐01042472; PUBMED: 25305763] ">Ehsani 2014</a> provided information on this outcome, reporting a total of seven cases of clearance (19 children; percentage of clearance: 36.8%). Five children out of 10 (50%) in the PDL + topical propranolol group and 2 out of 9 (22%) in the PDL group reached complete clearance of lesions. This study found no clear differences in terms of clearance when comparing PDL + topical propranolol with PDL alone (RR 2.25, 95% CI 0.57 to 8.86; <a href="./references#CD006545-fig-0029" title="">Analysis 8.1</a>). </p> </section> <section id="CD006545-sec-0168"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0169"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0007" title="EhsaniAH , NoormohammadpoorP , AbdolrezaM , BalighiK , ArianianZ , DaklanS . Combination therapy of infantile hemangioma with pulsed dye laser with topical propranolol: a randomized clinical trial. Archives of Iranian Medicine2014;17(10):657‐60. [CENTRAL: CN‐01042472; PUBMED: 25305763] ">Ehsani 2014</a> provided information about serious cardiovascular events and other adverse events, reporting zero cases for both outcomes. </p> </section> <section id="CD006545-sec-0170"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0171"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0172"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0173"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0174"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0175"> <h4 class="title">Comparison 9. Laser comparisons: PDL + topical timolol maleate versus PDL alone</h4> <p>For this comparison, we included information from one trial with 32 children (<a href="./references#CD006545-bbs2-0003" title="AsilianA , MokhtariF , KamaliAS , Abtahi‐NaeiniB , NilforoushzadehMA , MostafaieS . Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double‐blind randomized controlled trial. Advanced Biomedical Research.2015;4:257. [PUBMED: 26918239] ">Asilian 2015</a>). Children were divided into two groups: one group was treated with four sessions of PDL (585 nm, spot size 5 mm, fluence 9 J/cm², pulse duration 450 ms, without cooling, and spot overlap 20%) plus administration of timolol maleate gel 0.5%, while the other group received PDL plus lubricant gel as placebo. Duration of treatment was unclear; children were followed until six months. </p> <section id="CD006545-sec-0176"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p><a href="./references#CD006545-bbs2-0003" title="AsilianA , MokhtariF , KamaliAS , Abtahi‐NaeiniB , NilforoushzadehMA , MostafaieS . Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double‐blind randomized controlled trial. Advanced Biomedical Research.2015;4:257. [PUBMED: 26918239] ">Asilian 2015</a> provided information on this outcome, reporting a total of two cases of clearance (32 children; percentage of clearance: 6.2%). One child out of 16 (6.2%) in the PDL + topical timolol maleate group and 1 out of 16 (6.2%) in the PDL group reached complete clearance of lesions. This study found no differences in terms of clearance when comparing PDL + topical timolol maleate with PDL alone (RR 1.00, 95% CI 0.07 to 14.64; <a href="./references#CD006545-fig-0030" title="">Analysis 9.1</a>). </p> </section> <section id="CD006545-sec-0177"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0178"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0003" title="AsilianA , MokhtariF , KamaliAS , Abtahi‐NaeiniB , NilforoushzadehMA , MostafaieS . Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double‐blind randomized controlled trial. Advanced Biomedical Research.2015;4:257. [PUBMED: 26918239] ">Asilian 2015</a> provided information about severe adverse events such as hypotension, bradycardia, sleep disturbance, and anxiety, reporting zero cases. </p> </section> <section id="CD006545-sec-0179"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p><a href="./references#CD006545-bbs2-0003" title="AsilianA , MokhtariF , KamaliAS , Abtahi‐NaeiniB , NilforoushzadehMA , MostafaieS . Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double‐blind randomized controlled trial. Advanced Biomedical Research.2015;4:257. [PUBMED: 26918239] ">Asilian 2015</a> provided information about mean size reduction after treatment, reporting a mean of 17.62 cm (SD = 6.97) for the PDL + timolol maleate group versus a mean of 12 cm (SD = 5.71) for the PDL‐alone group. The mean size reduction after PDL + timolol maleate was 5.62 cm greater than after PDL alone (MD 5.62, 95% CI 1.21 to 10.03; <a href="./references#CD006545-fig-0031" title="">Analysis 9.2</a>). </p> </section> <section id="CD006545-sec-0180"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0181"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0182"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0183"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0184"> <h4 class="title">Comparison 10. Laser comparisons: Nd:YAG laser + oral propranolol versus Nd:YAG laser</h4> <p>For this comparison, we included information from two trials with a total of 107 children (<a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>; <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a>). In <a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>, one of the groups received Nd:YAG laser using spot diameter of 1.5‐ to 3.0‐millimetre handle; energy density at 170 to 240 J/cm² range; width from 20 to 50 each session every 6 weeks; the first 2 days after laser treatment start oral propranolol 0.5 mg/kg/day (twice daily) increased dosage 2 weeks later to 0.8 mg/kg/day, 4 weeks later increased to 1.0 mg/kg/day. The other group received only Nd:YAG laser with same parameters, one session every six weeks. Duration of treatment and follow‐up was six months in both cases. In <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a>, Group C received Nd:YAG once, with parameters adjusted according to lesion depth. Group B received propranolol 1.5 mg/kg/day over three doses per day for a total of six months. Treatment ranged from three to six months. Follow‐up was six months. </p> <section id="CD006545-sec-0185"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p><a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a> provided information on this outcome, reporting a total of 12 cases of clearance (67 children; percentage of clearance: 17.9%). Nine children out of 32 (28%) in Nd:YAG laser + oral propranolol group and 3 out of 35 (8.5%) in Nd:YAG laser group reached complete clearance of lesions. This study found no clear differences in terms of clearance when comparing Nd:YAG laser + oral propranolol with Nd:YAG laser alone, as the 95% confidence interval marginally included 1 (RR 3.28, 95% CI 0.97 to 11.06; <a href="./references#CD006545-fig-0032" title="">Analysis 10.1</a>). </p> </section> <section id="CD006545-sec-0186"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0187"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a> provided information about hyperpigmentation, reporting a total of seven cases (67 children; 10.4%). Four children out of 32 (12.5%) in the Nd:YAG laser + oral propranolol group and 3 out of 35 (8.5%) in the Nd:YAG laser group reported hyperpigmentation. This study found no differences in terms of hyperpigmentation when comparing Nd:YAG laser + oral propranolol with Nd:YAG laser alone (RR 1.46, 95% CI 0.35 to 6.02; <a href="./references#CD006545-fig-0033" title="">Analysis 10.2</a>). In addition, <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a> provided information on cases of pigmentation and thinning, reporting a total of five cases (40 children; 12.5%). Two children out of 20 (10%) in the Nd:YAG laser + oral propranolol group and 3 out of 20 (15%) in the Nd:YAG laser group reported this combined outcome. This study found no clear differences in terms of pigmentation and thinning when comparing Nd:YAG laser with oral propranolol (RR 0.67, 95% CI 0.12 to 3.57; <a href="./references#CD006545-fig-0034" title="">Analysis 10.3</a>). </p> <p>Both studies provided information about superficial scars, reporting a total of nine cases (107 children; 8.4%). Two children out of 52 (3.8%) in the Nd:YAG laser + oral propranolol group and 7 out of 55 (12.7%) in the Nd:YAG laser group reported superficial scars. This study found no clear difference in terms of superficial scars when comparing Nd:YAG laser + oral propranolol with Nd:YAG laser alone (RR 0.37, 95% CI 0.09 to 1.48; <a href="./references#CD006545-fig-0035" title="">Analysis 10.4</a>). </p> </section> <section id="CD006545-sec-0188"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p><a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a> provided information about "excellent response", defined as an improvement equal or superior to 95% performed by two clinicians, reporting a total of eight cases (40 children; 20%). Two children out of 20 (10%) in the Nd:YAG laser+ oral propranolol group and 6 out of 20 (30%) in the Nd:YAG laser‐alone group reported this response. The risk of excellent response after Nd:YAG laser + oral propranolol was 8.5 times that after Nd:YAG laser alone (RR 8.50, 95% CI 2.25 to 32.06; <a href="./references#CD006545-fig-0036" title="">Analysis 10.5</a>). </p> </section> <section id="CD006545-sec-0189"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0190"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0191"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0192"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0193"> <h4 class="title">Comparison 11. Laser comparisons: Nd:YAG laser + oral propranolol versus oral propranolol</h4> <p>For this comparison, we included information from two trials with a total of 102 children (<a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>; <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a>). In <a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>, one of the groups received Nd:YAG laser using spot diameter of 1.5‐ to 3.0‐millimetre handle; energy density at 170 to 240 J/cm² range; width from 20 to 50 each session every 6 weeks; the first 2 days after laser treatment start oral propranolol 0.5 mg/kg/day (twice daily) increased dosage 2 weeks later to 0.8 mg/kg/day, 4 weeks later increased to 1.0 mg/kg/day. The other group received only oral propranolol with the same scheme. Duration of treatment and follow‐up was six months in both cases. In <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a>, Group C received Nd:YAG once, with parameters adjusted according to lesion depth. Group B received propranolol 1.5 mg/kg/day over three doses per day for a total of six months. Treatment ranged from three to six months. Follow‐up was six months. </p> <section id="CD006545-sec-0194"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p><a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a> provided information on this outcome, reporting a total of 10 cases of clearance (62 children; percentage of clearance: 16.1%). Nine children out of 32 (28%) in the Nd:YAG laser + oral propranolol group and 1 out of 30 (3.3%) in the oral propranolol group reached complete clearance of lesions. The risk of clearance after Nd:YAG laser + oral propranolol was 8.44 times that after oral propranolol alone (RR 8.44, 95% CI 1.14 to 62.66; <a href="./references#CD006545-fig-0037" title="">Analysis 11.1</a>). </p> </section> <section id="CD006545-sec-0195"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0196"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a> provided information about hyperpigmentation, reporting a total of five cases (62 children; 8.06%). Four children out of 32 (12.5%) in the Nd:YAG laser + oral propranolol group and 1 out of 30 (3.3%) in the oral propranolol group reported hyperpigmentation. This study found no clear differences in terms of hyperpigmentation when comparing Nd:YAG laser + oral propranolol with oral propranolol (RR 3.75, 95% CI 0.44 to 31.68; <a href="./references#CD006545-fig-0038" title="">Analysis 11.2</a>). In addition, <a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a> provided information on cases of pigmentation and thinning, reporting a total of 11 cases (40 children; 27.5%). Two children out of 20 (10%) in the Nd:YAG laser + oral propranolol group and 9 out of 20 (45%) in the oral propranolol group reported this combined outcome. The risk of this combined outcome after Nd:YAG laser + oral propranolol was 78% lower than after oral propranolol alone (RR 0.22, 95% CI 0.05 to 0.90; <a href="./references#CD006545-fig-0039" title="">Analysis 11.3</a>). </p> <p>Both studies provided information about superficial scars, reporting a total of six cases (102 children; 5.8%). Two children out of 52 (3.8%) in the Nd:YAG laser + oral propranolol group and 4 out of 50 (8%) in the oral propranolol group reported superficial scars. This study found no clear differences in terms of superficial scars when comparing Nd:YAG laser + oral propranolol with oral propranolol (RR 0.60, 95% CI 0.05 to 7.63; <a href="./references#CD006545-fig-0040" title="">Analysis 11.4</a>). </p> </section> <section id="CD006545-sec-0197"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p><a href="./references#CD006545-bbs2-0027" title="ZhongS , TaoY , ZhouJ , YaoL , UuY , YanD , et al. Evaluation on efficacy of low dose propranolol combined with 1 064 nm Nd: YAG laser on mixed and deeper infantile hemangioma. Journal of Jilin University Medicine Edition2015;41(5):1032‐5. [CENTRAL: CN‐01177799] ">Zhong 2015</a> provided information about "excellent response", defined as an improvement equal or superior to 95% performed by two clinicians, reporting a total of 23 cases (40 children; 57.5%). Seventeen children out of 20 (85%) in the Nd:YAG laser group and 6 out of 20 (30%) in the oral propranolol group reported this response. Excellent response after Nd:YAG laser + oral propranolol was 2.83 times greater than after oral propranolol alone (RR 2.83, 95% CI 1.42 to 5.67; <a href="./references#CD006545-fig-0041" title="">Analysis 11.5</a>). </p> </section> <section id="CD006545-sec-0198"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0199"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0200"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0201"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0202"> <h4 class="title">Comparison 12. Laser comparisons: ⁹⁰SR‐⁹⁰Y radiation + topical timolol maleate versus ⁹⁰SR‐⁹⁰Y radiation </h4> <p>For this comparison, we included information from one trial with 72 children (<a href="./references#CD006545-bbs2-0028" title="ZhuHJ , LiuQ , DengXL , GuanYX . Efficacy of low‐dose 90Sr‐90Y therapy combined with topical application of 0.5% timolol maleate solution for the treatment of superficial infantile hemangiomas. Experimental and Therapeutic Medicine2015;10(3):1013‐8. [PUBMED: 26622431] ">Zhu 2015</a>). One of the groups received 1 to 2 courses of ⁹⁰SR‐⁹⁰Y (applicator area of 2x2 and a surface‐absorbed dose rate of 2.2 Gy/min) contact therapy and local external application of 0.5% topical timolol maleate solution on the area for 3 to 6 months. Children in the control group received an identical dosage and treatment course of ⁹⁰SR‐⁹⁰Y contact therapy with local topical application of normal saline for three to six months. In cases with a total haemangioma area of &lt; 20 cm², a single course of treatment consisted of a radiation dose of 2 to 2.4 Gy, once per day, for 5 consecutive days. In cases with a total haemangioma area of &gt; 20 cm², a single course of treatment consisted of a radiation dose of 1 to 1.2 Gy, once per day, for 10 consecutive days. Duration of treatment ranged from three to six months; children were followed until six months. </p> <section id="CD006545-sec-0203"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p><a href="./references#CD006545-bbs2-0028" title="ZhuHJ , LiuQ , DengXL , GuanYX . Efficacy of low‐dose 90Sr‐90Y therapy combined with topical application of 0.5% timolol maleate solution for the treatment of superficial infantile hemangiomas. Experimental and Therapeutic Medicine2015;10(3):1013‐8. [PUBMED: 26622431] ">Zhu 2015</a> provided information on this outcome, reporting a total of 55 cases of clearance (72 children; percentage of clearance: 76.3%). Thirty‐three children out of 37 (89.1%) in the ⁹⁰SR‐⁹⁰Y radiation + topical timolol maleate group and 22 out of 35 (62.8%) in the ⁹⁰SR‐⁹⁰Y radiation group reached complete clearance of lesions. Clearance after ⁹⁰SR‐⁹⁰Y radiation + topical timolol maleate was 1.42 times greater than after ⁹⁰SR‐⁹⁰Y radiation alone (RR 1.42, 95% CI 1.07 to 1.87; <a href="./references#CD006545-fig-0042" title="">Analysis 12.1</a>). </p> </section> <section id="CD006545-sec-0204"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0205"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0028" title="ZhuHJ , LiuQ , DengXL , GuanYX . Efficacy of low‐dose 90Sr‐90Y therapy combined with topical application of 0.5% timolol maleate solution for the treatment of superficial infantile hemangiomas. Experimental and Therapeutic Medicine2015;10(3):1013‐8. [PUBMED: 26622431] ">Zhu 2015</a> provided information about adverse events in general, such as mild itching, mild skin flaking, and pruritus, reporting a total of 22 cases (72 children; 30.5%). Twelve children out of 37 (32.4%) in the ⁹⁰SR‐⁹⁰Y radiation + topical timolol maleate group and 10 out of 35 (28.5%) in the ⁹⁰SR‐⁹⁰Y radiation group reported adverse events. This study found no differences in terms of adverse events when comparing ⁹⁰SR‐⁹⁰Y radiation + topical timolol maleate with ⁹⁰SR‐⁹⁰Y radiation alone (RR 1.14, 95% CI 0.56 to 2.29; <a href="./references#CD006545-fig-0043" title="">Analysis 12.2</a>). </p> </section> <section id="CD006545-sec-0206"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0207"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0208"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0209"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0210"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0211"> <h4 class="title">Comparison 13. Laser comparisons: sequential dual‐wavelength laser + oral propranolol versus concurrent dual‐wavelength laser + oral propranolol </h4> <p>For this comparison, we included information from one trial with 61 children (<a href="./references#CD006545-bbs2-0017" title="LuJ , KuangX , ZhaoJ , XiangY , HuangJ , ZengQ , et al. Concurrent versus sequential combination of propranolol and dual‐wavelength laser (585 nm and 1064 nm) to treat complicated infantile hemangiomas. International Journal of Clinical and Experimental Medicine2016;9(8):16132‐16138. [EMBASE: 20160650632] ">Lu 2016</a>). One of the groups received dual‐wavelength laser therapy after discontinuation of oral propranolol (1 to 2 mg/kg/d). Propranolol treatment was stopped when maximised treatment effect was achieved. The second group were treated with oral propranolol for one week before laser therapy was added concurrently. Duration of treatment and follow‐up was unclear. </p> <section id="CD006545-sec-0212"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0213"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0214"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0017" title="LuJ , KuangX , ZhaoJ , XiangY , HuangJ , ZengQ , et al. Concurrent versus sequential combination of propranolol and dual‐wavelength laser (585 nm and 1064 nm) to treat complicated infantile hemangiomas. International Journal of Clinical and Experimental Medicine2016;9(8):16132‐16138. [EMBASE: 20160650632] ">Lu 2016</a> narratively described general information about adverse events. The authors reported two cases of upper respiratory tract infection, three cases of mild hyperkalaemia, and one case with decreased appetite. </p> </section> <section id="CD006545-sec-0215"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p><a href="./references#CD006545-bbs2-0017" title="LuJ , KuangX , ZhaoJ , XiangY , HuangJ , ZengQ , et al. Concurrent versus sequential combination of propranolol and dual‐wavelength laser (585 nm and 1064 nm) to treat complicated infantile hemangiomas. International Journal of Clinical and Experimental Medicine2016;9(8):16132‐16138. [EMBASE: 20160650632] ">Lu 2016</a> provided information about the efficacy rating between the two groups evaluated by means of a 0‐to‐10 scale. Three researchers independently scored the treatment effect (changes of lesions appearance by digital photograph) by each month, and the average of these scores was reported. Complete resolution of the haemangioma was considered if the lesion achieved 1 or 0 points. At 3 months, the sequential‐treatment group obtained a mean score of 6.23 units (SD = 0.99), and the concurrent‐treatment group obtained a mean score of 7 units (SD = 0.46). The mean score after sequential dual‐wavelength laser + oral propranolol was 0.77 units lower than after concurrent dual‐wavelength laser + oral propranolol (MD ‐0.77, 95% CI ‐1.16 to ‐0.38; <a href="./references#CD006545-fig-0044" title="">Analysis 13.1</a>). </p> </section> <section id="CD006545-sec-0216"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0217"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0218"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0219"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0220"> <h4 class="title">Comparison 14. Propranolol comparisons: oral propranolol versus topical propranolol</h4> <p>For this comparison, we included information from one trial with 30 children (<a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a>). Children with problematic infantile haemangioma (rapidly progressive, compromising vital functions, or causing cosmetic disfigurement) were randomised into three groups. Group A received oral propranolol, 2 mg/kg/day divided into two daily doses. Group B received topical propranolol 1% ointment in a hydrophilic base, applied twice daily. The intervention ended if "complete resolution occurred, if a sustained plateau in the size of the hemangioma was reached for a period of 2 months of treatment or if any intolerable side effects from propranolol developed". Children were followed until six months. </p> <section id="CD006545-sec-0221"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p><a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a> provided information on this outcome, reporting a total of 12 cases of clearance (30 children; percentage of clearance: 40%). Nine children out of 15 (60%) in the oral propranolol group and 3 out of 15 (20%) in the topical propranolol group reached complete clearance of lesions. The risk of clearance after oral propranolol was three times that after topical propranolol (RR 3.00, 95% CI 1.01 to 8.95; <a href="./references#CD006545-fig-0045" title="">Analysis 14.1</a>). </p> </section> <section id="CD006545-sec-0222"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0223"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a> provided information about syncopal attack, reporting a total of three cases (30 children; 10%). Three children out of 15 (60%) in the oral propranolol group and 0 out of 15 (0%) in the topical propranolol group reported syncopal attack. This study found no clear differences (due to imprecision) in terms of syncopal attack when comparing oral propranolol with topical propranolol (RR 7.00, 95% CI 0.39 to 124.83; <a href="./references#CD006545-fig-0046" title="">Analysis 14.2</a>). </p> </section> <section id="CD006545-sec-0224"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0225"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0226"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0227"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0228"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0229"> <h4 class="title">Comparison 15. Propranolol comparisons: oral propranolol versus intralesional propranolol</h4> <p>For this comparison, we included information from one trial with 30 children (<a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a>). Children with problematic infantile haemangioma (rapidly progressive, compromising vital functions, or causing cosmetic disfigurement) were randomised into three groups. Group A received oral propranolol, 2 mg/kg/day divided into two daily doses. Group C received intralesional propranolol. The intervention ended if "complete resolution occurred, if a sustained plateau in the size of the hemangioma was reached for a period of 2 months of treatment or if any intolerable side effects from propranolol developed". Children were followed until six months. </p> <section id="CD006545-sec-0230"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p><a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a> provided information on this outcome, reporting a total of 11 cases of clearance (30 children; percentage of clearance: 36.6%). Nine children out of 15 (60%) in the oral propranolol group and 2 out of 15 (13.3%) in the intralesional propranolol group reached complete clearance of lesions. The risk of clearance after oral propranolol was 4.5 times that after intralesional propranolol (RR 4.50, 95% CI 1.16 to 17.44; <a href="./references#CD006545-fig-0047" title="">Analysis 15.1</a>). </p> </section> <section id="CD006545-sec-0231"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0232"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a> provided information about syncopal attack, reporting a total of three cases (30 children; 10%). Three children out of 15 (20%) in the oral propranolol group and 0 out of 15 (0%) in the intralesional propranolol group reported syncopal attack events. This study found no clear differences (due to imprecision) in terms of syncopal attack when comparing oral propranolol with intralesional propranolol (RR 7.00, 95% CI 0.39 to 124.83; <a href="./references#CD006545-fig-0048" title="">Analysis 15.2</a>). </p> </section> <section id="CD006545-sec-0233"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0234"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0235"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0236"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0237"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0238"> <h4 class="title">Comparison 16. Propranolol comparisons: topical propranolol versus intralesional propranolol</h4> <p>For this comparison, we included information from one trial with 30 children (<a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a>). Children with problematic infantile haemangioma (rapidly progressive, compromising vital functions, or causing cosmetic disfigurement) were randomised into three groups. Group B received topical propranolol 1% ointment in a hydrophilic base, applied twice daily. Group C received intralesional propranolol. The intervention ended if "complete resolution occurred, if a sustained plateau in the size of the hemangioma was reached for a period of 2 months of treatment or if any intolerable side effects from propranolol developed". Children were followed until six months. </p> <section id="CD006545-sec-0239"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p><a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a> provided information on this outcome, reporting a total of five cases of clearance (30 children; percentage of clearance: 16.6%). Three children out of 15 (20%) in the topical propranolol group and 2 out of 15 (13.3%) in the intralesional propranolol group reached complete clearance of lesions. This study found no clear differences in terms of clearance when comparing topical propranolol with intralesional propranolol (RR 1.50, 95% CI 0.29 to 7.73; <a href="./references#CD006545-fig-0049" title="">Analysis 16.1</a>). </p> </section> <section id="CD006545-sec-0240"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0241"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0024" title="ZaherH , RasheedH , EsmatS , GawdatHI , HegazyRA , El‐KomyM , et al. Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial. European Journal of Dermatology2013;23(5):646‐52. [CENTRAL: CN‐00961393; PUBMED: 24135427] ">Zaher 2013</a> provided information about syncopal attack, reporting zero events for this comparison. </p> </section> <section id="CD006545-sec-0242"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0243"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0244"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0245"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0246"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0247"> <h4 class="title">Comparison 17. Propranolol comparisons: oral propranolol versus oral atenolol</h4> <p>For this comparison, we included information from one trial with 23 children (<a href="./references#CD006545-bbs2-0001" title="Abarzua‐ArayaA , Navarrete‐DechentCP , HeusserF , RetamalJ , Zegpi‐TruebaMS . Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. Journal of the American Academy of Dermatology2014;70(6):1045‐9. [CENTRAL: CN‐00993183; PUBMED: 24656727] ">Abarzua‐Araya 2014</a>). Children were randomised to receive either atenolol or propranolol. Thirteen children receive propranolol in a dose of 2 mg/kg/d in three daily doses for 6 months, and 10 children receive atenolol in a dose of 1 mg/kg/d in a single daily dose for 6 months. Duration of treatment and follow‐up was six months in both cases. </p> <section id="CD006545-sec-0248"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p><a href="./references#CD006545-bbs2-0001" title="Abarzua‐ArayaA , Navarrete‐DechentCP , HeusserF , RetamalJ , Zegpi‐TruebaMS . Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. Journal of the American Academy of Dermatology2014;70(6):1045‐9. [CENTRAL: CN‐00993183; PUBMED: 24656727] ">Abarzua‐Araya 2014</a> provided information on this outcome, reporting a total of 13 cases of clearance (23 children; percentage of clearance: 56.5%). Six children out of 10 (60%) in the oral propranolol group and 7 out of 13 (53.8%) in the oral atenolol group reached complete clearance of lesions. This study found no differences in terms of clearance when comparing oral propranolol with oral atenolol (RR 1.11, 95% CI 0.55 to 2.27; <a href="./references#CD006545-fig-0050" title="">Analysis 17.1</a>). </p> </section> <section id="CD006545-sec-0249"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0250"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0001" title="Abarzua‐ArayaA , Navarrete‐DechentCP , HeusserF , RetamalJ , Zegpi‐TruebaMS . Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. Journal of the American Academy of Dermatology2014;70(6):1045‐9. [CENTRAL: CN‐00993183; PUBMED: 24656727] ">Abarzua‐Araya 2014</a> provided information about adverse events in general and serious cardiovascular events, reporting zero events for this comparison. </p> </section> <section id="CD006545-sec-0251"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0252"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0253"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0254"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0255"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0256"> <h4 class="title">Comparison 18. Propranolol comparisons: oral propranolol versus oral prednisolone</h4> <p>For this comparison, we included information from two trials with a total of 39 children (<a href="./references#CD006545-bbs2-0005" title="BaumanNM , McCarterRJ , GuzzettaPC , ShinJJ , OhAK , PreciadoDA , et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngology, Head &amp; Neck Surgery.2014;140(4):323‐30. [CENTRAL: CN‐00988156; PUBMED: 24526257] NCT00967226 . Propranolol versus prednisolone for treatment of symptomatic hemangiomas. clinicaltrials.gov/ct2/show/NCT00967226 (accessed 23 April 2010). ">Bauman 2014</a>; <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>). In <a href="./references#CD006545-bbs2-0005" title="BaumanNM , McCarterRJ , GuzzettaPC , ShinJJ , OhAK , PreciadoDA , et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngology, Head &amp; Neck Surgery.2014;140(4):323‐30. [CENTRAL: CN‐00988156; PUBMED: 24526257] NCT00967226 . Propranolol versus prednisolone for treatment of symptomatic hemangiomas. clinicaltrials.gov/ct2/show/NCT00967226 (accessed 23 April 2010). ">Bauman 2014</a>, participants were infants aged from two weeks to six months with actively proliferating and symptomatic IH. Nineteen were enrolled and randomly assigned to prednisolone (n = 8) or propranolol (n = 11), both treatments given at a dose of 2 mg/kg/d until halted owing to toxic effects or clinical response. Treatment was stopped if IH resolved; no measurable improvement was noted in the lesion at two sequential monthly evaluations; in the presence of severe adverse events; at caretaker's or physician request; or no clinical improvement after one month. Children were followed for at least four months. </p> <p>In <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>, 30 children aged from one week to eight months with potentially disfiguring or functionally threatening IH were randomised into three equal groups: Group A, propranolol (2 to 3 mg/kg/d); Group B, prednisolone (1 to 4 mg/kg/d); and Group C, receiving both for a minimum duration of three months. After discharge, all children were re‐evaluated after eight days of treatment and then every month for a minimum of three months. Duration of treatment was three months or more; children were followed until 18 months. </p> <section id="CD006545-sec-0257"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0258"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0259"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0005" title="BaumanNM , McCarterRJ , GuzzettaPC , ShinJJ , OhAK , PreciadoDA , et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngology, Head &amp; Neck Surgery.2014;140(4):323‐30. [CENTRAL: CN‐00988156; PUBMED: 24526257] NCT00967226 . Propranolol versus prednisolone for treatment of symptomatic hemangiomas. clinicaltrials.gov/ct2/show/NCT00967226 (accessed 23 April 2010). ">Bauman 2014</a> provided information about severe adverse events, such as Cushingoid appearance and gastrointestinal upset, reporting a total of six cases (19 children; 31.5%). One child out of 11 (9%) in the oral propranolol group and 5 out of 8 (62.5%) in the oral prednisolone group reported severe adverse events, and the corresponding risk ratio favoured the oral propranolol group; however, the confidence interval was wide and did marginally include 1 showing some uncertainty (RR 0.15, 95% CI 0.02 to 1.02; <a href="./references#CD006545-fig-0051" title="">Analysis 18.1</a>). </p> <p>Likewise, <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a> provided information about complications in general, reporting a total of 11 cases (20 children; 55%). Two children out of 10 (20%) in the oral propranolol group and 9 out of 10 (90%) in the oral prednisolone group reported complications. The risk of complications after oral propranolol was 78% lower than after oral prednisolone (RR 0.22, 95% CI 0.06 to 0.78; <a href="./references#CD006545-fig-0052" title="">Analysis 18.2</a>). <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a> also assessed the incidence of serious cardiovascular events such as bradycardia and hypotension, reporting zero events for both adverse events. </p> </section> <section id="CD006545-sec-0260"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p><a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a> provide information about two measures of resolution. The authors stated that "Measure of assessment for colour and size was based on Visual Analogue Scale (VAS) ranging from −10 to +10 by comparing follow‐up images to the baseline photograph pretreatment. Here, 0 represented the baseline photograph, a decrease resulting in a minus number and an increase in a + number" (<a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>). Regarding colour fading, <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a> reported a mean score of ‐9 units (SD = 1.7) in the visual analogue scale for the propranolol group, versus a mean of ‐8 units (SD = 2.9) for the prednisolone group. This study found no clear difference in terms of colour fading score when comparing oral propranolol with oral prednisolone (MD ‐1.00, 95% CI ‐3.08 to 1.08; <a href="./references#CD006545-fig-0053" title="">Analysis 18.3</a>). <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a> also assessed the percentage of mean size reduction after treatment, reporting a mean size of 89.8 (SD = 10.3) for the propranolol group, versus a mean size of 66.6 (SD = 41.6) for the prednisolone group. This study found no clear differences (due to imprecision) in terms of size reduction when comparing oral propranolol with oral prednisolone (MD 23.2, 95% CI ‐3.36 to 49.76; <a href="./references#CD006545-fig-0054" title="">Analysis 18.4</a>). </p> <p>Likewise, <a href="./references#CD006545-bbs2-0005" title="BaumanNM , McCarterRJ , GuzzettaPC , ShinJJ , OhAK , PreciadoDA , et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngology, Head &amp; Neck Surgery.2014;140(4):323‐30. [CENTRAL: CN‐00988156; PUBMED: 24526257] NCT00967226 . Propranolol versus prednisolone for treatment of symptomatic hemangiomas. clinicaltrials.gov/ct2/show/NCT00967226 (accessed 23 April 2010). ">Bauman 2014</a> reported information about the proportional change in the total surface area at four months. They found a mean of 0.64 (SD = 0.29) for the propranolol group, versus a mean of 0.41 (SD = 0.37) for the prednisolone group. This study found no differences in terms of changes in the total surface area when comparing oral propranolol with oral prednisolone (MD 0.23, 95% CI ‐0.08 to 0.54; <a href="./references#CD006545-fig-0055" title="">Analysis 18.5</a>). </p> </section> <section id="CD006545-sec-0261"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0262"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0263"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0264"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0265"> <h4 class="title">Comparison 19. Propranolol comparisons: oral propranolol versus oral captopril</h4> <p>For this comparison, we included information from one trial with 30 children (<a href="./references#CD006545-bbs2-0025" title="ZaherH , RasheedH , El‐KomyMM , HegazyRA , GawdatHI , Abdel HalimDM , et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial. Journal of the American Academy of Dermatology2016;74(3):499‐505. [CENTRAL: CN‐01138323; PUBMED: 26685718] ">Zaher 2016</a>). Children with problematic infantile haemangiomas were enrolled and randomly divided into two groups. Group A (n = 15) received oral propranolol (2 mg/kg/d, divided into two daily doses). Group B (n = 15) received oral captopril (0.5 to 1 mg/kg/d, in a titrating dose). Children were discharged and followed up on a weekly basis for the first month, every two weeks in the second month, and finally at four‐week intervals until four months after stopping treatment. The intervention ended if there was "complete resolution of IH, no initial or further improvement of IH (for 2 months), or intolerable side effects". Children were followed until four months. </p> <section id="CD006545-sec-0266"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p><a href="./references#CD006545-bbs2-0025" title="ZaherH , RasheedH , El‐KomyMM , HegazyRA , GawdatHI , Abdel HalimDM , et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial. Journal of the American Academy of Dermatology2016;74(3):499‐505. [CENTRAL: CN‐01138323; PUBMED: 26685718] ">Zaher 2016</a> provided information on this outcome, reporting a total of seven cases of clearance (30 children; percentage of clearance: 23.3%). Seven children out of 15 (46.6%) in the oral propranolol group and 0 out of 15 (0%) in the oral captopril group reached complete clearance of lesions. Due to the large 95% confidence interval, it is uncertain whether there is a difference in terms of clearance when comparing oral propranolol with oral captopril (RR 15.00, 95% CI 0.93 to 241.2; <a href="./references#CD006545-fig-0056" title="">Analysis 19.1</a>). </p> </section> <section id="CD006545-sec-0267"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0268"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a> provided information about cardiac side effects such as hypotension and dizziness, reporting a total of four cases (30 children; 13.3%). No children out of 15 (0%) in the oral propranolol group and 4 out of 15 (26.6%) in the oral captopril group reported cardiac side effects. This study found no clear difference (due to imprecision) in terms of cardiac side effects when comparing oral propranolol with oral captopril (RR 0.11, 95% CI 0.01 to 1.90; <a href="./references#CD006545-fig-0057" title="">Analysis 19.2</a>). </p> </section> <section id="CD006545-sec-0269"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0270"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0271"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0272"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0273"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0274"> <h4 class="title">Comparison 20. Propranolol comparisons: oral propranolol versus topical timolol maleate</h4> <p>For this comparison, we included information from one trial with 26 children (<a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a>). Children with superficial infantile haemangiomas were randomised into three equal groups: one group received oral propranolol, and a second group received topical timolol maleate. Treatment efficacy was evaluated based on clinical photographs taken at the onset of treatment, during treatment, and at the end of treatment. Treatment ended if lesions had regressed or after 6 months without improvement; children were followed from 3 to 12 months. </p> <section id="CD006545-sec-0275"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0276"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0277"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a> provided information about adverse events in general, such as severe diarrhoea, lethargy, and loss of appetite, reporting a total of three cases (26 children; 11.5%). Three children out of 13 (23%) in the oral propranolol group and 0 out of 13 (0%) in the topical timolol maleate group reported adverse events. This study found no clear difference in terms of adverse events when comparing oral propranolol with topical timolol maleate (RR 7.00, 95% CI 0.40 to 123.35; <a href="./references#CD006545-fig-0058" title="">Analysis 20.1</a>). We downgraded the quality of the evidence from high to very low due to unclear risk of selection and performance bias, as well as imprecision (see <a href="./full#CD006545-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD006545-sec-0278"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p><a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a> provided information about size reduction equal or superior to 50% after treatment, reporting a total of 17 cases (26 children; 65.3%). Nine children out of 13 (69.2%) in the oral propranolol group and 8 out of 13 (61.5%) in the topical timolol maleate group reached size reduction of ≥ 50% . This study found no differences in terms of this measurement when comparing oral propranolol with topical timolol maleate (RR 1.13, 95% CI 0.64 to 1.97; <a href="./references#CD006545-fig-0059" title="">Analysis 20.2</a>). We downgraded the quality of the evidence from high to low due to unclear risk of selection and performance bias, as well as imprecision (see <a href="./full#CD006545-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD006545-sec-0279"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0280"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0281"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0282"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0283"> <h4 class="title">Comparison 21. Propranolol comparisons: oral propranolol versus oral propranolol + oral prednisolone </h4> <p>For this comparison, we included information from two trials with a total of 60 children (<a href="./references#CD006545-bbs2-0002" title="AlyMMD , HamzaAF , Abdel KaderHM , SaafanHA , GhazyMS , RagabIA . Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. European Journal of Pediatrics2015;174(11):1503‐9. [CENTRAL: CN‐01106020; PUBMED: 25982338] ">Aly 2015</a>; <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>). In <a href="./references#CD006545-bbs2-0002" title="AlyMMD , HamzaAF , Abdel KaderHM , SaafanHA , GhazyMS , RagabIA . Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. European Journal of Pediatrics2015;174(11):1503‐9. [CENTRAL: CN‐01106020; PUBMED: 25982338] ">Aly 2015</a>, infants aged less than 9 months with cutaneous haemangiomas were randomly assigned into 2 groups: Group A received oral prednisolone 2 mg/kg/day in 2 divided doses for the initial 2 weeks combined with oral propranolol 2 mg/kg/day in 3 divided doses for 6 months, while Group B received oral propranolol alone in the same dose for 6 months. Duration of treatment was 24 weeks; children were followed until 9 months. </p> <p>In <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>, children aged from 1 week to 8 months with potentially disfiguring or functionally threatening IH were randomised into 3 equal groups: Group A, propranolol (2 to 3 mg/kg/d); Group B, prednisolone (1 to 4 mg/kg/d); and Group C, receiving both for a minimum duration of 3 months. After discharge, all children were re‐evaluated after eight days of treatment and then every month for a minimum of three months. Duration of treatment was three months or more; children were followed until 18 months. </p> <section id="CD006545-sec-0284"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0285"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0286"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p>Both studies provided information about adverse events in general, including bronchiolitis, upper respiratory tract infection, and Cushingoid appearance, reporting a total of 13 cases (60 children; 21.6%). Three children out of 30 (10%) in the oral propranolol group and 10 out of 30 (33.3%) in the oral propranolol + oral prednisolone group reported adverse events. The risk of adverse events after oral propranolol was 70% lower that after oral propranolol + oral prednisolone (RR 0.30, 95% CI 0.10 to 0.91; I² = 0%; <a href="./references#CD006545-fig-0060" title="">Analysis 21.1</a>). </p> </section> <section id="CD006545-sec-0287"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p><a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a> provided information about the percentage of mean size reduction on a visual analogue scale at 1.5 years' follow‐up, reporting a mean of 89.8 (SD = 10.3) for the propranolol group, versus a mean of 82.6 (SD = 10.4) for the propranolol + prednisolone group. This study found no clear differences in terms of size reduction when comparing oral propranolol with oral propranolol + oral prednisolone (MD 7.20, 95% CI ‐1.87 to 16.27; <a href="./references#CD006545-fig-0061" title="">Analysis 21.2</a>). </p> <p>Likewise, <a href="./references#CD006545-bbs2-0002" title="AlyMMD , HamzaAF , Abdel KaderHM , SaafanHA , GhazyMS , RagabIA . Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. European Journal of Pediatrics2015;174(11):1503‐9. [CENTRAL: CN‐01106020; PUBMED: 25982338] ">Aly 2015</a> reported decrease in redness in 23 children (40 children; 57.5%). Ten children out of 20 (50%) in the oral propranolol group and 13 out of 20 (65%) in the oral propranolol + oral prednisolone group reported decrease in redness. This study found no clear differences in terms of redness when comparing oral propranolol with oral propranolol + oral prednisolone (RR 0.77, 95% CI 0.45 to 1.32; <a href="./references#CD006545-fig-0062" title="">Analysis 21.3</a>). </p> </section> <section id="CD006545-sec-0288"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0289"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0290"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0291"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0292"> <h4 class="title">Comparison 22. Propranolol comparisons: oral propranolol versus oral ibuprofen + oral paracetamol </h4> <p>For this comparison, we included information from one trial with 64 children (<a href="./references#CD006545-bbs2-0022" title="TiwariP , PandeyV , GangopadhyayAN , SharmaSP , GuptaDK . Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. Oral &amp; Maxillofacial Surgery2016;20(1):73‐7. [PUBMED: 26481918] ">Tiwari 2016</a>). Children with ulcerated infantile haemangiomas of the head and neck region, without any prior treatment and with age older than one month, were randomised into two groups. Group A received oral propranolol at a dose of 2 mg/kg per day in three divided doses. Group B received oral ibuprofen and paracetamol in doses of 10 and 16.2 mg/kg 8‐hourly. Duration of treatment was unclear; follow‐up was performed until 12 months. </p> <section id="CD006545-sec-0293"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p><a href="./references#CD006545-bbs2-0022" title="TiwariP , PandeyV , GangopadhyayAN , SharmaSP , GuptaDK . Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. Oral &amp; Maxillofacial Surgery2016;20(1):73‐7. [PUBMED: 26481918] ">Tiwari 2016</a> provided information on this outcome, reporting a total of 11 cases of clearance (64 children; percentage of clearance: 17.1%). Eight children out of 32 (25%) in the oral propranolol group and 3 out of 32 (9.3%) in the oral ibuprofen + oral paracetamol group reached clearance of lesions. This study found no clear differences in terms of clearance when comparing oral propranolol with oral ibuprofen + oral paracetamol (RR 2.67, 95% CI 0.78 to 9.15; <a href="./references#CD006545-fig-0063" title="">Analysis 22.1</a>). </p> </section> <section id="CD006545-sec-0294"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0295"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0022" title="TiwariP , PandeyV , GangopadhyayAN , SharmaSP , GuptaDK . Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. Oral &amp; Maxillofacial Surgery2016;20(1):73‐7. [PUBMED: 26481918] ">Tiwari 2016</a> provided information about adverse events in general, including maculopapular generalised rash, reporting a total of three cases (64 children; 4.6%). Three children out of 32 (9.3%) in the oral propranolol group and 0 out of 32 (0%) in the oral ibuprofen + oral paracetamol group reported adverse events. This study found no clear differences (due to imprecision) in terms of adverse events when comparing oral propranolol with oral ibuprofen + oral paracetamol (RR 7.00, 95% CI 0.38 to 130.26; <a href="./references#CD006545-fig-0064" title="">Analysis 22.2</a>). </p> </section> <section id="CD006545-sec-0296"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p><a href="./references#CD006545-bbs2-0022" title="TiwariP , PandeyV , GangopadhyayAN , SharmaSP , GuptaDK . Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. Oral &amp; Maxillofacial Surgery2016;20(1):73‐7. [PUBMED: 26481918] ">Tiwari 2016</a> assessed the mean size of ulceration, reporting a mean of 3.25 cm (SD = 0.75) for the propranolol group, versus a mean of 2.94 cm (SD = 0.42) for the ibuprofen + paracetamol group. The mean size of ulceration after oral propranolol was 0.31 cm greater than after oral ibuprofen + oral paracetamol (MD 0.31, 95% CI 0.01 to 0.61; <a href="./references#CD006545-fig-0065" title="">Analysis 22.3</a>). </p> </section> <section id="CD006545-sec-0297"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0298"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0299"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0300"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0301"> <h4 class="title">Comparison 23. Propranolol comparisons: oral propranolol + topical timolol maleate versus oral propranolol </h4> <p>For this comparison, we included information from two trials with a total of 57 children (<a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a>; <a href="./references#CD006545-bbs2-0016" title="LiG , XuDP , TongS , XueL , SunNN , WangXK . Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions. Journal of Craniofacial Surgery2016;27(1):56‐60. [CENTRAL: CN‐01195472; PUBMED: 26716547] ">Li 2016</a>). In <a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a>, children with superficial infantile haemangiomas were randomised into three equal groups: one group received topical timolol maleate together with oral propranolol, and a second group received only oral propranolol. Treatment ended if lesions had regressed or after 6 months without improvement; children were followed from 3 to 12 months. </p> <p>In <a href="./references#CD006545-bbs2-0016" title="LiG , XuDP , TongS , XueL , SunNN , WangXK . Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions. Journal of Craniofacial Surgery2016;27(1):56‐60. [CENTRAL: CN‐01195472; PUBMED: 26716547] ">Li 2016</a>, children with mixed infantile haemangiomas in the oral and maxillofacial regions were randomised into two groups. Children in the experimental group (A) were treated with oral propranolol in combination with topical timolol maleate, and children in the control group (B) were treated with oral propranolol alone. Treatment was administered "for a maximum period of 8 months or complete regression of lesions". Children were followed until eight months. </p> <section id="CD006545-sec-0302"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0303"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0304"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a> provided information about adverse events in general, including severe diarrhoea, lethargy, and loss of appetite, reporting a total of four cases (26 children; 15.3%). One child out of 13 (7.6%) in the oral propranolol + topical timolol maleate group and 3 children out of 13 (23%) in the oral propranolol group reported adverse events. This study found no clear differences in terms of adverse events when comparing oral propranolol + topical timolol maleate with oral propranolol (RR 0.33, 95% CI 0.04 to 2.80; <a href="./references#CD006545-fig-0066" title="">Analysis 23.1</a>). Likewise, <a href="./references#CD006545-bbs2-0016" title="LiG , XuDP , TongS , XueL , SunNN , WangXK . Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions. Journal of Craniofacial Surgery2016;27(1):56‐60. [CENTRAL: CN‐01195472; PUBMED: 26716547] ">Li 2016</a> assessed the incidence of severe adverse events, finding zero events in both study arms. </p> </section> <section id="CD006545-sec-0305"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p><a href="./references#CD006545-bbs2-0016" title="LiG , XuDP , TongS , XueL , SunNN , WangXK . Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions. Journal of Craniofacial Surgery2016;27(1):56‐60. [CENTRAL: CN‐01195472; PUBMED: 26716547] ">Li 2016</a> reported information about colour fading and size reduction, based on visual analogue scale scores. For colour fading, the authors reported a mean of 8.36 (SD = 1.39) for the propranolol + timolol maleate group, versus a mean of 7.18 (SD = 1.71) for the propranolol group. The mean score for colour fading after oral propranolol + topical timolol maleate was 1.18 units greater than after oral propranolol (MD 1.18, 95% CI 0.09 to 2.27; <a href="./references#CD006545-fig-0067" title="">Analysis 23.2</a>). Regarding size reduction, <a href="./references#CD006545-bbs2-0016" title="LiG , XuDP , TongS , XueL , SunNN , WangXK . Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions. Journal of Craniofacial Surgery2016;27(1):56‐60. [CENTRAL: CN‐01195472; PUBMED: 26716547] ">Li 2016</a> found a mean of 8.0 (SD = 1.75) for the propranolol + timolol maleate group, versus a mean of 7.59 (SD = 1.8) for the propranolol group. This study found no clear difference in terms of size reduction when comparing oral propranolol + topical timolol maleate with oral propranolol (MD 0.41, 95% CI ‐0.84 to 1.66; <a href="./references#CD006545-fig-0068" title="">Analysis 23.3</a>). </p> <p>Likewise, <a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a> provided information on the number of cases with size reduction ≥ 50% after treatment, reporting a total of 20 cases (26 children; 76.9%). Eleven children out of 13 (84.6%) in the oral propranolol + topical timolol maleate group and 9 out of 13 (69.2%) in the oral propranolol group reached size reduction ≥ 50%. This study found no significant differences in terms of size reduction when comparing oral propranolol + topical timolol maleate with oral propranolol (RR 1.22, 95% CI 0.79 to 1.88; <a href="./references#CD006545-fig-0069" title="">Analysis 23.4</a>). </p> </section> <section id="CD006545-sec-0306"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0307"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0308"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0309"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0310"> <h4 class="title">Comparison 24. Propranolol comparisons: oral propranolol + topical timolol maleate versus topical timolol maleate </h4> <p>For this comparison, we included information from one trial with 26 children (<a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a>). Children with superficial infantile haemangiomas were randomised into three equal groups: one group received topical timolol maleate together with oral propranolol, and a second group received only topical timolol maleate. Treatment ended if lesions had regressed or after 6 months without improvement; children were followed from 3 to 12 months. </p> <section id="CD006545-sec-0311"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0312"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0313"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a> provided information about adverse events in general, including severe diarrhoea, lethargy, and loss of appetite, reporting one case that developed loss of appetite and vomiting (26 children; 3.84%). One child out of 13 (7.6%) in the oral propranolol + topical timolol maleate group and 0 out of 13 (0%) in the topical timolol maleate group reported adverse events. This study found no clear differences (due to imprecision) in terms of adverse events when comparing oral propranolol + topical timolol maleate with topical timolol maleate (RR 3.00, 95% CI 0.13 to 67.51; <a href="./references#CD006545-fig-0070" title="">Analysis 24.1</a>). </p> </section> <section id="CD006545-sec-0314"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p><a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a> provided information on the number of cases with size reduction ≥ 50% after treatment, reporting a total of 19 cases (26 children; 73%). Eleven children out of 13 (84.6%) in the oral propranolol + topical timolol maleate group and 8 out of 13 (61.5%) in the topical timolol maleate group reached size reduction ≥ 50%. This study found no significant differences in terms of size reduction when comparing oral propranolol + topical timolol maleate with topical timolol maleate (RR 1.38, 95% CI 0.84 to 2.24; <a href="./references#CD006545-fig-0071" title="">Analysis 24.2</a>). </p> </section> <section id="CD006545-sec-0315"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0316"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0317"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0318"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0319"> <h4 class="title">Comparison 25. Propranolol comparisons: oral propranolol + oral prednisolone versus oral prednisolone </h4> <p>For this comparison, we included information from one trial with 20 children (<a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>). Children aged from 1 week to 8 months with potentially disfiguring or functionally threatening IH were randomised into 3 groups: Group A, propranolol (2 to 3 mg/kg/d); Group B, prednisolone (1 to 4 mg/kg/d); and Group C, propranolol + prednisolone for a minimum duration of 3 months. After discharge, all children were re‐evaluated after eight days of treatment and then every month for a minimum of three months. Duration of treatment was three months or more; children were followed until 18 months. </p> <section id="CD006545-sec-0320"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p>We found no clear information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0321"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0322"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a> provided information about complications in general, including Cushingoid appearance and gastrointestinal upset, reporting a total of 16 cases (20 children; 80%). Nine children out of 10 (90%) in the oral propranolol + oral prednisolone group and 7 out of 10 (70%) in the oral prednisolone group reported adverse events. This study found no significant differences in terms of adverse events when comparing oral propranolol + oral prednisolone with oral prednisolone (RR 1.29, 95% CI 0.82 to 2.03; <a href="./references#CD006545-fig-0072" title="">Analysis 25.1</a>). </p> </section> <section id="CD006545-sec-0323"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p><a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a> provided information on two measures of resolution. Regarding colour fading, <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a> reported a mean score of ‐8 units (SD = 2.9) in the visual analogue scale for the propranolol + prednisolone group, versus a mean of ‐9 units (SD = 1.5) for the prednisolone group. This study found no differences in terms of colour‐fading score when comparing oral propranolol + oral prednisolone with oral prednisolone (MD 1.00, 95% CI ‐1.02 to 3.02; <a href="./references#CD006545-fig-0073" title="">Analysis 25.2</a>). <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a> also assessed the percentage of mean size reduction after treatment, reporting a mean size of 66.6 (SD = 41.6) for the propranolol + prednisolone group, versus a mean size of 82.6 (SD = 10.4) for the prednisolone group. This study found no clear differences (due to imprecision) in terms of size reduction when comparing oral propranolol + oral prednisolone with oral prednisolone (MD ‐16.00, 95% CI ‐42.58 to 10.58; <a href="./references#CD006545-fig-0074" title="">Analysis 25.3</a>). </p> </section> <section id="CD006545-sec-0324"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0325"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0326"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0327"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0328"> <h4 class="title">Comparison 26. Other comparisons: intralesional methylene blue versus intralesional triamcinolone </h4> <p>For this comparison, we included information from one trial with 268 children (<a href="./references#CD006545-bbs2-0008" title="FengLL , WangXJ , SunLQ , ZhangZR , MaCH . Clinical observation on efficacy of methylthionine chloride in the treatment of hemangiomas in children. Chinese Journal of Dermatology2000;33(4):284. [CENTRAL: CN‐00843680] ">Feng 2000</a>). In this trial, children were randomised into two groups. Group A received methylene blue 1% injection doses from 10 to 20 mg, once a week for four weeks. Group B received triamcinolone injection doses from 20 to 50 mg, once a week for four weeks. Duration of treatment was unclear; children were followed from one to three years. </p> <section id="CD006545-sec-0329"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p><a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a> provided information on this outcome, reporting a total of 172 cases of clearance (268 children; percentage of clearance: 64.1%). In this study, 129 children out of 150 (86%) in the intralesional methylene blue group and 43 out of 118 (36.4%) in the intralesional triamcinolone group reached clearance of lesions. Clearance after intralesional methylene blue was 2.36 times greater than after intralesional triamcinolone (RR 2.36, 95% CI 1.84 to 3.02; <a href="./references#CD006545-fig-0075" title="">Analysis 26.1</a>). </p> </section> <section id="CD006545-sec-0330"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0331"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0332"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0333"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0334"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0335"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0336"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0337"> <h4 class="title">Comparison 27. Other comparisons: oral prednisolone versus intravenous methylprednisolone</h4> <p>For this comparison, we included information from one trial with 20 children (<a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a>). Children with problematic haemangiomas from one to four months of age were randomised into two groups. In the oral group, infants received oral prednisolone, 2 mg/kg per day, in two divided doses for 3 months. This dose was followed by a tapering schedule (decreasing the dose by 1 mg per month) over 6 to 9 months to prevent rebound. The intravenous group received pulses of intravenous high‐dose corticosteroids monthly for three months. A pulse consisted of methylprednisolone in doses of 30 mg/kg per day infused over 1 hour daily for 3 days. Treatment was administered for at least three months; children were followed from three months to one year of life. </p> <section id="CD006545-sec-0338"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0339"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>The trial by <a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a> found a good correlation between the visual analogue scale scores of the size of the haemangioma as reported by the parents of the children and the blinded outcome assessors (correlation coefficient = 0.92). </p> </section> <section id="CD006545-sec-0340"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p>In the <a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a> trial, adverse events in the 20 children were recorded by the parents (parent diaries) and the clinicians (monitoring). Parental reports of adverse events were reported as median and range along with a P value for the following eight types. </p> <p> <ul id="CD006545-list-0014"> <li> <p>Irritability: median 1 (range 0 to 3) for oral group and 1.5 (0 to 3) for IV group (P = 0.85). </p> </li> <li> <p>Crying: median 1 (range 0 to 3) for oral group and 0.5 (0 to 2) for IV group (P = 0.58). </p> </li> <li> <p>Hyperactivity: both groups had a median 0 (range 0 to 2) (P = 1.00).</p> </li> <li> <p>Apathy: median 0 (range 0) for oral group and 0 (0 to 1) for IV group (P = 0.32).</p> </li> <li> <p>Insomnia: median 1 (range 0 to 3) for oral group and 0 (0 to 1) for IV group (P = 0.08). </p> </li> <li> <p>Vomiting: both groups had a median 0 (range 0 to 2) (P = 1.00).</p> </li> <li> <p>Abdominal pains: median 0 (range 0 to 2) for both groups (P = 0.34).</p> </li> <li> <p>Behavioural changes: median 0 (range 0) for oral group and 0 (0 to 1) for IV group (P = 0.32). </p> </li> </ul> </p> <p>One child in the oral prednisolone group required antihypertensive medication for persistent high blood pressure, and one child in each of the treatment groups experienced serious respiratory distress, but both made a full recovery. Although no difference in the children's growth factors (height and weight) were seen at 3 months, by 1 year children in the oral prednisolone group had evidence of growth retardation as compared to the intravenous methylprednisolone group (weight, P = 0.003; height, P &lt; 0.001). </p> </section> <section id="CD006545-sec-0341"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p>In the <a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a> trial, the 10 children in the oral prednisolone group had significantly greater reductions in the size of the haemangioma when compared to the 10 children in the intravenous methylprednisolone group at 1 year of age (MD 51.50 mm, 95% CI 21.49 to 81.51; <a href="./references#CD006545-fig-0076" title="">Analysis 27.1</a>). </p> </section> <section id="CD006545-sec-0342"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0343"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0344"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0345"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0346"> <h4 class="title">Comparison 28. Other comparisons: HIFU at 3.5 W versus HIFU at 4.5 W</h4> <p>For this comparison, we included information from one trial with 40 children (<a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>). In <a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>, the lesion surface was irradiated with 3 to 5 mm/second continuously by ultrasonic therapeutic apparatus at frequency of 9 MHz, impulse of 1000, and 10% of scanning overlap. The ultrasound was used three times as a course of treatment, with one‐month interval. Duration of treatment was unclear; children were followed until six months. </p> <section id="CD006545-sec-0347"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p><a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a> provided information on this outcome, reporting a total of 15 cases of clearance (40 children; percentage of clearance: 37.5%). Seven children out of 20 (35%) in HIFU at 3.5 W group and 8 out of 20 (40%) in HIFU at 4.5 W group reached clearance of lesions. This study found no significant differences in terms of clearance when comparing HIFU at 3.5 W with HIFU at 4.5 W (RR 0.88, 95% CI 0.39 to 1.95; <a href="./references#CD006545-fig-0077" title="">Analysis 28.1</a>). </p> </section> <section id="CD006545-sec-0348"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0349"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a> provided information about cases of ulceration or scars, reporting a total of seven cases (40 children; <a href="./references#CD006545-fig-0078" title="">Analysis 28.2</a>). No children out of 20 (0%) in HIFU at 3.5 W group and 7 out of 20 (35%) in HIFU at 4.5 W group reported ulcerations or scars. This study found no clear differences (due to imprecision) in terms of adverse events when comparing HIFU at 3.5 W with HIFU at 4.5 W (RR 0.07, 95% CI 0.00 to 1.09; <a href="./references#CD006545-fig-0078" title="">Analysis 28.2</a>). </p> </section> <section id="CD006545-sec-0350"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0351"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0352"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0353"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0354"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0355"> <h4 class="title">Comparison 29. Other comparisons: HIFU at 3.5 W versus HIFU at 4.0 W</h4> <p>For this comparison, we included information from one trial with 40 children (<a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>). In <a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>, the lesion surface was irradiated with 3 to 5 mm/second continuously by ultrasonic therapeutic apparatus at frequency of 9 MHz, impulse of 1000, and 10% of scanning overlap. The ultrasound was used three times as a course of treatment, with one‐month interval. Duration of treatment was unclear; children were followed until six months. </p> <section id="CD006545-sec-0356"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p><a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a> provided information on this outcome, reporting a total of 16 cases of clearance (40 children; percentage of clearance: 40%). Seven children out of 20 (35%) in HIFU at 3.5 W group and 9 out of 20 (45%) in HIFU at 4.0 W group reached clearance of lesions. This study found no significant differences in terms of clearance when comparing HIFU at 3.5 W with HIFU at 4.0 W (RR 0.78, 95% CI 0.36 to 1.68; <a href="./references#CD006545-fig-0079" title="">Analysis 29.1</a>). </p> </section> <section id="CD006545-sec-0357"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0358"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a> provided information about cases of ulceration or scars, reporting a total of four cases (40 children; 10%). No children out of 20 (0%) in HIFU at 3.5 W group and 4 out of 20 (20%) in HIFU at 4.0 W group reported ulceration or scars. This study found no clear differences (due to imprecision) in terms of adverse events when comparing HIFU at 3.5 W with HIFU at 4.0 W (RR 0.11, 95% CI 0.01 to 1.94; <a href="./references#CD006545-fig-0080" title="">Analysis 29.2</a>). </p> </section> <section id="CD006545-sec-0359"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0360"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0361"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0362"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0363"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> <section id="CD006545-sec-0364"> <h4 class="title">Comparison 30. Other comparisons: HIFU at 4.0 W versus HIFU at 4.5 W</h4> <p>For this comparison, we included information from one trial with 40 children (<a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>). In <a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a>, the lesion surface was irradiated with 3 to 5 mm/second continuously by ultrasonic therapeutic apparatus at frequency of 9 MHz, impulse of 1000, and 10% of scanning overlap. The ultrasound was used three times as a course of treatment, with one‐month interval. Duration of treatment was unclear; children were followed until six months. </p> <section id="CD006545-sec-0365"> <h5 class="title">Primary outcome 1: Clearance, as assessed by a clinician</h5> <p><a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a> provided information on this outcome, reporting a total of 17 cases of clearance (40 children; percentage of clearance: 42.5%). Nine children out of 20 (45%) in HIFU at 4.0 W group and 8 out of 20 (40%) in HIFU at 4.5 W group reached clearance of lesions. This study found no differences in terms of clearance when comparing HIFU at 4.0 W with HIFU at 4.5 W (RR 1.13, 95% CI 0.55 to 2.32; <a href="./references#CD006545-fig-0081" title="">Analysis 30.1</a>). </p> </section> <section id="CD006545-sec-0366"> <h5 class="title">Primary outcome 2: A subjective measurement of improvement</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0367"> <h5 class="title">Primary outcome 3: Adverse events</h5> <p><a href="./references#CD006545-bbs2-0009" title="FuS , WangB , HuangH , HuangL . Primary clinical application of high‐intensity focused ultrasound on infant hemangiomas. Chung‐Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative &amp; Reconstructive Surgery2011;25(12):1477‐80. [CENTRAL: CN‐00896632] FuSZ , WangB , HuangHP , HuangLL . Clinical study on hemangiomas treatment with high‐intensity focused ultrasound (60 cases). Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(4):252‐5. [CENTRAL: CN‐00966758] ">Fu 2012</a> provided information about cases of ulceration or scars, reporting a total of 11 cases (40 children; 27.5%). Four children out of 20 (20%) in HIFU at 4.0 W group and 7 out of 20 (35%) in HIFU at 4.5 W group reported ulceration or scars. This study found no clear differences in terms of adverse events when comparing HIFU at 4.0 W with HIFU at 4.5 W (RR 0.57, 95% CI 0.20 to 1.65; <a href="./references#CD006545-fig-0082" title="">Analysis 30.2</a>). </p> </section> <section id="CD006545-sec-0368"> <h5 class="title">Secondary outcome 1: Other measures of resolution</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0369"> <h5 class="title">Secondary outcome 2: Proportion of parents who consider their child still has a problem</h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0370"> <h5 class="title">Secondary outcome 3: Proportion of children who consider they still have a problem, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0371"> <h5 class="title">Secondary outcome 4: Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> <section id="CD006545-sec-0372"> <h5 class="title">Secondary outcome 5: Requirement for surgical correction, as assessed by a physician, at any follow‐up </h5> <p>We found no information on this outcome for this comparison.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006545-sec-0373" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006545-sec-0373"></div> <section id="CD006545-sec-0374"> <h3 class="title" id="CD006545-sec-0374">Summary of main results</h3> <p>This systematic review identified 28 controlled trials with 1728 children enrolled and randomised. </p> <p>We selected information for three important comparisons, which we summarised in three tables: <a href="./full#CD006545-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD006545-tbl-0002">summary of findings Table 2</a>; and <a href="./full#CD006545-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD006545-sec-0375"> <h4 class="title">Oral propranolol versus placebo (3 parallel studies; 312 children)</h4> <p>Moderate‐quality evidence showed that compared with placebo, 3 mg/kg/day of propranolol probably improves clinician‐assessed clearance at 24 weeks (based on 156 children, from one study) and probably leads to a clinician‐assessed change in mean haemangioma volume at 24 weeks, as another measure of resolution (based on 40 children, from one study). We found no evidence of a difference in terms of short‐ or long‐term severe adverse events between the two groups (based on 509 children, from three studies) or in terms of cardiovascular adverse events, bronchospasm, or hypoglycaemia events (based on low‐quality evidence). </p> </section> <section id="CD006545-sec-0376"> <h4 class="title">Topical timolol maleate versus placebo (1 parallel study; 41 children)</h4> <p>Clinician‐assessed clearance was not reported for this comparison. Low‐quality evidence indicated that achieving clinician‐confirmed reduction of redness at 24 weeks (used as a measure of resolution) may be increased with topical timolol maleate 0.5% gel applied twice daily, as opposed to placebo (based on 41 children, from one study). Regarding short‐ or long‐term serious cardiovascular events, in both groups there were zero events of bradycardia and hypotension (based on low‐quality evidence from 41 children in one study). No other safety data were assessed. </p> </section> <section id="CD006545-sec-0377"> <h4 class="title">Oral propranolol versus topical timolol maleate (1 parallel study; 26 children)</h4> <p>Clinician‐assessed clearance was not reported for this comparison. There was no evidence of a difference between oral propranolol (via a tablet, at a 1.0 mg/kg dose, taken once per day) and topical timolol maleate (0.5% eye drops applied twice daily) in producing a 50% or greater reduction in haemangioma size at 24 weeks (based on 26 children from one study; low‐quality evidence). Regarding short‐ or long‐term general adverse events, although there were more events in the oral propranolol group such as severe diarrhoea, lethargy, and loss of appetite, this result was based on a low number of events and very low‐quality evidence; therefore, we are uncertain about the safety implications (based on 26 children from one study). </p> <p>For the three comparisons just discussed, the following outcomes, measured at any follow‐up, were not reported. </p> <p> <ul id="CD006545-list-0015"> <li> <p>A subjective measure of improvement, as assessed by the parent or child.</p> </li> <li> <p>Proportion of parents who consider their child still has a problem.</p> </li> <li> <p>Proportion of children who consider they still have a problem.</p> </li> <li> <p>Aesthetic appearance as assessed by physician, child, or parent.</p> </li> </ul> </p> <p>We found little evidence for a number of outcomes, especially patient‐reported outcomes, such as subjective measure of improvement, proportion of children who consider they still have a problem, proportion of parents who consider their child still has a problem, and aesthetic appearance. Furthermore, we included no trials assessing a large number of haemangioma treatments, such as argon laser, carbon dioxide laser, erbium laser, excision, cryotherapy, imiquimod, interferon alpha, vincristine, and rapamycin. </p> </section> </section> <section id="CD006545-sec-0378"> <h3 class="title" id="CD006545-sec-0378">Overall completeness and applicability of evidence</h3> <p>We aimed to include all interventions recommended for the management of infantile haemangiomas in children, and found a wide variety of different interventions and comparisons. We included a total of 12 interventions (not including combinations of these interventions) and 30 comparisons. Most of the included interventions were evaluated in single studies, precluding meta‐analysis. Due to the low quality of the evidence found for our key comparisons and incomplete coverage in terms of outcomes of interest and interventions, the external validity of the review is poor. </p> <p>Propranolol (oral, topical, and intralesional), currently the first‐line recommended intervention for IH, was the most assessed intervention (in 16 studies). However, some trials included in this systematic review assessed the efficacy of less used, and perhaps less important, treatments, such as bleomycin and radiation, whilst we found no evidence from randomised trials related to efficacy and safety of potential interventions such as argon laser, carbon dioxide laser, erbium laser, excision, cryotherapy, imiquimod, interferon alpha, vincristine, or rapamycin. Information about ongoing trials may be useful in clarifying the role of these potential treatments in the management of infantile haemangiomas in children (<a href="./references#CD006545-bbs2-0081" title="NCT01147601 . Topical Timolol 0.5% solution for proliferating infantile haemangiomas. clinicaltrials.gov/ct2/show/NCT01147601?term=NCT01147601 (accessed 25 March 2011). ">NCT01147601</a>; <a href="./references#CD006545-bbs2-0082" title="NCT02913612 . Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) (TIM01). clinicaltrials.gov/ct2/show/NCT02913612 Date first received: 12 August 2016. ">NCT02913612</a>). </p> <p>Data were lacking for a number of outcomes, especially patient‐relevant outcomes, such as reports of improvement by parents/children or aesthetic/cosmetic assessment, among others. Results for these outcomes could provide critical information about the patient/carer perspective on the benefits and harms of the proposed interventions for the treatment of this condition. </p> <p>Furthermore, it is difficult to ascertain the applicability of the results in terms of population because the age of the children was reported inconsistently; numerous subtypes of haemangiomas were included; and some trials did not provide information on haemangioma type. Lack of data also meant we were unable to undertake subgroup analysis by haemangioma type, although we did note that evidence was scarce for complicated scenarios such as ulcerated or problematic IH. </p> </section> <section id="CD006545-sec-0379"> <h3 class="title" id="CD006545-sec-0379">Quality of the evidence</h3> <p>This systematic review included only randomised controlled trials, as this design is considered the gold‐standard for assessing the efficacy of an intervention. However, although we included 28 trials that were eligible according to the inclusion criteria, we considered the quality of the evidence for the three most important comparisons mainly moderate or low. One of the reasons for this rating was the unclear risk of bias in several elements related to the methodological quality of included trials. For example, blinding of outcomes assessment was reported for 13 trials (<a href="./references#CD006545-bbs2-0002" title="AlyMMD , HamzaAF , Abdel KaderHM , SaafanHA , GhazyMS , RagabIA . Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. European Journal of Pediatrics2015;174(11):1503‐9. [CENTRAL: CN‐01106020; PUBMED: 25982338] ">Aly 2015</a>; <a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a>; <a href="./references#CD006545-bbs2-0007" title="EhsaniAH , NoormohammadpoorP , AbdolrezaM , BalighiK , ArianianZ , DaklanS . Combination therapy of infantile hemangioma with pulsed dye laser with topical propranolol: a randomized clinical trial. Archives of Iranian Medicine2014;17(10):657‐60. [CENTRAL: CN‐01042472; PUBMED: 25305763] ">Ehsani 2014</a>; <a href="./references#CD006545-bbs2-0010" title="GongH , XuD‐P , LiY‐X , ChengC , LiG , WangX‐K . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. British Journal of Oral &amp; Maxillofacial Surgery2015;53(9):836‐40. [CENTRAL: CN‐01125564; PUBMED: 26427968] ">Gong 2015</a>; <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0013" title="KesselsJP , HamersET , OstertagJU . Superficial hemangioma: pulsed dye laser versus wait‐and‐see. Dermatologic Surgery2013;39(3 Pt 1):414‐21. [CENTRAL: CN‐00966183; PUBMED: 23279058] ">Kessels 2013</a>; <a href="./references#CD006545-bbs2-0014" title="Leaute‐LabrezeC , Dumas de la RoqueE , NackaF , AbouelfathA , GrenierN , RebolaM , et al. Double‐blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants &lt; 4 months of age. British Journal of Dermatology2013;169(1):181‐3. [CENTRAL: CN‐00977604; PUBMED: 23301692] ">Leaute‐Labreze 2013</a>; <a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>; <a href="./references#CD006545-bbs2-0016" title="LiG , XuDP , TongS , XueL , SunNN , WangXK . Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions. Journal of Craniofacial Surgery2016;27(1):56‐60. [CENTRAL: CN‐01195472; PUBMED: 26716547] ">Li 2016</a>; <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>; <a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a>; <a href="./references#CD006545-bbs2-0020" title="TanM , DuanB , ZhouCM , GongH . The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2012;28(3):164‐8. [CENTRAL: CN‐01124671; PUBMED: 22870700] ">Tan 2012</a>; <a href="./references#CD006545-bbs2-0025" title="ZaherH , RasheedH , El‐KomyMM , HegazyRA , GawdatHI , Abdel HalimDM , et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial. Journal of the American Academy of Dermatology2016;74(3):499‐505. [CENTRAL: CN‐01138323; PUBMED: 26685718] ">Zaher 2016</a>), whereas the remaining trials did not report this information in a clear way. We considered only three studies at low risk of bias for the three blinding items (<a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a>; <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0014" title="Leaute‐LabrezeC , Dumas de la RoqueE , NackaF , AbouelfathA , GrenierN , RebolaM , et al. Double‐blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants &lt; 4 months of age. British Journal of Dermatology2013;169(1):181‐3. [CENTRAL: CN‐00977604; PUBMED: 23301692] ">Leaute‐Labreze 2013</a>). Likewise, there was some evidence of selective omissions of outcomes from publications for six trials (<a href="./references#CD006545-bbs2-0008" title="FengLL , WangXJ , SunLQ , ZhangZR , MaCH . Clinical observation on efficacy of methylthionine chloride in the treatment of hemangiomas in children. Chinese Journal of Dermatology2000;33(4):284. [CENTRAL: CN‐00843680] ">Feng 2000</a>; <a href="./references#CD006545-bbs2-0011" title="HogelingM , AdamsS , WargonO . A randomized controlled trial of Propranolol for infantile haemangiomas. Australasian Journal of Dermatology2011;52(Suppl 2):4. [EMBASE: 70558759] HogelingM , AdamsS , WargonO . A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics2011;128(2):e259‐66. [PUBMED: 21788220] WargonO . Randomised placebo controlled trial: Safety and efficacy of topical timolol maleate gel vs placebo for small superficial infantile haemangiomas. Australasian Journal of Dermatology2013;54(Suppl 2):22‐3. [EMBASE: 71067708] ">Hogeling 2011</a>; <a href="./references#CD006545-bbs2-0012" title="JungEG . X‐ray therapy for hemangiomatas [Die strahlentherapie der hamangiome]. Dermatologica1976;153(2):86‐7. [CENTRAL: CN‐00784697] JungEG , KohlerU . Regression of haemangiomata in infants after x‐ray treatment and mock‐radiation [Rückbildung frühkindlicher hämangiome nach röntgen‐ und pseudobestrahlung]. Archives of Dermatological Research1977;259(1):21‐8. [CENTRAL: CN‐00614355] ">Jung 1977</a>; <a href="./references#CD006545-bbs2-0018" title="MalikMA , MenonP , RaoKL , SamujhR . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. Journal of Pediatric Surgery2013;48(12):2453‐9. [CENTRAL: CN‐00921325; PUBMED: 24314186] ">Malik 2013</a>; <a href="./references#CD006545-bbs2-0019" title="PopeE , KrafchikBR , MacarthurC , StempakD , StephensD , WeinsteinM , et al. Oral versus high‐dose pulse corticosteroids for problematic infantile hemangiomas: a randomized controlled trial. Pediatrics2007;119(6):e1239‐e1247. [CENTRAL: CN‐00588641; PUBMED: 17485449] ">Pope 2007</a>; <a href="./references#CD006545-bbs2-0023" title="XuWL . The research of pingyangmycin emulsion on proliferation of tumor cell apoptosis in capillary hemangiomas [translation]. Shijiazhuang, Hebei, China: Hebei Medical University, 2003. XuWL , NiuAG , LiSL , LiZD . Pingyangmycin emulsion inducing apoptosis in infantile proliferating capillary hemangiomas. Zhonghua Zheng Xing Wai Ke za Zhi = Zhonghua Zhengxing Waike Zazhi [Chinese Journal of Plastic Surgery]2006;22(5):362‐4. [CENTRAL: CN‐00730309] XuWL , NiuAG , LiZD , LiSL , ShiBJ , ZhangYB , et al. Effect of pingyangmycin emulsion on the microenvironment of infantile proliferating capillary hemangioma. World Journal of Pediatrics2006;2(3):217‐22. ">Xu 2006</a>; <a href="./references#CD006545-bbs2-0026" title="ZhangL , MaiHM , ZhengJ , ZhengJW , ChenZG , WangYA , et al. Preliminary study on plasma RPN concentration of patients with infantile hemangioma treated with propranolol. International journal of clinical and experimental medicine2013;6(5):342‐5. [CENTRAL: CN‐00906420; PUBMED: 23724152] ">Zhang 2013</a>), especially concerning the safety of the assessed interventions. In addition, one of the factors that led to us downgrading the quality of evidence was small sample sizes. As mentioned above, most of the comparisons were based on a single trial with a small number of recruited children; only four trials recruited more than 100 children (<a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a>; <a href="./references#CD006545-bbs2-0008" title="FengLL , WangXJ , SunLQ , ZhangZR , MaCH . Clinical observation on efficacy of methylthionine chloride in the treatment of hemangiomas in children. Chinese Journal of Dermatology2000;33(4):284. [CENTRAL: CN‐00843680] ">Feng 2000</a>; <a href="./references#CD006545-bbs2-0012" title="JungEG . X‐ray therapy for hemangiomatas [Die strahlentherapie der hamangiome]. Dermatologica1976;153(2):86‐7. [CENTRAL: CN‐00784697] JungEG , KohlerU . Regression of haemangiomata in infants after x‐ray treatment and mock‐radiation [Rückbildung frühkindlicher hämangiome nach röntgen‐ und pseudobestrahlung]. Archives of Dermatological Research1977;259(1):21‐8. [CENTRAL: CN‐00614355] ">Jung 1977</a>; <a href="./references#CD006545-bbs2-0015" title="Léauté‐LabrèzeC , HoegerP , Mazereeuw‐HautierJ , GuibaudL , BaselgaE , PosiunasG , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine.2015;372(8):735‐46. [CENTRAL: CN‐01052642; PUBMED: 25693013] ">Leaute‐Labreze 2015</a>). Due to these limitations, our confidence in the effect estimate is limited, and we considered that the true effect may be different from the estimate of the effect showed in this present review. </p> </section> <section id="CD006545-sec-0380"> <h3 class="title" id="CD006545-sec-0380">Potential biases in the review process</h3> <p>We aimed to minimise potential biases during the development of this review. We followed the methodology for systematic reviews outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006545-bbs2-0126" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration, 2011. ">Higgins 2011</a>). We feel that this review was comprehensive in identifying clinical trials addressing the issue of efficacy and safety of suggested interventions for the management of infantile haemangiomas. However, insufficient information was available for seven studies to classify them as included or excluded, because they were published only as conference proceedings, or because we did not have access to the full texts. The fact that these studies have not yet been incorporated into the review may be a potential source of bias. In addition, we considered two of the studies as 'ongoing' due to their date of publication as abstracts. We may be able to decide whether or not to include them once they are published as full texts. </p> <p>We modified some of the methods planned for and used in the original review published by <a href="./references#CD006545-bbs2-0168" title="Leonardi‐BeeJ , BattaK , O’BrienC , Bath‐HextallFJ . Interventions for infantile haemangiomas (strawberry birthmarks) of the skin. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD006545.pub2] ">Leonardi‐Bee 2011</a>: changes included the need to add current interventions used in the treatment of IH (such as oral propranolol), modification of primary and secondary outcomes, and assessment of evidence using the GRADE approach, among other changes (see <a href="#CD006545-sec-0409">Differences between protocol and review</a> for more information). These modifications could be a potential source of bias in the review process. In addition, due to scarcity of data for most of the comparisons, we did not perform the planned investigation of heterogeneity and sensitivity analysis. </p> </section> <section id="CD006545-sec-0381"> <h3 class="title" id="CD006545-sec-0381">Agreements and disagreements with other studies or reviews</h3> <p>We identified and selected five reviews published in the last five years on the management of IH in children. A recent systematic review of the literature highlighted several potential pharmacotherapy treatments for management of IH (<a href="./references#CD006545-bbs2-0097" title="ChinnaduraiS , SnyderK , SatheN , FonnesbeckC , MoradA , LikisFE , et al. In: Agency for Healthcare Research and Quality, editor(s). Diagnosis and Management of Infantile Hemangioma. Vol. AHRQ Publication No.16‐EHC002‐EF, Rockville MD: Agency for Healthcare Research and Quality, 2016. ">Chinnadurai 2016b</a>); the authors of this review included randomised trials as well as observational evidence to address several potential interventions for the management of infantile haemangiomas, and found evidence that propranolol had the highest clearance rate, with high variability, under a network meta‐analysis approach. These findings are also in agreement with <a href="./references#CD006545-bbs2-0131" title="IzadpanahA , IzadpanahA , KanevskyJ , BelzileE , SchwarzK . Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta‐analysis. Plastic Reconstructive Surgery2013;131(3):601‐13. [PUBMED: 23142941] ">Izadpanah 2013</a>, a systematic review and meta‐analysis, which suggests that propranolol therapy could potentially be superior to other alternatives of management of IH in children. Our results also found propranolol to be one of the interventions with clear evidence of benefits, a comprehensive assessment of adverse events, as well as a considerable number of studies focused on its efficacy and safety. However, unlike <a href="./references#CD006545-bbs2-0097" title="ChinnaduraiS , SnyderK , SatheN , FonnesbeckC , MoradA , LikisFE , et al. In: Agency for Healthcare Research and Quality, editor(s). Diagnosis and Management of Infantile Hemangioma. Vol. AHRQ Publication No.16‐EHC002‐EF, Rockville MD: Agency for Healthcare Research and Quality, 2016. ">Chinnadurai 2016b</a> and <a href="./references#CD006545-bbs2-0131" title="IzadpanahA , IzadpanahA , KanevskyJ , BelzileE , SchwarzK . Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta‐analysis. Plastic Reconstructive Surgery2013;131(3):601‐13. [PUBMED: 23142941] ">Izadpanah 2013</a>, we added an assessment of the evidence using the GRADE approach, finding issues related to potential risk of bias and imprecision, which raise uncertainty in the estimated effect, especially those effects related to adverse events (see <a href="#CD006545-sec-0379">Quality of the evidence</a>). </p> <p>Regarding laser treatments, other authors have remarked that evidence is limited by low sample size, lack of comparisons of the same modalities, and variations in the used laser settings including wavelength and cooling protocols (<a href="./references#CD006545-bbs2-0096" title="ChinnaduraiS , SatheNA , SurawiczT . Laser treatment of infantile hemangioma: A systematic review. Lasers in Surgery &amp; Medicine2016;48(3):221‐233. [PUBMED: 26711436] ">Chinnadurai 2016a</a>). However, in an additional systematic review and meta‐analysis, <a href="./references#CD006545-bbs2-0153" title="ShenL , ZhouG , ZhaoJ , LiP , XuQ , DongY , et al. Pulsed dye laser therapy for infantile hemangiomas: a systemic review and meta‐analysis. QJM : Monthly Journal of the Association of Physicians2015;108(6):473‐80. [PUBMED: 25376585] ">Shen 2015</a> found that despite the few trials included in the review, PDL should be considered as a treatment modality, especially for superficial haemangiomas. Our findings from <a href="./references#CD006545-bbs2-0004" title="BattaK , GoodyearH , MossC , WilliamsH , HillerL , WatersR . Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5‐year analysis. British Journal of Dermatology2008;159(Suppl 1):113‐27. [CENTRAL: CN‐00784022] BattaK , GoodyearHM , MossC , WilliamsHC , HillerL , WatersR . Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1‐year analysis. Lancet2002;360(9332):521‐7. [CENTRAL: CN‐00410133] BattaK , WatersR , TitleyM , GoodyearH , MossC . Experience in the very early treatment of childhood haemangiomas with the 585 nm pulsed dye laser (PDL). British Journal of Dermatology2000;143(Suppl 57):42‐85. [CENTRAL: CN‐00783264] ">Batta 2002</a>, an included study, suggested that there was no evidence of a difference in achieving clearance of the haemangioma between PDL and wait‐and‐see (i.e. active monitoring), but fewer adverse events were generally observed with wait‐and‐see. </p> <p><a href="./references#CD006545-bbs2-0163" title="XuS , JiaR , GeS , LinM , FanX . Treatment of periorbital infantile haemangiomas: a systematic literature review on propranolol or steroids. Journal of Paediatrics and Child Health2014;50(4):271‐9. [PUBMED: 24754793] ">Xu 2014</a> gathered evidence under a systematic approach related to the efficacy and safety of propranolol versus corticosteroids for the treatment of periorbital infantile haemangiomas, finding only case series addressing this comparison. The authors concluded that propranolol may be an effective and even safer intervention for periorbital IHs compared with corticosteroids. This conclusion was based on the results of studies some of which were neither randomised nor controlled. We did not find evidence from randomised trials addressing this issue. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006545-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006545-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/full#CD006545-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD006545-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/full#CD006545-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD006545-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/full#CD006545-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pulsed dye laser versus wait‐and‐see, Outcome 1 Clearance." data-id="CD006545-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Pulsed dye laser versus wait‐and‐see, Outcome 1 Clearance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pulsed dye laser versus wait‐and‐see, Outcome 2 Adverse events: skin atrophy." data-id="CD006545-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Pulsed dye laser versus wait‐and‐see, Outcome 2 Adverse events: skin atrophy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pulsed dye laser versus wait‐and‐see, Outcome 3 Adverse events: skin hypopigmentation." data-id="CD006545-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Pulsed dye laser versus wait‐and‐see, Outcome 3 Adverse events: skin hypopigmentation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pulsed dye laser versus wait‐and‐see, Outcome 4 Adverse events: minimal crusting." data-id="CD006545-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Pulsed dye laser versus wait‐and‐see, Outcome 4 Adverse events: minimal crusting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pulsed dye laser versus wait‐and‐see, Outcome 5 Adverse events: pain." data-id="CD006545-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Pulsed dye laser versus wait‐and‐see, Outcome 5 Adverse events: pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pulsed dye laser versus wait‐and‐see, Outcome 6 Other measures of resolution: no redness." data-id="CD006545-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Pulsed dye laser versus wait‐and‐see, Outcome 6 Other measures of resolution: no redness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pulsed dye laser versus wait‐and‐see, Outcome 7 Parents who consider that their child still has a problem." data-id="CD006545-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Pulsed dye laser versus wait‐and‐see, Outcome 7 Parents who consider that their child still has a problem. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pulsed dye laser versus wait‐and‐see, Outcome 8 Aesthetic appearance: better cosmetic outcome." data-id="CD006545-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Pulsed dye laser versus wait‐and‐see, Outcome 8 Aesthetic appearance: better cosmetic outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pulsed dye laser versus wait‐and‐see, Outcome 9 Requirement for surgical correction." data-id="CD006545-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Pulsed dye laser versus wait‐and‐see, Outcome 9 Requirement for surgical correction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral propranolol versus placebo, Outcome 1 Clearance, as assessed by a clinician." data-id="CD006545-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Oral propranolol versus placebo, Outcome 1 Clearance, as assessed by a clinician. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral propranolol versus placebo, Outcome 2 Serious adverse events." data-id="CD006545-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Oral propranolol versus placebo, Outcome 2 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral propranolol versus placebo, Outcome 3 Serious cardiovascular adverse events." data-id="CD006545-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Oral propranolol versus placebo, Outcome 3 Serious cardiovascular adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral propranolol versus placebo, Outcome 4 Other adverse events." data-id="CD006545-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Oral propranolol versus placebo, Outcome 4 Other adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral propranolol versus placebo, Outcome 5 Other measures of resolution: change in volume." data-id="CD006545-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Oral propranolol versus placebo, Outcome 5 Other measures of resolution: change in volume. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral propranolol versus placebo, Outcome 6 Other measures of resolution: no improvement in redness." data-id="CD006545-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Oral propranolol versus placebo, Outcome 6 Other measures of resolution: no improvement in redness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Topical timolol maleate versus placebo, Outcome 1 Other measures of resolution (6 months)." data-id="CD006545-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Topical timolol maleate versus placebo, Outcome 1 Other measures of resolution (6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Topical bleomycin versus placebo, Outcome 1 Other measures of resolution: reduction in size at day 7." data-id="CD006545-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Topical bleomycin versus placebo, Outcome 1 Other measures of resolution: reduction in size at day 7. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 X‐ray radiation versus sham radiation, Outcome 1 Clearance." data-id="CD006545-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 X‐ray radiation versus sham radiation, Outcome 1 Clearance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Topical timolol maleate versus Nd:YAG laser, Outcome 1 Other measures of resolution (continuous)." data-id="CD006545-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Topical timolol maleate versus Nd:YAG laser, Outcome 1 Other measures of resolution (continuous). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Topical timolol maleate versus Nd:YAG laser, Outcome 2 Other measures of resolution (dichotomous)." data-id="CD006545-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Topical timolol maleate versus Nd:YAG laser, Outcome 2 Other measures of resolution (dichotomous). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Nd:YAG laser versus oral propranolol, Outcome 1 Clearance." data-id="CD006545-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Nd:YAG laser versus oral propranolol, Outcome 1 Clearance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Nd:YAG laser versus oral propranolol, Outcome 2 Adverse events: hyperpigmentation." data-id="CD006545-fig-0025" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Nd:YAG laser versus oral propranolol, Outcome 2 Adverse events: hyperpigmentation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Nd:YAG laser versus oral propranolol, Outcome 3 Adverse event: pigmentation and thinning." data-id="CD006545-fig-0026" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Nd:YAG laser versus oral propranolol, Outcome 3 Adverse event: pigmentation and thinning. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Nd:YAG laser versus oral propranolol, Outcome 4 Adverse events: superficial scar." data-id="CD006545-fig-0027" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Nd:YAG laser versus oral propranolol, Outcome 4 Adverse events: superficial scar. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Nd:YAG laser versus oral propranolol, Outcome 5 Other measures of resolution: excellent response." data-id="CD006545-fig-0028" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Nd:YAG laser versus oral propranolol, Outcome 5 Other measures of resolution: excellent response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Pulsed dye laser + topical propranolol versus pulsed dye laser, Outcome 1 Clearance, as assessed by a clinician." data-id="CD006545-fig-0029" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Pulsed dye laser + topical propranolol versus pulsed dye laser, Outcome 1 Clearance, as assessed by a clinician. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Pulsed dye laser + topical timolol maleate versus pulsed dye laser, Outcome 1 Clearance." data-id="CD006545-fig-0030" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Pulsed dye laser + topical timolol maleate versus pulsed dye laser, Outcome 1 Clearance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Pulsed dye laser + topical timolol maleate versus pulsed dye laser, Outcome 2 Other measures of resolution: mean size reduction." data-id="CD006545-fig-0031" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Pulsed dye laser + topical timolol maleate versus pulsed dye laser, Outcome 2 Other measures of resolution: mean size reduction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Nd:YAG laser + oral propranolol versus Nd:YAG laser, Outcome 1 Clearance." data-id="CD006545-fig-0032" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Nd:YAG laser + oral propranolol versus Nd:YAG laser, Outcome 1 Clearance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Nd:YAG laser + oral propranolol versus Nd:YAG laser, Outcome 2 Adverse events: hyperpigmentation." data-id="CD006545-fig-0033" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Nd:YAG laser + oral propranolol versus Nd:YAG laser, Outcome 2 Adverse events: hyperpigmentation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Nd:YAG laser + oral propranolol versus Nd:YAG laser, Outcome 3 Adverse events: pigmentation and thinning." data-id="CD006545-fig-0034" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Nd:YAG laser + oral propranolol versus Nd:YAG laser, Outcome 3 Adverse events: pigmentation and thinning. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Nd:YAG laser + oral propranolol versus Nd:YAG laser, Outcome 4 Adverse events: superficial scar." data-id="CD006545-fig-0035" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 Nd:YAG laser + oral propranolol versus Nd:YAG laser, Outcome 4 Adverse events: superficial scar. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-010-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-010-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Nd:YAG laser + oral propranolol versus Nd:YAG laser, Outcome 5 Other measures of resolution: excellent response." data-id="CD006545-fig-0036" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-010-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10 Nd:YAG laser + oral propranolol versus Nd:YAG laser, Outcome 5 Other measures of resolution: excellent response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-010-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Nd:YAG laser + oral propranolol versus oral propranolol, Outcome 1 Clearance." data-id="CD006545-fig-0037" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Nd:YAG laser + oral propranolol versus oral propranolol, Outcome 1 Clearance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Nd:YAG laser + oral propranolol versus oral propranolol, Outcome 2 Adverse events: hyperpigmentation." data-id="CD006545-fig-0038" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Nd:YAG laser + oral propranolol versus oral propranolol, Outcome 2 Adverse events: hyperpigmentation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-011-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-011-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Nd:YAG laser + oral propranolol versus oral propranolol, Outcome 3 Adverse events: pigmentation and thinning." data-id="CD006545-fig-0039" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-011-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 Nd:YAG laser + oral propranolol versus oral propranolol, Outcome 3 Adverse events: pigmentation and thinning. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-011-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-011-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-011-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Nd:YAG laser + oral propranolol versus oral propranolol, Outcome 4 Adverse events: superficial scar." data-id="CD006545-fig-0040" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-011-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11 Nd:YAG laser + oral propranolol versus oral propranolol, Outcome 4 Adverse events: superficial scar. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-011-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-011-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-011-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Nd:YAG laser + oral propranolol versus oral propranolol, Outcome 5 Other measures of resolution: excellent response." data-id="CD006545-fig-0041" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-011-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11 Nd:YAG laser + oral propranolol versus oral propranolol, Outcome 5 Other measures of resolution: excellent response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-011-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 ⁹⁰SR‐⁹⁰Y radiation + topical timolol maleate versus ⁹⁰SR‐⁹⁰Y radiation, Outcome 1 Clearance." data-id="CD006545-fig-0042" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 ⁹⁰SR‐⁹⁰Y radiation + topical timolol maleate versus ⁹⁰SR‐⁹⁰Y radiation, Outcome 1 Clearance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 ⁹⁰SR‐⁹⁰Y radiation + topical timolol maleate versus ⁹⁰SR‐⁹⁰Y radiation, Outcome 2 Adverse events." data-id="CD006545-fig-0043" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 ⁹⁰SR‐⁹⁰Y radiation + topical timolol maleate versus ⁹⁰SR‐⁹⁰Y radiation, Outcome 2 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Sequential dual‐wavelength laser + oral propranolol versus concurrent dual‐wavelength laser + oral propranolol, Outcome 1 Other outcomes of resolution: mean efficacy rating." data-id="CD006545-fig-0044" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Sequential dual‐wavelength laser + oral propranolol versus concurrent dual‐wavelength laser + oral propranolol, Outcome 1 Other outcomes of resolution: mean efficacy rating. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Oral propranolol versus topical propranolol, Outcome 1 Clearance." data-id="CD006545-fig-0045" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 Oral propranolol versus topical propranolol, Outcome 1 Clearance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-014-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-014-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Oral propranolol versus topical propranolol, Outcome 2 Adverse events: syncopal attack." data-id="CD006545-fig-0046" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-014-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14 Oral propranolol versus topical propranolol, Outcome 2 Adverse events: syncopal attack. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-014-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-015-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-015-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Oral propranolol versus intralesional propranolol, Outcome 1 Clearance." data-id="CD006545-fig-0047" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-015-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 Oral propranolol versus intralesional propranolol, Outcome 1 Clearance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-015-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-015-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-015-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Oral propranolol versus intralesional propranolol, Outcome 2 Adverse events: syncopal attack." data-id="CD006545-fig-0048" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-015-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15 Oral propranolol versus intralesional propranolol, Outcome 2 Adverse events: syncopal attack. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-015-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-016-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-016-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Topical propranolol versus intralesional propranolol, Outcome 1 Clearance." data-id="CD006545-fig-0049" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-016-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16 Topical propranolol versus intralesional propranolol, Outcome 1 Clearance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-016-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-017-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-017-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Oral atenolol versus oral propranolol, Outcome 1 Clearance." data-id="CD006545-fig-0050" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-017-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17 Oral atenolol versus oral propranolol, Outcome 1 Clearance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-017-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-018-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-018-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Oral propranolol versus oral prednisolone, Outcome 1 Severe adverse events." data-id="CD006545-fig-0051" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-018-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18 Oral propranolol versus oral prednisolone, Outcome 1 Severe adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-018-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-018-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-018-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Oral propranolol versus oral prednisolone, Outcome 2 Adverse events: complications in general." data-id="CD006545-fig-0052" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-018-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.2</div> <div class="figure-caption"> <p>Comparison 18 Oral propranolol versus oral prednisolone, Outcome 2 Adverse events: complications in general. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-018-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-018-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-018-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Oral propranolol versus oral prednisolone, Outcome 3 Other measures of resolution: colour fading." data-id="CD006545-fig-0053" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-018-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.3</div> <div class="figure-caption"> <p>Comparison 18 Oral propranolol versus oral prednisolone, Outcome 3 Other measures of resolution: colour fading. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-018-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-018-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-018-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Oral propranolol versus oral prednisolone, Outcome 4 Other measures of resolution: mean size reduction." data-id="CD006545-fig-0054" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-018-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.4</div> <div class="figure-caption"> <p>Comparison 18 Oral propranolol versus oral prednisolone, Outcome 4 Other measures of resolution: mean size reduction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-018-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-018-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-018-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Oral propranolol versus oral prednisolone, Outcome 5 Other measures of resolution: proportional change in the total surface area." data-id="CD006545-fig-0055" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-018-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.5</div> <div class="figure-caption"> <p>Comparison 18 Oral propranolol versus oral prednisolone, Outcome 5 Other measures of resolution: proportional change in the total surface area. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-018-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-019-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-019-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Oral propranolol versus oral captopril, Outcome 1 Clearance." data-id="CD006545-fig-0056" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-019-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19 Oral propranolol versus oral captopril, Outcome 1 Clearance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-019-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-019-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-019-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Oral propranolol versus oral captopril, Outcome 2 Adverse events: cardiac side effects." data-id="CD006545-fig-0057" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-019-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.2</div> <div class="figure-caption"> <p>Comparison 19 Oral propranolol versus oral captopril, Outcome 2 Adverse events: cardiac side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-019-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-020-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-020-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Oral propranolol versus topical timolol maleate, Outcome 1 Adverse events." data-id="CD006545-fig-0058" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-020-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20 Oral propranolol versus topical timolol maleate, Outcome 1 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-020-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-020-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-020-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Oral propranolol versus topical timolol maleate, Outcome 2 Other measures of resolution: size reduction &gt; 50%." data-id="CD006545-fig-0059" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-020-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.2</div> <div class="figure-caption"> <p>Comparison 20 Oral propranolol versus topical timolol maleate, Outcome 2 Other measures of resolution: size reduction &gt; 50%. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-020-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-021-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-021-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Oral propranolol versus oral propranolol + oral prednisolone, Outcome 1 Adverse events in general." data-id="CD006545-fig-0060" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-021-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21 Oral propranolol versus oral propranolol + oral prednisolone, Outcome 1 Adverse events in general. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-021-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-021-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-021-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Oral propranolol versus oral propranolol + oral prednisolone, Outcome 2 Other measures of resolution: mean size reduction." data-id="CD006545-fig-0061" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-021-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.2</div> <div class="figure-caption"> <p>Comparison 21 Oral propranolol versus oral propranolol + oral prednisolone, Outcome 2 Other measures of resolution: mean size reduction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-021-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-021-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-021-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Oral propranolol versus oral propranolol + oral prednisolone, Outcome 3 Other measures of resolution: decrease in redness." data-id="CD006545-fig-0062" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-021-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.3</div> <div class="figure-caption"> <p>Comparison 21 Oral propranolol versus oral propranolol + oral prednisolone, Outcome 3 Other measures of resolution: decrease in redness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-021-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-022-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-022-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Oral propranolol versus oral ibuprofen + oral paracetamol, Outcome 1 Clearance." data-id="CD006545-fig-0063" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-022-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22 Oral propranolol versus oral ibuprofen + oral paracetamol, Outcome 1 Clearance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-022-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-022-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-022-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Oral propranolol versus oral ibuprofen + oral paracetamol, Outcome 2 Adverse events." data-id="CD006545-fig-0064" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-022-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.2</div> <div class="figure-caption"> <p>Comparison 22 Oral propranolol versus oral ibuprofen + oral paracetamol, Outcome 2 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-022-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-022-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-022-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Oral propranolol versus oral ibuprofen + oral paracetamol, Outcome 3 Other measures of resolution: mean size of ulceration." data-id="CD006545-fig-0065" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-022-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.3</div> <div class="figure-caption"> <p>Comparison 22 Oral propranolol versus oral ibuprofen + oral paracetamol, Outcome 3 Other measures of resolution: mean size of ulceration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-022-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-023-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-023-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Oral propranolol + topical timolol maleate versus oral propranolol, Outcome 1 Adverse events in general." data-id="CD006545-fig-0066" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-023-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.1</div> <div class="figure-caption"> <p>Comparison 23 Oral propranolol + topical timolol maleate versus oral propranolol, Outcome 1 Adverse events in general. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-023-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-023-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-023-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Oral propranolol + topical timolol maleate versus oral propranolol, Outcome 2 Other measures of resolution: colour fading/visual analogue scale score." data-id="CD006545-fig-0067" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-023-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.2</div> <div class="figure-caption"> <p>Comparison 23 Oral propranolol + topical timolol maleate versus oral propranolol, Outcome 2 Other measures of resolution: colour fading/visual analogue scale score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-023-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-023-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-023-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Oral propranolol + topical timolol maleate versus oral propranolol, Outcome 3 Other measures of resolution: size reduction/visual analogue scale score." data-id="CD006545-fig-0068" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-023-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.3</div> <div class="figure-caption"> <p>Comparison 23 Oral propranolol + topical timolol maleate versus oral propranolol, Outcome 3 Other measures of resolution: size reduction/visual analogue scale score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-023-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-023-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-023-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Oral propranolol + topical timolol maleate versus oral propranolol, Outcome 4 Other measures of resolution: size reduction &gt; 50%." data-id="CD006545-fig-0069" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-023-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.4</div> <div class="figure-caption"> <p>Comparison 23 Oral propranolol + topical timolol maleate versus oral propranolol, Outcome 4 Other measures of resolution: size reduction &gt; 50%. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-023-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-024-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-024-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Oral propranolol + topical timolol maleate versus topical timolol maleate, Outcome 1 Adverse events." data-id="CD006545-fig-0070" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-024-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.1</div> <div class="figure-caption"> <p>Comparison 24 Oral propranolol + topical timolol maleate versus topical timolol maleate, Outcome 1 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-024-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-024-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-024-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Oral propranolol + topical timolol maleate versus topical timolol maleate, Outcome 2 Other measures of resolution: size reduction &gt; 50%." data-id="CD006545-fig-0071" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-024-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.2</div> <div class="figure-caption"> <p>Comparison 24 Oral propranolol + topical timolol maleate versus topical timolol maleate, Outcome 2 Other measures of resolution: size reduction &gt; 50%. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-024-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-025-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-025-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 25 Oral prednisolone versus oral prednisolone + oral propranolol, Outcome 1 Adverse events: complications." data-id="CD006545-fig-0072" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-025-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.1</div> <div class="figure-caption"> <p>Comparison 25 Oral prednisolone versus oral prednisolone + oral propranolol, Outcome 1 Adverse events: complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-025-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-025-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-025-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 25 Oral prednisolone versus oral prednisolone + oral propranolol, Outcome 2 Other measures of resolution: colour fading." data-id="CD006545-fig-0073" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-025-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.2</div> <div class="figure-caption"> <p>Comparison 25 Oral prednisolone versus oral prednisolone + oral propranolol, Outcome 2 Other measures of resolution: colour fading. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-025-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-025-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-025-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 25 Oral prednisolone versus oral prednisolone + oral propranolol, Outcome 3 Other measures of resolution: mean size reduction." data-id="CD006545-fig-0074" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-025-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.3</div> <div class="figure-caption"> <p>Comparison 25 Oral prednisolone versus oral prednisolone + oral propranolol, Outcome 3 Other measures of resolution: mean size reduction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-025-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-026-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-026-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 Intralesional methylene blue versus intralesional triamcinolone, Outcome 1 Clearance." data-id="CD006545-fig-0075" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-026-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.1</div> <div class="figure-caption"> <p>Comparison 26 Intralesional methylene blue versus intralesional triamcinolone, Outcome 1 Clearance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-026-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-027-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-027-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 27 Oral prednisolone versus intravenous methylprednisolone, Outcome 1 Other measures of resolution: haemangioma size." data-id="CD006545-fig-0076" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-027-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.1</div> <div class="figure-caption"> <p>Comparison 27 Oral prednisolone versus intravenous methylprednisolone, Outcome 1 Other measures of resolution: haemangioma size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-027-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-028-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-028-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 28 HIFU 3.5 W versus HIFU 4.5 W, Outcome 1 Clearance." data-id="CD006545-fig-0077" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-028-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.1</div> <div class="figure-caption"> <p>Comparison 28 HIFU 3.5 W versus HIFU 4.5 W, Outcome 1 Clearance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-028-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-028-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-028-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 28 HIFU 3.5 W versus HIFU 4.5 W, Outcome 2 Adverse events: ulceration or scars." data-id="CD006545-fig-0078" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-028-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.2</div> <div class="figure-caption"> <p>Comparison 28 HIFU 3.5 W versus HIFU 4.5 W, Outcome 2 Adverse events: ulceration or scars. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-028-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-029-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-029-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 29 HIFU 3.5 W versus HIFU 4.0 W, Outcome 1 Clearance." data-id="CD006545-fig-0079" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-029-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.1</div> <div class="figure-caption"> <p>Comparison 29 HIFU 3.5 W versus HIFU 4.0 W, Outcome 1 Clearance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-029-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-029-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-029-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 29 HIFU 3.5 W versus HIFU 4.0 W, Outcome 2 Adverse events: ulceration or scars." data-id="CD006545-fig-0080" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-029-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.2</div> <div class="figure-caption"> <p>Comparison 29 HIFU 3.5 W versus HIFU 4.0 W, Outcome 2 Adverse events: ulceration or scars. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-029-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-030-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-030-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 30 HIFU 4.0 W versus HIFU 4.5 W, Outcome 1 Clearance." data-id="CD006545-fig-0081" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-030-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.1</div> <div class="figure-caption"> <p>Comparison 30 HIFU 4.0 W versus HIFU 4.5 W, Outcome 1 Clearance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-030-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006545-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/urn:x-wiley:14651858:media:CD006545:CD006545-CMP-030-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_t/tCD006545-CMP-030-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 30 HIFU 4.0 W versus HIFU 4.5 W, Outcome 2 Adverse events: ulceration or scars." data-id="CD006545-fig-0082" src="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-030-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.2</div> <div class="figure-caption"> <p>Comparison 30 HIFU 4.0 W versus HIFU 4.5 W, Outcome 2 Adverse events: ulceration or scars. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/media/CDSR/CD006545/image_n/nCD006545-CMP-030-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006545-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral propranolol compared to placebo for infantile haemangiomas of the skin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral propranolol compared to placebo for infantile haemangiomas (strawberry birthmarks) of the skin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infantile haemangiomas (strawberry birthmarks) of the skin<br/> <b>Setting:</b> all settings (outpatient care)<br/> <b>Intervention:</b> oral propranolol<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral propranolol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance, as assessed by a clinician at any follow‐up ‐</b> 3 mg/kg/day </p> <p>24 weeks' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>604 per 1000<br/> (153 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 16.61</b><br/> (4.22 to 65.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>MODERATE</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>A subjective measure of improvement, as assessed by the parent or child, at any follow‐up</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events experienced at short or long term ‐</b> Serious adverse events </p> <p>24 weeks' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000<br/> (12 to 124) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b><br/> (0.33 to 3.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>509<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>LOW</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other measures of resolution, as assessed by a clinician, at any follow‐up ‐</b> percentage change in mean haemangioma volume at 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean: ‐14.1% (SD not reported)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean: ‐60% (SD not reported)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD</p> <p><b>45.9% lower</b> </p> <p>(80.2% lower to 11.6% lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean difference was reported by the study authors, but no SDs were reported for group means. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of parents who consider their child still has a problem, at any follow‐up ‐</b> not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of children who consider they still have a problem, at any follow‐up ‐</b> not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up ‐</b> not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group (the event rate in the single study or the mean event rate in the meta‐analysis) and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for imprecision (wide confidence interval around the estimate of the effect).<br/> <sup>2</sup>Downgraded by two levels for imprecision (wide confidence interval around the estimate of the effect and low number of events).<br/> <sup>3</sup>Downgraded by one level for risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral propranolol compared to placebo for infantile haemangiomas of the skin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/full#CD006545-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006545-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical timolol compared to placebo for infantile haemangiomas of the skin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Topical timolol maleate compared to placebo for infantile haemangiomas (strawberry birthmarks) of the skin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infantile haemangiomas (strawberry birthmarks) of the skin<br/> <b>Setting:</b> all settings (outpatient care)<br/> <b>Intervention:</b> topical timolol maleate<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with topical timolol maleate</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance, as assessed by a clinician at any follow‐up</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>A subjective measure of improvement, as assessed by the parent or child, at any follow‐up</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events experienced at short or long term ‐</b> </p> <p>Serious cardiovascular adverse events ‐ bradycardia</p> <p>24 weeks' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events of bradycardia reported in <a href="./references#CD006545-bbs2-0006" title="ChanH , McKayC , AdamsS , WargonO . RCT of timolol maleate gel for superficial infantile hemangiomas in 5‐ to 24‐week‐olds. Pediatrics2013;131(6):e1739‐47. [CENTRAL: CN‐00876607] ">Chan 2013</a>. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other measures of resolution, as assessed by a clinician, at any follow‐up ‐</b> no redness </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>369 per 1000<br/> (50 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 8.11</b><br/> (1.09 to 60.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of parents who consider their child still has a problem, at any follow‐up</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of children who consider they still have a problem, at any follow‐up ‐</b> not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up ‐</b> not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group (the event rate in the single study) and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by two levels for imprecision (low number of participants and events).<br/> <sup>2</sup>Downgraded by two levels for imprecision (wide confidence interval around the estimate of the effect and low number of participants and events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical timolol compared to placebo for infantile haemangiomas of the skin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/full#CD006545-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006545-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oral propranolol compared to topical timolol for infantile haemangiomas of the skin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral propranolol compared to topical timolol maleate for infantile haemangiomas (strawberry birthmarks) of the skin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infantile haemangiomas (strawberry birthmarks) of the skin<br/> <b>Setting:</b> all settings (outpatient care)<br/> <b>Intervention:</b> oral propranolol<br/> <b>Comparison:</b> topical timolol maleate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with topical timolol maleate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral propranolol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance, as assessed by a clinician at any follow‐up</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>A subjective measure of improvement, as assessed by the parent or child, at any follow‐up</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events experienced at short or long term ‐</b> general adverse events </p> <p>24 weeks' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 7.00</b><br/> (0.40 to 123.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>VERY LOW</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were 3 events in the oral propranolol group and no events in the topical timolol maleate group. Due to no events in the control group, absolute events could not be calculated. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other measures of resolution, as assessed by a clinician, at any follow‐up ‐</b> size reduction ≥ 50% </p> <p>24 weeks' follow up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>615 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>695 per 1000<br/> (394 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b><br/> (0.64 to 1.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of parents who consider their child still has a problem, at any follow‐up</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of children who consider they still have a problem, at any follow‐up</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aesthetic appearance as assessed by physician, child, or parent, at any follow‐up</b> ‐ not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any studies reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group (the event rate in the single study) and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by three levels: one level due to unclear risk of selection and performance bias and two levels for imprecision (wide confidence interval around the estimate of the effect and low number of participants and events).<br/> <sup>2</sup>Downgraded by two levels: one level due to unclear risk of selection and performance bias and one level for imprecision (small sample size). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oral propranolol compared to topical timolol for infantile haemangiomas of the skin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/full#CD006545-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Pulsed dye laser versus wait‐and‐see</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.62, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events: skin atrophy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.46 [1.36, 8.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events: skin hypopigmentation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [1.57, 5.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events: minimal crusting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.27, 93.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events: pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.27, 93.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Other measures of resolution: no redness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.83 [1.75, 13.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Parents who consider that their child still has a problem <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.56, 2.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Aesthetic appearance: better cosmetic outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.71, 4.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Requirement for surgical correction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [0.64, 8.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Pulsed dye laser versus wait‐and‐see</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral propranolol versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance, as assessed by a clinician <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 1 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.48 [3.41, 53.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 3 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.61 [4.22, 65.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.33, 3.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious cardiovascular adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.03, 14.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.10, 6.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Other adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Bronchospasm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.04, 3.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Bronchitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.62 [0.79, 40.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Bronchiolitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.42, 4.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.03, 14.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Sleep disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.79, 3.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Other measures of resolution: change in volume <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐45.9 [‐80.20, ‐11.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Other measures of resolution: no improvement in redness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.00 [0.52, 156.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral propranolol versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Topical timolol maleate versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Other measures of resolution (6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No redness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.11 [1.09, 60.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 IH volume reduction of ≥ 5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.21 [1.28, 21.21]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Topical timolol maleate versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Topical bleomycin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Other measures of resolution: reduction in size at day 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.0 [1.34, 328.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Topical bleomycin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">X‐ray radiation versus sham radiation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.63, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">X‐ray radiation versus sham radiation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Topical timolol maleate versus Nd:YAG laser</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Other measures of resolution (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.91 [‐1.27, ‐0.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Haemoglobin level (redness)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.91 [‐1.27, ‐0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Other measures of resolution (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.90, 10.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Excellent improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.90, 10.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Topical timolol maleate versus Nd:YAG laser</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Nd:YAG laser versus oral propranolol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.28, 23.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events: hyperpigmentation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.28, 23.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse event: pigmentation and thinning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.11, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events: superficial scar <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.24, 9.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Other measures of resolution: excellent response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.08, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Nd:YAG laser versus oral propranolol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Pulsed dye laser + topical propranolol versus pulsed dye laser</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance, as assessed by a clinician <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.57, 8.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Pulsed dye laser + topical propranolol versus pulsed dye laser</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Pulsed dye laser + topical timolol maleate versus pulsed dye laser</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 14.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Other measures of resolution: mean size reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.62 [1.21, 10.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Pulsed dye laser + topical timolol maleate versus pulsed dye laser</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Nd:YAG laser + oral propranolol versus Nd:YAG laser</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.28 [0.97, 11.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events: hyperpigmentation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.35, 6.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events: pigmentation and thinning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.12, 3.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events: superficial scar <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.09, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Other measures of resolution: excellent response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.5 [2.25, 32.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Nd:YAG laser + oral propranolol versus Nd:YAG laser</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Nd:YAG laser + oral propranolol versus oral propranolol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.44 [1.14, 62.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events: hyperpigmentation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.75 [0.44, 31.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events: pigmentation and thinning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.05, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events: superficial scar <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.05, 7.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Other measures of resolution: excellent response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [1.42, 5.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Nd:YAG laser + oral propranolol versus oral propranolol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">⁹⁰SR‐⁹⁰Y radiation + topical timolol maleate versus ⁹⁰SR‐⁹⁰Y radiation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.07, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.56, 2.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">⁹⁰SR‐⁹⁰Y radiation + topical timolol maleate versus ⁹⁰SR‐⁹⁰Y radiation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Sequential dual‐wavelength laser + oral propranolol versus concurrent dual‐wavelength laser + oral propranolol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Other outcomes of resolution: mean efficacy rating <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.77 [‐1.16, ‐0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Sequential dual‐wavelength laser + oral propranolol versus concurrent dual‐wavelength laser + oral propranolol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Oral propranolol versus topical propranolol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [1.01, 8.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events: syncopal attack <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.39, 124.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Oral propranolol versus topical propranolol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Oral propranolol versus intralesional propranolol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.5 [1.16, 17.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events: syncopal attack <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.39, 124.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Oral propranolol versus intralesional propranolol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Topical propranolol versus intralesional propranolol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.29, 7.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Topical propranolol versus intralesional propranolol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Oral atenolol versus oral propranolol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.55, 2.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Oral atenolol versus oral propranolol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Oral propranolol versus oral prednisolone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Severe adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.02, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events: complications in general <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.06, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Other measures of resolution: colour fading <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐3.08, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Other measures of resolution: mean size reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.20 [‐3.36, 49.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Other measures of resolution: proportional change in the total surface area <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [‐0.08, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Oral propranolol versus oral prednisolone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Oral propranolol versus oral captopril</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.0 [0.93, 241.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events: cardiac side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Oral propranolol versus oral captopril</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Oral propranolol versus topical timolol maleate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.40, 123.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Other measures of resolution: size reduction &gt; 50% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.64, 1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Oral propranolol versus topical timolol maleate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Oral propranolol versus oral propranolol + oral prednisolone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse events in general <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.10, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Other measures of resolution: mean size reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.20 [‐1.87, 16.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Other measures of resolution: decrease in redness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.45, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Oral propranolol versus oral propranolol + oral prednisolone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Oral propranolol versus oral ibuprofen + oral paracetamol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.67 [0.78, 9.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.38, 130.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Other measures of resolution: mean size of ulceration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Oral propranolol versus oral ibuprofen + oral paracetamol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Oral propranolol + topical timolol maleate versus oral propranolol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse events in general <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 2.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Other measures of resolution: colour fading/visual analogue scale score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.09, 2.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Other measures of resolution: size reduction/visual analogue scale score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [‐0.84, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Other measures of resolution: size reduction &gt; 50% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.79, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Oral propranolol + topical timolol maleate versus oral propranolol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Oral propranolol + topical timolol maleate versus topical timolol maleate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 67.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Other measures of resolution: size reduction &gt; 50% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.84, 2.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Oral propranolol + topical timolol maleate versus topical timolol maleate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">Oral prednisolone versus oral prednisolone + oral propranolol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse events: complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.82, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Other measures of resolution: colour fading <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐1.02, 3.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Other measures of resolution: mean size reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.0 [‐42.58, 10.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">Oral prednisolone versus oral prednisolone + oral propranolol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">Intralesional methylene blue versus intralesional triamcinolone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [1.84, 3.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">Intralesional methylene blue versus intralesional triamcinolone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">Oral prednisolone versus intravenous methylprednisolone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Other measures of resolution: haemangioma size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>51.5 [21.49, 81.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">Oral prednisolone versus intravenous methylprednisolone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">HIFU 3.5 W versus HIFU 4.5 W</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.39, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events: ulceration or scars <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.00, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">HIFU 3.5 W versus HIFU 4.5 W</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">HIFU 3.5 W versus HIFU 4.0 W</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.36, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events: ulceration or scars <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">HIFU 3.5 W versus HIFU 4.0 W</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006545-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">HIFU 4.0 W versus HIFU 4.5 W</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.55, 2.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events: ulceration or scars <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.20, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">HIFU 4.0 W versus HIFU 4.5 W</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006545.pub3/references#CD006545-tbl-0033">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006545.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006545-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006545-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006545-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD006545-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD006545-note-0003">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD006545-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD006545-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006545\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006545\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006545\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006545\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006545\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006545\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006545\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006545\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006545\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006545\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006545\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006545\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006545\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006545\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006545\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006545\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006545\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006545\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xsb6SJyC&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006545.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006545.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006545.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006545.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006545.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727446459"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006545.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727446463"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006545.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eac3ecd9af573',t:'MTc0MDcyNzQ0Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 